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Abstract 
Abstract 
Tllis thesis presents research into the design and synthesis of conformationally restricted 
and epoxide-based peptidomimetics. The introduction reviews the general topic of 
peptidomimetics, agents that either imitate or block the action of a peptide at the receptor 
level. The development of peptidomimetics is discussed and different types of 
peptidomimetics are surveyed. 
Chapter 1 presents the design and synthesis of conformationally restricted cis peptide 
bond mimics. The convenient preparation of dipeptide surrogates whlch contain a 
1,2-pyrrole moiety, designed to mimic the cis peptide bond, is reported. Protection of the 
amino terminus, and chain extension, by coupling of an amino acid residue at the 
carboxyl terminus, are demonstrated. 
Chapter 2 presents the design, synthesis, and in vitro testing of a series of epoxide-based 
peptidomimetics, designed as inhlbitors of the HIV Protease (HIV PR). Included are a 
series of pseudosymmetrical epoxides, designed to capitalise on the unique symmetry of 
the HIV PR. Unfortunately, these compounds were found to be inactive. However, a 
further series of epoxide-based compounds, inspired by the known inhibitor of the HIV 
PR, 1,2-epoxy-3-(p-nitrophenoxy)propane, displayed good inhlbitory activity. 
Chapter 3 presents an investigation of the "Horner-Wadsworth-Emmons" (HWE) 
reaction, an extension of a synthesis presented in Chapter 2. The effect of the aldehyde 
reactant and of the phosphonate reagent on the stereochemical outcome of the HWE 
reaction is examined. The nature of the aldehyde substituent was found to influence the 
Abstract 
stereochemistry of the product. For example, conjugated aldehydes were found to favour 
the formation of the E olefin, while alpha-branched aldehydes favoured the Z olefin. 
Further, the nature of the phosphoryl ester was shown to have a significant influence on 
the stereochemistry of the product. Large alkyl groups were found to favour the 
formation of theE olefin, while electron withdrawing substituents strongly favoured the 
formation of the Z olefin. 
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Introduction 
Part 1. Development of Peptidomimetics 
Numerous examples of biologically active peptides have been discovered and 
characterised over the past few decades.0.1 Biologically active peptides act as 
neurotransmitters, neuromodulators, and hormones, influencing a multitude of 
physiological processes in a living organism. o.1, 0'2 By interaction with a specific receptor, 
these peptides control a series of vital functions such as cell-cell communication, 
metabolism, immune defence, digestion, respiration, sensitivity to pain, reproduction, 
behaviour, and electrolyte levels.0·1 Therefore, biologically active peptides are of 
enormous interest in medicine and medicinal cbemistry.0.1 Examples of such peptides, 
including Angiotensin II and Somatostatin, are discussed later.0·1• 0·2 
The use of biologically active peptides as therapeutic agents is often severely limited by 
their pharmacological properties.0.1 In particular, degradation in the gut and serum, poor 
absorption after oral ingestion, and rapid excretion through the liver and kidneys, restrict 
their usefulness as drugs.0·1 To overcome such problems, peptidomimetics (agents that 
either imitate or block the action of a peptide at the receptor level) have become 
extremely important. OJ, 0'2 A successful peptidomimetic has sufficient secondary structure 
and other structural features (such as functional groups) analogous to those of the original 
peptide to enable it to displace the peptide from its receptor. However, it must be 
sufficiently non-peptidic to escape the problems of degradation and bioavailability 
associated with peptides.0·2 Fmther, the development of peptidomimetics with increased 
efficiency and selectivity has led to a reduction in side effects, and peptidomimetics 
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which block the action of a peptide (thereby acting as a receptor antagonist or an enzyme 
inhibitor) have resulted in new types of treatment for a number of diseases.o.1, o.z 
The pharmacological requirements of a peptidomimetic include metabolic stability, good 
bioavailability, high affinity and selectivity for its target, and minimal side effects. The 
usual approach to the design of peptidomimetics requires the discovery of a lead structure 
(a starting point for development) which can be optimised, for example, using molecular 
modelling programs.0·2 The native peptide often serves as a lead structure, although 
inhibitors and structures obtained from the screening of natural products and of 
compound libraries are also frequently utilised.0'2 Knowledge of the conformational, 
chemical, and electronic properties of the native peptide and its receptor, together with 
their mode of interaction (for example, the mechanism of enzyme catalysis), is central to 
the optimisation of a lead structure.0·2 However, the rational design of peptidomimetics, 
based on the knowledge of a peptide and/or its receptor (in the absence of a lead 
structure), is the goal of peptidomimetics today. 
Part 2. Types of Peptidomimetics 
Modification of a Peptide Backbone 
Modification of a peptide backbone refers primarily to the exchange of units in the 
peptide chain and/or to the introduction of additional fragments.0·2 This generally leads to 
an increase in the biological half-life in comparison to that of the native peptide.0·1 A 
common approach to the modification of a peptide backbone is replacement of an amide 
bond with a suitable mimic. This is particularly important in the development of enzyme 
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inhibitors. For example, replacement of an amide (NH-C=O), by an alkene (CH=CH) or a 
ketomethylene (CH2C=O), can result in a compound resistant to hydrolysis.0·2 Further, 
the use of a hydroxyethylene group (CH2CHOH) in place of an amide has resulted in 
some potent inhibitors, for example of the Human Immunodeficiency Virus protease 
(HIV PR).0'3' 0.4 The HIV PR is a virally encoded protease, essential to the life cycle of 
HIV.03 Hydroxyethylene inhibitors of the HIV PR are discussed in the introduction to 
Chapter 2 of this thesis. 
Further, approaches to the modification of a peptide backbone include the extension of a 
peptide chain by the addition of extra groups (Figure 0.1) or the exchange of individual 
units. For example, the carbonyl group (C=O) of an amino acid is sometimes replaced by 
a thio (C=S) or methylene (CH2), while the amine group (NH) may be replaced by an 
oxygen or sulfur.0·2 The CH group of an amino acid may also be replaced, for example, 
by a nitrogen atom to give an azapeptide (Figure 0.1). 
Figure 0.1. Modification of the peptide backbone by the addition of extra groups or 
exchange of individual units. 
Azapeptide 
0 
Chain Extension 
(X=O, CH2, NH) 
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The development of the therapeutic agent Captopril (0.1) is an extremely important 
example of enzyme inhibition by modification of a peptide backbone.0'2' 05 Captopril 
prevents the release of the hypertensive peptide hormone Angiotensin II (0.2) by 
inhibiting the enzyme responsible for its production-Angiotensin Converting Enzyme 
(ACE).0·2• 0·5 Lowering of the Angiotensin II level reduces pathologically increased blood 
pressure and thus the incidents of heart failure and strokes.0·2• 05 Captopril was developed 
from the lead structure (0.3), a simple dipeptide shown to be a weak inhibitor of 
ACE. 0·2• o.s Replacement of the terminal amine of 0.3 by a mercapto group, gave the 
potent and orally active drug Captopril (0.1).0'2' o.s The mercapto group was introduced to 
co-ordinate with a zinc ion known to be located in the active site of ACE.0·2• o.s 
HS 
0.1 0.3 
Asp-Arg-Val-Try-Ile-His-Pro-Phe 0.2 
Stabilisation of Conformation by Bridging 
A successful method for the development of peptidomimetics involves the development 
of conformationally restricted analogues that imitate the receptor bound conformation of 
biologically active peptides.0·1 Such analogues show increased resistance towards 
proteolytic degradation, enhanced metabolic stability, and better selectivity for their 
target.0·1 The biologically active conformation of a peptide may be stabilised or 
constrained by the introduction of a bridge between different parts of the molecule, 
making the molecule more rigid.0·2 A bridge may occur within a single amino acid 
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residue (as in 0.4), but generally involves several residues and may either be the result of 
a link between two amino acid side chains (0.5), between two backbone units (0.6), or 
between a backbone unit and a side chain, for example, as in compound 0.7, a potent 
inhibitor of ACE.o.t,o.z 
RHN 
s-s 1\ R' 
'l -N N-< 
NACO,R' >-----< r-
H R 0 0 
0 0.5 0.6 
0 
Further, conformationally constrained peptidomimetics, where the peptide (amide) bond 
is replaced by a ring structure, are the subject of Chapter 1 of this thesis. Examples in 
which the peptide bond is replaced by a tetrazole ring,0·6' 0·7 a benzene ring,0·8 and a 
pyrrole ring (in order to mimic the cis conformation of a peptide bond) are discussed in 
detail. 
Global Restrictions of Conformation 
Global restrictions in the conformation of a peptide are possible by limiting the flexibility 
of a peptide strand through the introduction of mimetics which enforce a defined 
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secondary structure.0'1 In addition to a.-helix and P-sheet structures, turning points are 
essential conformational components of peptides.0·2 The P-tum, generally considered to 
be the most important turning point in a peptide chain, is formed from four amino acids 
and is stabilised by a hydrogen bond between the amino group of the first amino acid and 
the carbonyl group of the fourth amino acid, as shown in Figure 0.2.0'2 
Figure 0.2. The structure of a typical P-tum. 
There are numerous examples of mimics designed to stabilise a P-tum, ranging from non-
peptide components, such as 0.8,0·2 to recognisable peptide chains as in 0.9.0.1 Compound 
0.9 was designed to simulate the P-tum, postulated between the Phe 7 and Thr10 residues of 
the cyclic peptide somatostatin (0.10).0'1 Somatostatin (0.10) inhibits the release of 
growth hormone from the pituitary gland.0'1 
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Me 
N-M•ATTyr-D-/ 
Phe-Val-Lys 0.9 
Scaffold Peptidomimetics 
H-Ala-Gly-CrLys-Asn-Phe-Phe-rrp 
HO-Cys-Ser-Thr-Phe-Thr-Lys 0.10 
This class of peptidomimetics utilises a completely unnatural framework to support 
elements of the original peptide which are responsible for its effectiveness.0·2 Since it is 
possible to employ a framework based on a natural product or drug whose oral absorption 
is established, the potential exists for the development of mimetics with enhanced 
bioavailability. Compound 0.11 provides an example of a scaffold mimetic of 
somatostatin (0.10).o.t,o.2 Here, 3-deoxy-13-D-glucose serves as a scaffold for the 
attachment of the first three side chains (Phe, Trp, and Lys) of the 13-tum, postulated for 
somatostatin (0.10).0'1 Compound 0.11 binds to the somatostatin receptor in the pituitary 
with an ICso value of 1.3 JIM. o.1, 0·9 
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Modification of Amino Acid Side Chains 
The development of conformationally restricted and/or metabolically stable 
peptidomimetics may be approached by the modification of amino acid side chains.0.1 A 
common strategy involves the replacement of a natural (L) amino acid with the unnatural 
(D) form.0·1• 0·2 For example, compound 0.9, designed to simulate the ~-turn postulated for 
the cyclic peptide somatostatin (0.10) (discussed above), utilises D-Trp to stabilise this 
structural characteristic.0·1 Another approach to the modification of amino acid side 
chains involves the introduction of sterically demanding groups which limit the range of 
available conformations. Compounds 0.12 and 0.13 are examples of sterically demanding 
analogues of the amino acid Phe and are components of peptidomimetics which bind at 
the Angiotensin II receptor.0·1 
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C02H 
C02H NH2 
0.12 0.13 
Non-Peptide Mimetics 
Non-peptide mimetics have generally been discovered in the course of random screening 
of large numbers of compounds. o.z They belong to various classes of organic compounds 
and usually have no apparent structural relationship with the natural peptide ligand.0·2 
Compound 0.14 is an example of a non-peptide mimetic of Angiotensin II (0.2) which 
displays potent antagonistic activity at the Angiotensin II receptor.0·2 A further example 
of a non-peptide mimetic, 1,2-epoxy-3-(p-nitrophenoxy)propane is an irreversible 
inhibitor of the HIV PR03' 0·10and has served as a lead structure for the development of a 
series of epoxide-based inhibitors of the HIV PR, described in Chapter 2 of this thesis. 
N ~b 
N 
0.14 1 ,2-epoxy-3-(p-nitrophenoxy)propane 
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Chapter 1. Peptide Bonds Mimics 
Introduction 
The peptide (amide) bond is one of the most important structural features of pep tides and 
proteins.u Individual amino acids are connected by a peptide (amide) bond between the 
carboxyl group of one residue and the amino group of the subsequent residue.Lt, 1.2 It is 
widely accepted that the peptide (amide) bond possesses considerable double bond 
character due to delocalisation of the lone pair of electrons on the nitrogen (Figure 
1.1) .u. 1.2 Thus, ami des are planar structures and a peptide bond is shorter than an 
N-C (alkyl) bond.1.1,1.2 Most importantly, there is a considerable barrier to bond rotation 
and, therefore, the peptide bond exhibits isomerism, existing in trans and cis 
configurations (Figure 1.2).1.1, t.z The trans configuration generally predominates in 
secondary amides as it is considerably more stable than the cis configuration (LlG=-2.6 
kilocalories/mol).1.2 
Figure 1.1. De localisation of the lone pair of electrons on the nitrogen in the peptide 
(amide) bond. 
o-
-•------•~ "~~ 
H 
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Figure 1.2. The trans and cis configurations of the peptide bond in a dipeptide. 
R 
~ .. ~1co2H H2N' T 
0 R' 
trans Configuration cis Configuration 
Note: This assignment is standard practice in peptide chemistry and does not recognise the 
higher priority of the carbonyl.13·1.4 
The configuration of a peptide (amide) bond is of considerable importance in biological 
systems.u Peptides achieve their biological function through interaction with another 
molecule, termed the receptor. Receptor-peptide interactions are very specific, requiring 
the peptide to adopt a particular three dimensional structure. Thus the peptide 
conformation, including the trans: cis population of the peptide bond, affects biological 
activity. Angiotensin II, an eight residue peptide involved in blood pressure regulation 
(discussed in the introduction to this thesis), provides an example ofthis.13 A study 
found that the biological activity of Angiotensin II correlates directly to the percentage of 
the cis peptide bond present between the His and Pro residues (His and Pro are located at 
positions six and seven of the peptide).1.3 This suggests that either the cis peptide bond or 
the conformation of the peptide associated with it may be important for high affinity 
receptor interaction.1.3 
The occurrence of a cis peptide bond in peptides and proteins is generally associated with 
a Pro residue,1.2• 1.4,1.5 although there are several examples of cyclic peptides1.6• L? and 
even a membrane bound linear peptidel.8 containing a cis peptide bond without a Pro. 
The barrier to bond rotation in a peptide bond involving Pro is small (~G=-0.5 
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kilocalories/mol) and as a result readily detectable quantities of both trans and cis 
isomers are often present at equilibrium.1.2 There is considerable evidence that Pro 
isomerism has many important biochemical roles including controlling the rate of protein 
folding, triggering transmembrane signalling, providing recognition in peptide antigens, 
and regulating the activation and breakdown of peptide hormones.1.4 For example, in 
bovine pancreatic trypsin inhibitor, yeast cytochrome c, ribonuclease Tl, and thioredoxin, 
the rate at which each of these proteins can fold to their native conformation is affected 
by site-specific mutagenesis of specific Pro residues contained in the proteins.1.9 In each 
case, removal of critical Pro residues eliminates some folding phases detected in wild-
type proteins.1.9 Further, a number of peptidases, such as aminopeptidase P, do not 
hydrolyse cis peptide bonds N-terminal to a Pro residue.uo Thus, the processing of 
peptide chains may depend on the conversion of a cis peptide bond to the trans form. uo 
The elucidation of the bioactive conformation of peptides is a challenging target. Central 
to this is the determination of local structural features, such as the peptide bond 
configuration. The use of peptidomimetics, which incorporate conformationally 
restricted analogues of a peptide bond into bioactive peptides, is an important approach to 
the study of the bioactive conformation of peptides. Further, the study of these peptide 
bond mimics offers the potential to discover analogues with improved stability, 
bioselectivity, and bioavailability. TheE olefin is one of numerous examples of peptide 
bond mimics and has been successfully employed to mimic the trans peptide bond since 
it closely resembles its three dimensional structure.L9 
A number of conformationally restricted mimics of a cis peptide bond have also been 
developed. A frequent approach to constraining a peptide bond in the cis conformation is 
13 
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to tether the alpha carbons of two adjacent amino acids to form cyclic dipeptide 
derivatives, such as 1.1, 1.2, and, 1.3.1.4, Lll Compounds of the type 1.1 have been 
successfully incorporated into an analogue ofbradykinin1.5 (discussed later) and have 
been used to probe the catalytic mechanism of cyclophilin.r.2 Interest in cyclophilin, a 
family of enzymes responsible for peptide bond isomerism N-terminal to Pro, has 
increased due to the finding that they are the receptors for the immunosuppressive drug 
Cyclosporin A.I.2 X-ray studies suggest that the active site of cyclophilin is preorganised 
to bind substrates in a well defined conformation characterised by a cis peptide bond N-
terminal to a Pro residue.1.2 Further, the crystal structures of four dipeptides bound to 
cyclophilin show that, in all cases, the peptide bond exists entirely in the cis 
configuration.L2 To probe the enzyme bound conformation in solution, a series of 
conformationally constrained cis dipeptide mimics of the type 1.1 were developed.1.2 
Two examples, 1.4a and 1.4b displayed exceptionally high affinity for cyclophilin, 
similar to that of Cyclosporin A.l.2 This suggests that 1.4a and 1.4b closely resemble the 
backbone conformation of enzyme bound dipeptides and therefore that the cis isomer is 
selectively bound to cyclophilin in solution.r.2 
14 
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RRN 
0 
1.3 
0 
1.4a R==CH2Ph 
1.4b R=CH(Me)2 
A further class of cis peptide bond mimics employs an aromatic ring in place of the 
peptide bond. By incorporating amino acids at the one and two positions of the ring, the 
resulting dipeptide is effectively locked in a cis conformation. Compound 1.5, a Gly-Phe 
mimic, provides a simple racemic example.u2 Compound 1.5 was incorporated into the 
highly active somatostatin analogue (1.6) (somatostatin is a peptide which inhibits the 
release of growth hormone and is discussed in the introduction to this thesis) .1.12 The 
bioactive conformation of 1.6 is thought to require the cis configuration of the Phe-Pro 
peptide bond.u2 When the Phe-Pro moiety of 1.6 was replaced by the mimic (1.5), one 
ofthe isomers ofthe resultant peptidomimetic exhibited high biological activity.u2 This 
supports the proposed cis configuration for the Phe-Pro bond, in the bioactive 
conformation of the somatostatin analogue (1.6).1.12 
Me 
I 
BocN 
CH2Ph 1.5 
cyclo (Pro-Phe-D-Trp-Lys-Thr-Phe) 1.6 
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The dipeptide analogue (1.7), where the peptide bond is replaced by a tetrazole ring, has 
attracted considerable attention.u3, 1.14• 1.15• 1.16 Initial synthetic procedures to this target 
resulted in racemisation at one orboth chiral centres adjacent to the tetrazole ring.u3 
However, a recent preparation has overcome these difficulties.u4 The tetrazole dipeptide 
analogue (1.7) has been incorporated into a number of biologically active peptides, 
including another cyclic analogue of somatostatin giving 1.8.u4, 1.15• l.l? The solution 
structure of 1.8, determined by NMR data and conformational analysis, was shown to be 
very similar to solution structures reported for cyclic hexapeptide analogues of 
somatostatin.u7 This demonstrates that the tetrazole ring can function as an effective cis 
peptide bond mimic in solution.u7 The potency of 1.8 was found to be 83% of that of 
somatostatin. l.l? 
cyclo (Ala-Tyr-D-Trp-Lys-Val-Phe-'Jf[CN4]) 1.8 
('lf[CN4] represents the tetrazole ring) 
Further, tetrazole-based peptidomimetics have been employed in an attempt to elucidate 
the bioactive conformation of substrates and inhibitors of the Human Immunodeficiency 
Virus protease (HIV PR).1.1 8, 1.19 The HIV PR is a virally encoded protease, essential to 
the life cycle of HIV and is discussed in detail in Chapter 2 of this thesis. The tetrazole-
based peptidomimetic (1.9) is a analogue of the known inhibitor JG 365 (1.10) and was 
found to be a moderate inhibitor of the HIV PR (IC50 51 J..tM).u9 Crystallographic 
evidence suggests that JG 365 (1.10) adopts a "cis-like" geometry in the active site of the 
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HIV PR.u9 It was reasoned that the presence of the tetrazole ring would force compound 
1.9 into a bioactive conformation similar to that of JG 365 (1.10). u 9 
AcHNSer-Leu-AsnNH 
-
0 
1.10 ILe-ValOMe 
QC=N-(2-Quinolinylcarbonyl) 
Another peptidomimetic, compound 1.11, is an analogue of the bioactive peptide 
cholecystokinin, which acts as a gastrointestinal mediator and as a neurotransmitter. us It 
has been suggested that the cis conformation about the Trp-N-(Me )Nle peptide bond is 
responsible for the activity of 1.11 at the cholecystokinin receptor .us However, 
replacement of the Trp-N-(Me)Nle moiety in 1.11, by the tetrazole mimic 
(Try\ji[CN4]Nle ), abolished its activity .us This suggested that the cis conformation about 
the Trp-N-(Me)Nle peptide bond is not responsible for the activity of 1.11.1.15 
Gly-Trp-N-(Me )Nle-Asp-PheNH2 1.11 
The biologically active peptide, bradykinin (1.12), is a potent mediator of blood vessel 
dilation, muscle contraction, pain, inflammation, and vascular permeability .15 It has been 
suggested that the cis conformation of the Ser-Pro peptide bond is recognised at the 
bradykinin receptor.'-5 However, peptidomimetics, in which the Ser-Pro moiety was 
17 
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replaced by the cis peptide bond mimic (1.7, RIR1=Me) were inactive.u4 Further, when 
the cis peptide bond mimic (1.1) (mentioned above) was incorporated into 1.12 (replacing 
the Ser-Pro moiety) a significant decrease in activity resulted.1.5 These studies suggest 
that the cis Ser-Pro conformation is not recognised at the bradykinin receptor.1.5 
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg 1.12 
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Results and Discussion 
Part 1. The Design and Synthesis of a Cis Peptide Bond Mimic 
This section presents the design and synthesis of the heterocyclic pyrrole (1.13), 
developed a.-; a cis peptide bond mimic. As discussed in the introduction to this chapter, 
cis peptide bond mimics, such as 1.7, provide an important tool to enhance metabolic 
stability and probe receptor specificity in biological systems.u6 The methodology has 
been developed to connect a number of amino acids to Gly, giving the dipeptide analogue 
(1.13). The presence of the pyrrole ring locks 1.13 into the conformation adopted by a 
dipeptide possessing a cis peptide bond (see Figure 1.3). Further, it has been 
demonstrated that the amino group of 1.13 can be protected, allowing chain extension at 
the carboxyl terminus to give compounds of the type 1.14. 
Figure 1.3. The cis peptide bond mimic (1.13) compared to a natural dipeptide. 
cis Amide Bond Mimic (1.13) Dipeptide (cis configuration) 
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The heterocylic pyrrole (1.13) possesses a number of advantages over other cis peptide 
bond mimics, such as 1.5 and 1.7. Importantly, the synthesis of 1.13 enables control of 
the stereochemistry of the C terminal amino acid, whereas 1.5 is racemic at the CHCH2Ph 
carbon.u2 Further, the presence of a nitrogen in the ring of 1.13 provides a closer mimic 
to a natural peptide bond than the benzene ring of 1.5, with a five membered ring (as in 
1.13) producing less steric bulk than a six membered ring (as in 1.5). Finally, problems 
of racemisation and cyclisation associated with the original synthesis of the tetrazole 
(1.7) are avoided.u6 
Me 
I 
BocN 
1.5 1.7 
The synthesis of compound 1.13 is shown in Scheme 1.1. Step 1, the insertion of an 
amino acid into 2,5-dimethoxytetrahydrofuran to give the pyrrole (1.15), 1.2o, 1.21 has been 
demonstrated for a variety of amino acids and even proposed as a method of N-protection 
of amino acids.1.21 Here, compounds 1.15b and 1.15d were prepared as demonstrated by 
Kashima et al.1.21 and, further, 1.15c was synthesised by this methodL21 (see Scheme 1.1). 
Although the acidic reaction conditions encouraged polymerisation of the pyrrole 
nucleus, the crude reaction mixtures were successfully purified by column 
chromatography. To demonstrate that racemisation at the carbon alpha to the nitrogen 
had not occurred, 1.15b was hydrolysedL22 to give the free acid (1.16). Compound 1.16 
was then coupled to L-Phe ethyl ester hydrochloride, under standard conditions, '-23 to 
give 1.17 (see Scheme 1.2). Analysis, by 1H NMR spectroscopy, revealed the presence 
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of a single diastereoisomer in the crude reaction mixture, demonstrating the enantiomeric 
purity of 1.15b (>95% ). 
Scheme l.l 
MeO-D--OMe 
0 
1.13aR=H 
1.13b R=Me 
1.13c R=CH2CH(Me)z 
Step 1 a o~ Step 2b 
-----~~ . N 
MeO,CAR 1.15 
1.15b R=Me 
1.15c R=CH2CH(Me)z 
1.15d R=CH2Ph 
H 
1.18b R=Me 
1.18c R=CH2CH(Me)2 
1.18d R=CH2Ph 
~3c 
H 
N 
~o,cAR u9 
1.19aR=H * 
1.19b R=Me 
1.19c R=CH2CH(Me)z 
1.19d R=CH2Ph 
a.1.21 potassium acetate, HCl H2NCHRC02Me, acetic acid. b.1.22 trimethyl orthoformate, 
titanium tetrachloride, CH2Clz. cL22 MeOH, NaOH, water. d.L24' 1.25 ammonium acetate, 
sodium cyanoborohydride, MeOH. 
* Compound 1.19a was synthesised according to Nudelman et al.L26 (see Scheme 1.4). 
Scheme 1.2 
Stepla o~ 
• 
Step2b. 0 
N 
Et02CY~0Me 
"' 0 1.17 
Ph 
a.1.22 MeOH, NaOH, water. bt.23 L-Phe ethyl ester hydrochloride, Et3N, DCC, CH2Cb. 
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The formylation of 1.15 was initially achieved by the Vilsmeier formylation, 1.27 but the 
reaction gave low yields and an alternative method was investigated. Formylation of 
1.15c, using trimethylorthoformate in the presence of titanium tetrachloride (step 2, 
Scheme 1.1),1.22 had already been demonstrated to give 1.18c and also the 3-formylated 
product (1.20c).1.22 The formylationl.22 of 1.15b and 1.15d was investigated (step 2, 
Scheme 1.1). Formylation1.22 of 1.15b gave a mixture of 1.18b (42%) and the previously 
unreported 3-formylated product (1.20b) (15%), separable by column chromatography. 
Interestingly, formylationl.22 of 1.15d gave only the 2-substituted product 1.18d, also 
unreported. 
1.20bR=Me 
1.20c R=CHCH2(Me )z 
Step 3 (Scheme 1.1), the ester hydrolysis, has been demonstrated for 1.18c, giving 
1.19c.l.22 Hydrolysis of 1.18b and 1.18d were also achieved by this methodl.22 to give 
1.19b and 1.19d, respectively (compound 1.19a was synthesised by an literature 
procedure, 1.26 discussed later). 
H 
1.18a R1=Et 
1.19a R1=H 
Step 4 (Scheme 1.1), the reductive aminationl.24, t.zs of 1.19, effectively introduces a 
second amino acid (Gly) at the 2-position of the pyrrole ring, giving the desired cis 
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locked dipeptide analogue (1.13). Initial investigations into the reductive 
aminationL24, 1.25 of the ethyl ester (1.18a) (synthesised by a literature procedure1.28) gave 
a complex mixture of pyrrolic compounds. However, reductive aminationt.24' t.zs of the 
free acid (1.19a) gave a much cleaner reaction mixture. The reaction was carried out 
using sodium cyanoborohydride and ammonium acetate in methanol. 1.24' 1.25 The product 
(1.13a) conveniently precipitated from the reaction mixture as white crystals, which 
proved to be water soluble and required no further purification. Similarly, reductive 
aminationl.24'1.25 of both 1.19b and 1.19c gave 1.13b and 1.13c, respectively. 
Unfortunately, both these products are soluble in methanol and thus did not precipitate 
from the reaction mixture. Removal of the large excess of ammonium acetate was 
achieved by freeze drying. 
Scheme 1.3 
Step la 
.... 
Boc!IN~ 
N 
H02C~R 
1.21aR=H 
1.21bR=Me 
+Step zb 
BooHN~ 
N 
Eto2cY!l0R 
R1 0 
1.14a R1R 1=H 
1.14b R=Me, R 1=CH2Ph 
a.1.29 Et3N, "Boc-on", acetone/water. b.t.23 HCl H2NCHR1C02Et, Et3N, DCC, HOBT, 
23 
Chapter 1 
To demonstrate chain extension at the carboxyl terminus of the dipeptide mimetics and 
thus the feasibility of the incorporation of structures of the type 1.13 into a linear peptide, 
the synthetic pathway shown in Scheme 1.3 was investigated. Step 1, the protection of 
the amino terminus, enables chain extension of the carboxyl terminus. The reaction of 
both 1.13a and 1.13b with 2-(tert-butoxycarbonyloxyimino )-2-phenylacetonitrile ("Boc-
on"), according to an established method, 1.29 gave the protected amines 1.21a and 1.2lb, 
respectively. 
Compounds 1.21a and 1.21b were initially isolated from the reaction mixture as the water 
soluble triethylamine salts (1.22a and 1.22b). The 1H NMR spectra of 1.22a and 1.22b 
revealed the presence of one equivalent of triethylamine, unable to be removed, even at 
w-3 mm Hg. Compounds 1.22a and 1.22b were converted to the corresponding free 
acids (1.21a and 1.21b) by a standard procedure.1.29 
1.22aR=H 
1.22bR=Me 
Step 2 (Scheme 1.3), the dicyclohexylcarbodiimide (DCC) coupling1.23 of 1.21 and an 
amino acid, demonstrated chain extension at the carboxyl terminus. Initially Gly ethyl 
ester hydrochloride was coupledr.23 with 1.21a and the product, tentatively assigned to 
the structure (1.14a), was isolated by column chromatography. Unfortunately, 1.14a was 
unstable and a mass spectrum was unable to be obtained. To investigate chain extension 
further, 1.21b was coupledt.23 with L-Phe ethyl ester hydrochloride, giving 1.14b 
(Scheme 1.3). Compound 1.14b was stable and able to be fully characterised. A 
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1H NMR of the crude reaction mixture indicated that a single stereoisomer had formed 
(Schemes 1.1 and 1.3). 
Initially, an alternative investigation into the synthesis of compounds of the type 1.18 
concentrated on theN-alkylation of 2-formyl pyrrole (Scheme 1.4). This reaction has 
been reported to give 1.18a, 1.18b, and 1.19a.L26' 1.28' 1.30 Although the reaction is 
relatively simple and high yielding, inherent problems render it unsuitable for the 
development of a general method. Firstly, since a clean SN2 reaction cannot be 
guaranteed, the reaction does not allow control of the stereochemistry at the carbon alpha 
to the nitrogen in compounds such as 1.18b. Secondly, there is a limited range of bromo 
ester starting materials commercially available, severely restricting the versatility at R. 
Therefore, the investigation of this synthesis was discontinued in favour of the 
enantioselective and general synthesisl.22 shown in Scheme 1.1. However, compound 
1.19a was conveniently synthesised by this method.1.26 
Scheme 1.4 
H 
0 
N 
H 
H 
1 1.18a R=H, R =Et 
1.18b R/R 1=Me 
1.19a RIR 1=H 
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Part 2. Structure Assignment 
COMPOUND 1.13a 
The 1H NMR spectrum of compound 1.13a was assigned with the aid of nuclear 
Overhauser enhancement (nOe) experiments. Irradiation at o 6.76 (assigned H5 on the 
basis of chemical shift) gave a strong enhancement at o 6.13, thus assigned to H4 (see 
Figure 1.4 for numbering of the pyrrole ring). Further, an nOe was observed between the 
signals at o 6.76 (H5) and 8 4.49 (thus assigned CfuC02H) and between the signals at 
8 6.33 (H3) and o 4.13 (thus assigned CfuNH2). The pattern of signals for the pyrrole 
protons proved to be characteristic of compounds of the type 1.13 (see Table 1.1). To 
assign the 13C NMR spectrum of compound 1.13a, a heteronuclear correlation 
(HETCOR) experiment was performed to distinguish the CH2NH2 carbon at o 41.4 from 
the CH2C02H carbon at o 51.6. The pattern of the pyrrole carbons also proved to be 
characteristic of compounds ofthe type 1.13 (see Table 1.2.). 
Table 1.1. 1H NMR Signals (o) for the Pyrrole Protons of 1.13, 1.21, and, 1.22 
Compound H3 H4 HS 
1.13a 6.33 6.13 6.76 
1.13b 6.29 6.14 6.88 
1.13c 6.18 5.97 6.71 
1.21a 6.13 6.13 6.61 
1.21b 5.99 6.14 6.77 
1.22a 6.05 6.06 6.64 
1.22b 5.97 6.09 6.79 
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Figure 1.4. Numbering of the pyrrole ring. 
3 4 
R,;/[)s 
N 
I 
R 
1 ,2-disubstituted Pyrrole 1 ,3-disubstituted Pyrrole 
Table 1.2. 13C NMR Signals (a) for the Pyrrole Carbons of 1.13, 1.21. and, 1.22 
Compound C2 C3 C4 C5 
1.13a 123.0 113.0 108.6 126.7 
1.13b 122.0 112.9 108.6 123.0 
1.13c 122.2 112.2 107.8 122.0 
1.21a 127.4 111.5 107.9 123.3 
1.21b 127.7 110.2 107.8 119.0 
1.22a 128.9 109.8 107.4 124.4 
1.22b 129.2 109.1 107.7 120.5 
Amino acids, peptides, and their analogues exist in three pH inter-dependent forms: an 
amine salt (A), a zwitterion (B), or a carboxylate salt (C), as shown in Figure 1.5.1.31 
Infrared and microanalytical data suggested that compound 1.13a exists in the 
zwitterionic form (B, Figure 1.5). The infrared spectrum of 1.13a gave absorptions at 
1576 and 1399 cm-1, characteristic of the C02- anion.1.32 Further, micro-analysis was 
consistent with the absence of a counterion, eliminating compounds both of the type A 
and C (Figure 1.5). 
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Figure 1.5. pH Inter-dependent forms of amino acids, peptides, and their analogues. 
COMPOUND 1.13b 
Compound 1.13b was purified by recrystallisation from methanol and ethyl acetate. The 
1H NMR spectrum of 1.13b was assigned by comparison to that of 1.13a and by 
homonuclear decoupling experiments. The pyrrole protons displayed a similar pattern to 
those of 1.13a (see Table 1.1). Decoupling experiments showed that the signals at S 4.65 
(CHMe) and at S 1.55 (CHMe) were mutually coupled (confirming the assignment of the 
signal at o 4.65 (CHMe), which was partially obscured by the D20 solvent peak). The 
13C NMR spectrum of 1.13b was assigned on the basis of a HETCOR experiment, which 
distinguished between signals at o 41.4 (CH2NH2) and S 57.3 (QHMe) and enabled 
assignment of the pyrrole carbons (Table 1.2. ). In the infrared spectrum of 1.13b, 
absorptions at 1601 and 1388 cm-1 indicated the presence of a carboxylate anion. 
Attempts to obtain a satisfactory micro analysis were unsuccessful. 
COMPOUND 1.13c 
The NMR spectra of 1.13c were assigned by comparison to those of 1.13a and 1.13b. 
The signals for the pyrrole protons followed the pattern typical of compounds of the type 
(1.13) (Table 1.1). A HETCOR experiment distinguished between the signals at o 40.4 
(CH2NH2) and o 39.8 (QH2CH). An infrared spectrum gave absorptions at 1605 and 
1338 cm-1, suggesting a carboxylate anion. 
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COMPOUND 1.14a 
The 1H NMR spectrum of compound 1.14a was assigned with the aid of nOe 
experiments, which distinguished between the CfuNHBoc and CH2CO resonances. 
Enhancements were obtained between the resonances at o 4.67 (CfuCO) and 0 6.69 (HS) 
and between the resonances at 0 4.36 (CfuNHBoc) and 0 6.15 (H3) (see Figure 1.4 for 
numbering of the pyrrole ring). The 13C NMR spectrum of compound 1.14a was 
assigned, on the basis of a HETCOR experiment which clearly distinguished the 
CH2CONH carbon (at o 50.3) from the CH2C02Et carbon (at 0 41.1) and enabled the 
assignment of the pyrrole carbons. Unfortunately, compound 1.14a was unstable and 
thus mass spectral and micro analytical data were unable to be obtained. 
COMPOUND 1.14b 
To assign the 1H NMR spectrum of compound 1.14b, homonuclear decoupling 
experiments were performed to distinguish between the broad signals at 0 4.98 and 
0 4.74, due to the CHMe and CHCH2Ph protons, respectively. The CfuNH protons gave 
rise to a broad doublet of doublets at 0 4.11. The 13C NMR spectrum compound 1.14b 
was assigned by comparison to that of compound 1.21b and the L-Phe ethyl ester 
cation.1.33 Compound 1.14b proved to be more stable than compound 1.14a and a 
satisfactory mass spectrum was obtained. 
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COMPOUND 1.17 
To our knowledge, compound 1.17 is previously unreported and was therefore fully 
characterised. The 1H NMR spectrum of 1.17 was assigned by comparison to that of 
1.15b and L-Phe.L21' 1.34 To assign the 13C NMR spectrum, a HETCOR experiment was 
required to distinguish the resonances at o 58.5 and o 61.5, as the CHMe and CHCH2Ph 
carbons, respectively. 
COMPOUND 1.18d 
The 1H NMR spectra of 2-formylated pyrroles, such as 1.18d, displayed a distinct pattern 
for signals in the pyrrole region of the spectrum. As shown in Table 1.3, resonances were 
found for H3 close to o 7 .0, for H4 between o 6.2 and o 6.4, and H5 close to o 7.2 (see 
Figure 1.4 for numbering of the pyrrole ring). Further, the signal due to the aldehyde 
proton was found close too 9.5, and the alpha proton (CHR) showed an downfield shift 
to lie between o 5.9 and o 6.1 (due to the deshielding effect ofthe carbonyl group). The 
1H NMR spectrum of compound 1.18d displayed this characteristic pattern of 2-
formylation, although the signal for H5 was shifted upfield too 7.01 (Table 1.3). The 
aldehyde signal was also in an upfield position at o 9.43. The signal for the alpha proton 
(CHR) demonstrated a characteristic downfield shift too 6.06. The signal for H5 was 
obscured by signals due to the phenyl group, and homonuclear decoupling experiments 
were required to assign H5. Irradiation at o 6.91 (H3) gave simplification at o 6.06 (H4) 
and o 7.01 (thus assigned to H5). Irradiation at o 7.01 gave simplification at o 6.06 (H4) 
and o 6.91 (H3). 
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Table 1.3. 1H NMR Signals (8) for 2-Formyl Pyrroles (1.18) & 3-Formyl Pyrroles (1.20) 
Compound H2 H3 H4 H5 CHO CHR 
1.18b 7.0 6.32 7.18(br) 9.52 5.90 
1.18c 6.97 6.33 7.20(br) 9.53 6.10 
1.18d 6.91 6.22 7.01 9.43 6.06 
1.20b 7.41 6.67 6.76 9.77 4.80 
1.20c 7.37 6.56 6.73 9.80 4.65 
COMPOUND 1.19d 
Compound 1.19d is previously unreported and was thus fully characterised. NMR 
spectra were assigned by comparison to those of compound 1.18d. 
COMPOUND 1.20b 
The 1H NMR spectrum of compound 1.20b was assigned by comparison to literature data 
for compound 1.20c. 1.22 The signals for the pyrrole protons exhibited a characteristic 
pattern, confirming 3-substitution (see Table 1.3). Further, the aldehyde proton resonated 
at 8 9.77 and the alpha proton (CHR) at 8 4.80. Table 1.3 demonstrates that these shifts 
are distinct from the signals observed for 2-formylated pyrroles, such as 1.18d discussed 
above. 
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COMPOUNDS 1.21a and 1.2lb 
The NMR spectra of compound 1.21a were assigned by comparison to those of 
compound 1.22a and further by nOe experiments, which distinguished between the 
CHzNH and CH2C02H proton resonances. Irradiation at 0 6.13 (H3) gave an 
enhancement at 0 4.27 (thus assigned CH2NH) and irradiation at 0 6.61(H5) led to an 
enhancement at o 4.71 (thus assigned CH2C02H) (see Figure 1.4 for numbering of the 
pyrrole ring). The 1H NMR spectrum of compound 1.21b was difficult to assign due to 
extreme broadening of the signals for the CHMe and CHzNH protons and nOe 
experiments were performed. Irradiation at o 5.99 (H3) gave an enhancement at o 4.55 
(CH2NH), and irradiation at 0 4.55 gave an enhancement at o 5.99 (H3) and o 4.05. 
Further, irradiation at o 4.05 gave an enhancement at o 4.55. This nOe between o 4.05 
and 0 4.55 suggested that both these signals were due to the CHzNH signal. This was 
confirmed by proton-proton correlation spectroscopy (COSY), which distinctly showed 
correlation between these signals. 
COMPOUNDS 1.22a and 1.22b 
A marked upfield shift was observed for the signal due to H3 in the 1H NMR spectra of 
1.22a and 1.22b (in comparison to 1.13a and 1.13b )-see Table 1.1. This is presumably 
due to the effect of the Boc group. For compound 1.22b, nOe experiments distinguished 
the signals at o 6.09 and o 5.97, due to H4 and H3 respectively. Irradiation of the doublet 
of doublets at o 4.26, due to the CH2NH protons, gave a strong enhancement at o 5.97 
(thus assigned to H3), and irradiation at o 5.97 gave a weak enhancement for signals due 
to CHzNH and H4, confirming the assignment. However, for compound 1.22a, nOe 
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experiments failed to distinguish between the signals at o 6.05 and o 6.06 (H3 and H4), 
although the broad nature of the signal at o 6.05 suggested assignment to H3. The signal 
due to H3 was broadened in compounds 1.22b, 1.21a, and 1.21b. To further assign the 
1H NMR spectrum of compound 1.22a, the signals due to CH2C02H and CHzNH were 
distinguished by a HETCOR experiment which correlated the 1H NMR resonance at 
o 4.44 to the 13C NMR signal at o 50.8 (assigned to the CH2C02H carbon on the basis of 
chemical shift and distinguished from the signal for the CH2NH2 carbon, which is 
broadened and close to o 40). Table 1.2 lists the 13C NMR resonances for the pyrrole 
carbons of 1.22a and 1.22b. For compound 1.22b, the signals due C3 and C4 were 
distinguished on the basis of a HETCOR experiment, and those for compound 1.22a were 
assigned by comparison to 1.22b. For both compounds, the signals for C3 were 
broadened and the resonances for C2 demonstrated a downfield shift on addition of 
"Boc" (in comparison to 1.13a and 1.13b)-see Table 1.2. 
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Experimental 
General Procedure 
Melting points (m.p.) were taken on a Reichert hot-stage microscope and are uncorrected. 
Nuclear Magnetic Resonance (NMR) spectra were recorded on either a Varian CFT300 
or aXL300 spectrometer. Mass spectra (MS) were obtained on a Kratos MS80RFA 
spectrometer. Infrared (IR) spectra were recorded on a Shimadzu FTIR-8201PC 
spectrophotometer. The amino acids (glycine ethyl ester hydrochloride, L-phenylalanine 
ethyl ester hydrochloride, and L-leucine methyl ester hydrochloride) were commercially 
available. 
Preparation1.24' 1.25 of N-Carboxymethyl-2-aminomethylpyrrole (1.13a) 
To a stirring solution of 882 mg (5.7 mmol) of 1.19a (synthesised by a literature 
procedure1.26) and 3.624 g (47 mmol) of ammonium acetate in dry methanol (MeOH) 
(20 ml), was added 195 mg (3.1 mmol) of sodium cyanoborohydride and stirring was 
continued at room temperature (r.t.). Compound 1.13a formed as a white precipitate 
overnight and was isolated by filtration (585 mg, 67%) m.p. 170-172 °C. 
Spectral data for 1.13a: 
1H NMR (Dp) 8 6.76 (m, 1H, H5); 6.33 (m, 1H, H3); 6.13 (m, 1H, H4); 4.49 (s, 2H, 
CfuC02); 4.13 (s, 2H, CH2NH2). 13C NMR (D20) 8177.5 (C02); 126.7 (C5); 123.0 (C2); 
113.0 (C3); 108.6 (C4); 51.6 ~H2CO); 41.4 (CH2NH). MS (m/z) 154 (M+, 59%); 152 
(M+-2H, 6%); 139 ( M+-NH, 8%). Anal. Calculated for C7H12N20 3: C 48.8, H 7.0, N 
16.3. Found: C 49.1, H 7.0, N 16.5. FTIR (KBrDisc) 319l(br); 2361; 1576 cm-1• 
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Preparation1.24' 1.zs of (S)-N-0-CarboxyethyD-2-aminomethylpyrrole (1.13b) 
To a stirring solution of 615 mg (3.7 mmol) of 1.19b and 2.274 g (29.5 mmol) of 
ammonium acetate in MeOH (9.3 ml), was added 126 mg (2.0 mmol) of sodium 
cyanoborohydride. The resultant solution was stirred at r.t. for two days, and the solvent 
was evaporated under reduced pressure. Water (100 ml) was then added to the residue, 
the mixture was washed with ethyl acetate (3x), and the aqueous layer was freeze dried to 
remove the ammonium acetate. The resultant solid was recrystallised from methanol and 
ethyl acetate to give 1.13b as white crystals (306 mg, 49%.) m.p.170 °C (decomposed). 
Spectral data for 1.13b: 
1H NMR (Dp) o 6.88 (m, 1H, H5); 6.29 (m, 1H, H3); 6.14 (m, 1H, H4); 4.65 (q, 1H, 
1=7.2 Hz, CHMe); 4.14 (q, 2H, 1=7.3 Hz, CH2); 1.55 (d, 3H, 1=7.0 Hz, CHMe). 
13C NMR (D20) o 179.4 (COz); 123.0 (C5); 122.0 (C2); 112.9 (C3); 108.6 (C2); 57.3 
(CHMe); 41.4 (CH2NH); 18.0 (CHMe). HRMS Calculated for C8H11N20 2Naz: 
213.06165. Found: 213.06167. FTIR (thin film) 3424; 2988; 1601 cm-1• 
Preparation1.24• 1.25 of (S)-N-(1-Carboxy-3-methylbutyl)-2-aminomethylpyrrole (1.13c) 
To a stirring solution of 767 mg (3.5 mmol) of 1.19c (synthesised by a literature 
procedureL22) and 2.120 g (27.5 mmol) of ammonium acetate in MeOH (9.2 ml), was 
added 113 mg (1.8 mmol) sodium cyanoborohydride. The resultant solution was stirred 
at r.t. for two days and the solvent was evaporated under reduced pressure. Water (100 
ml) was then added to the residue, the mixture was washed with ethyl acetate (3x), and 
the aqueous layer was freeze dried to remove the ammonium acetate to give a white solid 
(466 mg, 64%) m.p. 195 °C (decomposed). 
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Spectral data for 1.13c: 
1H NMR (CD30D) b 6.71 (m, 1H, H5); 6.18 (m, 1H, H3); 5.97 (m, 1H, H4); 4.60 (m, lH, 
CHC02); 4.07 (q, 2H, J=13.7 Hz, C!LNH2); 1.80 (m, 2H, CHC!b); 1.16 (m, 1H, 
CH(Me)z); 0.71 (d, 3H, J=6.8 Hz, Me); 0.69 (d, 3H, J=6.8 Hz, Me). 13C NMR (D20) 
o 178.7 (C02); 122.2 (C2); 122.0 (C5); 112.2 (C3); 107.8 (C4); 60.1 (CHC02); 40.4 
(CH2NH); 39.8 (CH2CH); 24.4 (CH(Me)2); 22.2 (Me); 21.0 (Me). HRMS Calculated for 
C11H17N20 2 : 209.12899. Found: 209.12869. FTIR (thin film) 3453; 2955; 1677; 
1605 cm-1• 
Preparation 1.23 of N- [(Ethoxycarbonylmethyl)carbamoylmethyll-2-tert-
butoxycarbonylaminomethylpyrrole (1.14a) 
To a stirring solution of 70 mg (0.28 mmol) of 1.21a in dichloromethane (CH2Cl2) (3.0 
ml), were added 0.28 mmol of each glycine ethyl ester hydrochloride (39 mg), 
triethylamine (Et3N) (28 mg), dicyclohexylcarbodiimide (DCC) (58 mg), and 1-
hydroxybenzotriazole (HOBT) (38 mg). The resultant solution was stirred at r.t. 
overnight, after which the solvent was removed under reduced pressure. Ethyl acetate 
was then added to the residue to precipitate the dicyclohexylurea (DCU) byproduct, 
which was removed by filtration. The filtrate was washed (3x) with saturated sodium 
bicarbonate (NaHC03), dried with magnesium sulfate (MgS04), and the solvent was 
evaporated under reduced pressure. The crude mixture was purified by column 
chromatography on silica (70% dichloromethane, 30% ethyl acetate) to give 1.14a as a 
yellow oil (28 mg, 30%). 
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Spectral data for 1.14a: 
1H NMR (CDCb) o 6.69 ( m, 1H, H5); 6.21 (m, 1H, H4); 6.15 (m(br), 1H, H3); 4.67 (s, 
2H, CH2CONH); 4.36 (s, 2H, C.HzNHBoc); 4.16 (q, 2H, J = 7.0 Hz, C.HzMe); 3.95 (d, 
2H, 1=5.5 Hz, C.HzC02Et); 1.47 (s, 9H, C(Me)3); 1.24 (t, 3H, 1=1.0 Hz, CH2Me). 
13C NMR (CDCh) o 169.3, 168.8 (CO); 154.7 (C02C(Me)g); 128.0 (C2); 123.2 (C5); 
111.7 (C3); 109.1 (C2); 81.5 (C(Me)g); 61.5 (CH2Me); 50.3 (CH2CONH); 41.1 
(CH2C02Et); 39.6(br) (CH2NHBoc); 28.2 C(Me)3); 14.1 (CH2Me). FTIR (nujol) 
3318(br); 2979; 2931; 1746; 1681 cm-1• 
Preparation 1.23 of (S,S)-N-[{1-Ethoxycarbonyl-2-phenylethyl)-1-carbamoylethyll-2-tert-
butoxycarbonylaminomethylpyrrole Cl.l4b) 
To a stirring solution of 46 mg (0.17 mmol) of 1.2lb in CH2Clz (2.0 ml), were added 0.17 
mmol of each L-phenylalanine ethyl ester hydrochloride (39 mg), Et3N (16 mg), DCC (35 
mg), and HOBT (24 mg). The resultant solution was stirred at r.t. overnight, after which 
the solvent was removed under reduced pressure. Ethyl acetate was added to the residue 
to precipitate the DCU byproduct, which was removed by filtration. The filtrate was 
washed (3x) with saturated NaHC03, dried with MgS04, and the solvent was evaporated 
under reduced pressure. The crude mixture was purified by column chromatography on 
silica (70% petroleum ether, 30% ethyl acetate) to give 1.14b as a yellow oil (24 mg, 
32%). 
Spectral data for 1.14b: 
1H NMR (CDCh) 8 7.20 ( m, 3H, ArH); 6.96 (m, 2H, A:rH); 6.60 (m, IH, H5); 6.17 (m, 
1H, H4); 6.07 (m, IH, H3); 4.98 (m(br), 1H, CHMe); 4.74 (X part ABX, 1H, hx=5.3 Hz, 
JBx=6.3 Hz, CHCH2); 4.11 (dd (br), 2H, 1=15.2, 157.3 Hz, C.HzNH); 4.10 (q, 2H, 
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J=6.9 Hz, CH2Me); 3.07 (A part ABX, 1H, JAB=13.6 Hz, hx=5.3 Hz, CHCfu); 2.94 (B 
part ABX, 1H, hB=13.6, JBx=6.3 Hz, CHCfu); 1.43 (s, 9H, C(Me)3); 1.38 (d(br), 3H, 
J=7.2 Hz, CHMe); 1.20 (t, 3H, J=6.9 Hz, CH2Me). 13C NMR (CDC13) o 170.9, 164.8 
(CO); 154.4 ~02C(Me)3); 135.6, 129.3, 128.4, 127.0 (Ar); 118.7 (C5); 111.1(br) (C4); 
108.9 (C3); 106.5 (C2); 81.3 ~(Me)3); 61.4 (CH2Me); 54.6 ~HCH2); 52.9 ~HMe); 
39.0(br) ~H2NH); 37.5 (CH2Ph); 28.2 (C(Me)3); 17.6 (CHMe); 14.1 (CH2Me). HRMS 
Calculated for C24H33N30 5 : 443.24200. Found: 443.2419. FTIR (thin film) 2977; 1739; 
1681 cm-1• 
Preparation l.Zl of (S)-N-(1-Methoxycarbonyl-3-methylbutyl)pyrrole (1.15c) 
To a stirring solution of 5.214 g (28.7 mmol) of L-leucine methyl ester and 4.610 g (47.0 
mmol) of potassium acetate in acetic acid (25 ml), was added 3.670 g (28.7 mmol) of 2,5-
dimethoxyterahydrofuran. The resultant solution was heated under reflux for 3.5 hours, 
after which water (25 ml) was added and the mixture was neutralised with solid NaHC03• 
The organic layer was extracted into ethyl acetate, dried with MgS04, and evaporated 
under reduced pressure. The crude product was purified by column chromatography on 
silica (70% petroleum ether, 30% ethyl acetate) to give 1.15c as a colourless oil (2.714 g, 
48%). Spectral data for 1.15c was identical to published data. 1·22 
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Preparation of (S,S)-N-[(1-Ethoxycarbonyl-2-phenylethyl)-1-carbarnoylethyl]-
pyrrole (1.17) 
Step 11.22 
To a stirring solution of 183 mg (1.2 mmol) of 1.15b (synthesised by a literature 
procedure1.21) in MeOH (10 ml), was added 60 mg (1.5 mmol) of sodium hydroxide 
(NaOH) in water (2.0 ml). The resultant solution was heated uuder reflux overnight, after 
which water (30 ml) was added and the mixture was washed with ether. The aqueous 
layer was acidified (10% hydrochloric acid (HCI)) and the product was extracted into 
ether, dried (MgS04), and the solvent was evaporated under reduced pressure to give the 
intermediate (1.16) as a white solid (120 mg, 72 %) m.p. 87-89 °C. 
Step 21.23 
To a stirring solution of 100 mg (0.72 mmol) of the intermediate (1.16) in CH2Ch 
(3.0 ml), were added 0.70 mmol of each L-phenylalanine ethyl ester hydrochloride 
(181 mg), Et3N (80 mg), and DCC (163 mg). The resultant solution was stirred at r.t. 
overnight, after which the solvent was removed under reduced pressure. Ethyl acetate 
was then added to the residue to precipitate the DCU byproduct, which was removed by 
filtration. The filtrate was washed (3x) with saturated NaHC03, dried with MgS04, and 
the solvent was evaporated under reduced pressure. The crude mixture was purified by 
column chromatography on silica (60% dichloromethane, 30% ethlyl acetate) to give 
(1.17) as a yellow oil (148 mg, 65%). 
Spectral data for 1.16: 
1H NMR (CD30D) o 6.75 (t, 2H, 1=2.3 Hz, H2); 6.05 (t, 2H, 1=2.1 Hz, H3); 4.82 (q, lH, 
1=7.3 Hz, CHMe); 1.64 (d, 3H, 1=7.5 Hz, CHMe). 
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Spectral data for 1.17: 
1H NMR (CDCh) 8 7.23 (m, 3H, ArH); 6.96 (m, 2H, ArH); 6.62 (m, 2H, H2); 6.22 (m, 
2H, H3); 5.63 (d(br), 1H, J=7.0 Hz, NH); 4.73 (X part ABX, 1H, hx=6.1 Hz, JBx=6.5 Hz, 
CHCH2); 4.64 (q, lH, J=7.0 Hz, CHMe); 4.13 (q, 1H, J=7.0 Hz, OCH2); 3.08 (A part 
ABX, 1H, hB=7 .0 Hz, hx=6.1 Hz, CHCHz); 2.93 (B part ABX, 1H, hB=7 .0 Hz, 
JBx=6.5 Hz, CHC.tlz); 1.67 (d, 3H, J=7.1 Hz, CHMe); 1.22 (t, 3H, J=7.0 Hz, CH2Me). 
13C NMR (CDCb) o 171.4, 170.9 (CO); 135.4, 129.2, 128.5, 127.1 (Ar); 119.6 (C2); 
109.7 (C3); 61.5 (CHCH2); 58.5 (CHMe); 52.9 (CH2Me); 37.5 (CHCH2); 17.4 (CHMe); 
14.1 (CH2Me). HRMS Calculated for CtaH22Nz03: 314.16303 Found: 314.1631. FTIR 
(thin film) 3315; 2933; 2856; 1738; 1681; 1650 cm-1• 
Preparation 1.22 of (S)-N-Cl-Methoxycarbonylethyl)-2-formylpyrrole (1.18b) and (S)-N-0-
MethoxycarbonylethyD-3-formylpyrrole (1.20b) 
To a stirring solution of 1.004 g (9.4 mmol) oftrimethylorthoformate in CH2C}z (25 ml), 
at -40 °C, under a nitrogen atmosphere, was added 1.770 g (9.3 mmol) of titanium 
tetrachloride, followed by 1.200 g (7.8 mmol) of 1.15b (synthesised by a literature 
procedure1.21), also in CH2Cl2 (10 ml). The resultant mixture was stirred at -40 °C for 
1.5 hours and then allowed to warm to r.t. Water (5.0 ml) was added and the organic 
layer wa..;; extracted into ether, dried over MgS04, and evaporated under reduced pressure. 
Column chromatography on silica (30% ethyl acetate, 70% petroleum ether) gave 1.18b 
(594 mg, 42%) and 1.20b (218 mg, 15%) as colourless oils. Spectral data for 1.18b was 
identical to published data.130 
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Spectral data for 1.20b: 
1H NMR (CDCh) o 9.77 (s, 1H, CHO); 7.41 (m, 1H, H2); 6.76 (m, lH, HS); 6.67 (m, 1H, 
H4); 4.80 (q, 1H, 1=7.5 Hz, CHMe); 3.76 (s, 3H, C02Me); 1.77 (d, 3H, 1=7.0 Hz, 
CHMe). 13C NMR (CDCb) o 185.1 (CHO); 170.5 (C02); 128.2 (C2); 126.5 (C3); 122.5 
(C5); 107.8 (C4); 57.1 (CHMe); 52.6 (OMe); 18.0 (CHMe). HRMS Calculated for 
C9HuN03: 181.07389. Found: 181.0737. FTIR (thin fllm,) 3118; 2954; 2810; 1747; 
1666 cm-1• 
Preparation 1'22 of (S)-N-( 1-Methoxycarbonyl-2-phenylethyl)-2-formylpyrrole (1.18d) 
To a stirring solution of 1.581 g (14.9 mmol) oftrimethylorthoformate in CH2Cl2 (50 ml), 
at -40 °C, under a nitrogen atmosphere, was added 2.827 g (14.9 mmol) of titanium 
tetrachloride, followed by 2.845 g (12.4 mmol) of l.lSd (synthesised by a literature 
procedureL21) also in CH2Cl2 (2.5 ml). The resultant mixture was stirred at -40 °C for 
1.5 hours and then allowed to warm to r.t. Water (25 ml) was added and the organic layer 
was extracted into ether, dried over MgS04, and evaporated under reduced pressure. 
Column chromatography on silica (20% ethyl acetate, 80% petroleum ether) gave 1.18d 
as a yellow oil (2.400 g, 75%). 
Spectral data for 1.18d: 
1H NMR (CDCh) o 9.43 (d, 1H, 1=1.0 Hz, CHO); 7.20 (m, 5H, ArH); 7.01 (m, 1H, HS); 
6.91 (m, 1H, H3); 6.22 (m, 1H, H4); 6.06 (X part ABX (br), 1H, hx=5.9 Hz, 1Bx=9.7 Hz, 
CHCH2); 3.74 (s, 3H, Me); 3.55 (A part ABX, 1H, hB=14.2 Hz, hx=5.9 Hz, Clli); 3.26 
(B part ABX, IH, hB=14.2 Hz, 1Bx=9.7 Hz, CHz). 13C NMR (CDCb) o 179.5 (CHO); 
170.3 (C02); 136.0, 128.9, 128.4, 126.9 (Ar); 130.6 (C5); 128.2 (C2); 125.6 (C3); 110.2 
(C4); 61.0 (CHCH2); 52.6 (Me); 39.0 (CH2). MS (m/z) 258 (22%, M+); 257 (100%, 
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M+-H); 240 (2%); 229 (2%); 228 (4%); 226 (4%); 198 (30%). FTIR (thin film) 3101; 
3029; 2953; 1743; 1604cm-1• 
Preparation 1.22 of (S>-N-0-Carboxyethyl)-2-formylpyrrole (1.19b) 
To a stirring solution of 500 mg (2.7 mmol) of 1.18b in MeOH, was added 135 mg (3.2 
mmol) of NaOH in water ( 4.7 ml). The resultant mixture was heated under reflux 
overnight and then water (50 ml) was added and the mixture was washed with ether. The 
aqueous layer was acidified (10% HCl) and the product was extracted into ether, dried 
(MgS04), and the solvent was evaporated under reduced pressure to give 1.19b as a white 
solid (374 mg, 83% ). Spectral data for 1.19b was identical to published data.uo 
Preparation 1.22 of (S)-N-( 1-Carboxy-2-phenylethyl)-2-formylpyrrole (1.19d) 
To a stirring solution of 300 mg (1.2 mmol) of 1.18d in MeOH (15 ml), was added 56 mg 
(1.4 mmol) of NaOH in water (2.0 ml). The resultant solution was heated under reflux 
overnight, after which water (30 ml) was added and the mixture was washed with ether. 
The aqueous layer was acidified (10% HCl) and the product was extracted into ether, 
dried (MgS04), and the solvent was evaporated under reduced pressure to give 1.19d as 
an orange solid (238 mg, 82%.) m.p. 119-121 °C. 
Spectral data for 1.19d: 
1H NMR (CDCh) o 9.42 (d, 1H, J=0.7 Hz, CHO); 8.15 (s(br), 1H, OH); 7.18 (3H, m, 
ArH); 6.96 (m, 4H, ArH, H5, and H3); 6.20 (m, 1H, H4); 6.00 (X part ABX(br), 1H, 
hx=4.8 Hz, Jsx=10.0 Hz, CHCH2); 3.60 (A part ABX, 1H, ha=14.5 Hz, hx= 4.8 Hz, 
CHCH2); 3.31 (B part ABX, 1H, hs=14.5 Hz, 1sx=l0.0 Hz, CHC.Hz). 13C NMR (CDCb) 
42 
Chapter 1 
8 179.9 (CHO); 174.1 (C02); 135.9, 128.9, 128.5, 127.0 (Ar); 131.3 (C5); 126.2 (C3); 
110.4 (C4); 61.2 (QHCH2); 38.4 (CHCH2). MS (rnlz) 243 (67%, M+); 199 (11 %, M+-
C02); 198 (5%, M"-C02H); 170 (5%); 168 (18%); 167 (9%). FTIR (KBr Disc) 2926(br); 
1737; 1658; 1622; 1530 cm-1• 
Preparation1'29 of N-(Carboxymethyl)-2-tert-butoxycarbonylaminomethylpyrrole (1.21a) 
Step 1 
To a stirring solution of 600 mg (3.9 mmol) of 1.13a aud 788 mg (7.8 mmol) of Et3N in 
acetone aud water (1:1) (70 ml), was added 1921 mg (7.8 mmol) of2-(tert-
butoxycarbonyloxyimino)-2-phenylacetonitrile ("Boc-on"). The resultant solution was 
stirred at r.t overnight, filtrated, aud the solvent was removed from the filtrate under 
reduced pressure to give the intermediate (1.22a) as a colourless oil (818 mg, 59%). 
Step 2 
A solution of 818 mg (2.3 mmol) of the intermediate (1.22a) in water (20 ml), at 0 °C, 
was adjusted to pH 2 with 5 M HCI. The product was then extracted into ethyl acetate, 
washed with 5% HCl, aud dried (MgS04). The solvent was removed under reduced 
pressure to yield 1.21a as a colourless oil (489 mg, 49%). 
Spectral data for the intermediate (1.22a): 
1H NMR (D20) 8 6.64 (m, lH, H5); 6.06 (m, 1H, H4); 6.05 (m(br), lH, H3); 4.44 (s, 2H, 
CIL,CO); 4.23 (s(br), 2H, CH2NH); 3.12 (q, 6H, J=7.5 Hz, N(CH2Me)3); 1.20 (t, 9H, 
J=7.0 Hz, N(CH2Me)3); 1.40 (s, 9H, C(Me)3). 13C NMR (D20) 8 177.0 (C02); 157.2 
(C02C(Me)3); 128.9 (C2); 124.4 (C5); 109.8(br) (C3); 107.6 (C4); 82.9 (C(Me)3); 50.8 
(CH2CO); 47.4 N(QH2Me)3); 40.9(br) (QH2NH); 28.5 (C(Me)3); 9.0 (N(CH2Me)3). 
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Spectral data for 1.21a: 
1H NMR (CDCb) a 8.65 (s(br), 1H, OH); 6.61 (m, 1H, H5); 6.13 (m, 2H, H4 and H3); 
4.71 (s, 2H, CfuCO); 4.27 (s, 2H, CHzNH); 1.45 (s, 9H, C(Me)3). 13C NMR (CDCh) 
a 176.9 (C02H); 154.9 (C02C(Me)3); 127.4 (C2); 123.3 (C5); 111.5 (C3); 107.9 (C4); 
81.7 (.C(Me)3); 48.1 (CH2CO), 39.5(br) (CH2NH); 28.3 (C(Me)3). MS (rnlz) 254 (15%, 
~); 197 (30%, ~-Bu); 153 (17%). FTIR (nujol) 4325; 2724; 1727 cm-1. 
Preparation1·29 of (S)-N-(1-CarboxyethyD-2-tert-butoxycarbonylaminomethyl-
pyrrole (1.21b) 
Step 1 
To a stirring solution of 54 mg (0.32 mmol) of 1.13b and 65 mg (0.64 mmol) of Et3N in 
acetone and water (1:1) (5.5 ml), was added 158 mg (0.64 mmol) of "Boc-on". The 
resultant solution was stirred at r.t. overnight, filtrated, and the solvent was removed from 
the filtrate under reduced pressure to give the intermediate (1.22b) as a colourless oil 
(65 mg, 55%). 
Step 2 
A solution of 65 mg (0.18 mmol) of the intermediate (1.22b) in water (1.0 ml), at 0 °C, 
and was adjusted to pH 2 with 5 M HCI. The product was then extracted into ethyl 
acetate, washed with 5% HCI, and dried (MgS04). The solvent was removed under 
reduced pressure to yield 1.21b as a colourless oil (37 mg, 43% ). 
Spectral data for the intermediate (1.22b): 
1H NMR (D20) a 6.79 (m, lH, H5); 6.09 (m, lH, H4); 5.97 (m, 1H, H3); 4.60 (q, 1H, 
J=7.0 Hz, CHMe); 4.26 (dd, 2H, J=16.2, 58.9 Hz, CH2NH); 3.10 (q, 6H, 1=7.3 Hz, 
N(CHzMe)3); 1.50 (d, 3H, J=7.3 Hz, CHMe); 1.41 (s, 9H, C(Me)3); 1.19 (t, 9H, 1=5.6 Hz, 
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N(CH2Me)3). 13C NMR (Dp) 8 179.8 (COz); 157.3 (Q02C(Me)3); 129.2 (C2); 120.5 
(C5); 109.1 (C3); 107.7 (C4); 83.0 (Q(Me)3); 57.0 (CHMe); 47.3 (N(QH2Me)3); 41.l(br) 
(QHzNH); 28.5 (C(Me)3); 19.3 (CHMe); 9.1 (N(CH2Me)3). 
Spectral data for 1.21b: 
1H NMR (CDCh) 8 9.08 (s(br), 1H, OH); 6.77 (m, 1H, H5); 6.14 (m, 1H, H4); 5.99 (m, 
1H, H3); 4.55 (m (br), 1H, CHzNH); 4.29 (m(br), 1H, CHMe); 4.05 (m (br), 1H, 
CHzNH); 1.68 (d, 3H, J=7.4Hz, CHMe); 1.40 (s, 9H, C(Me)J). 13C NMR (CDC13) 
8 176.9 (Q02H); 155.1 (Q02C(Me)3); 127.7 (C2); 119.0 (C5); 110.2(br) (C3); 107.8 (C4); 
81.4 (Q(Me)3); 52.9 (CHMe); 39.2(br) (CH2NH); 28.2 (C(Me)3); 17.7 (CHMe). MS 
(m/z) 268 (55%, M+); 224 (5%, ~-COz); 224 (8%, M+-C02H); 212 (66%); 211 (92%, 
~-Bu, 92%). FTIR (nujol) 3363; 2977; 1733; 1682 cm-1• 
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Chapter 2. Epoxide-Based Inhibitors of the HIV Protease 
Introduction 
The spread of Acquired Immune Deficiency Syndrome (AIDS) has reached catastrophic 
dimensions.2·1• 2·2• 2·3 It is currently estimated that there are ten million people infected and 
that this figure could rise to 20 million by the year 2000.2'3 This pandemic has promoted 
an unprecedented scientific and clinical effort to understand and to combat this lethal 
disease. 2'1' 2'2 
AIDS results from infection of the lymphocytes by the Human Immunodeficiency Virus 
(HIV), causing serious defects in cell mediated immunity.2·1 This results in opportunistic 
infections, neurological and neoplastic diseases, and ultimately death.2.1 An 
understanding of the molecular events critical to the replication of HIV has enabled the 
development of chemotherapeutic interventions. Inhibitors of reverse transcriptase, such 
as azidothymidine (AZT), and more recently HIV protease inhibitors are currently in 
clinical use for the treatment of AIDS. 2·2• 2.4 
Part L Biochemistry of HIV 
HIV has been identified as a retrovirus of the Lentiviridae family, existing as two 
genetically distinct subtypes, denoted as HIV 1 and HIV 2.2·1•2·2 HIV 1 is the pathogen of 
greater consequence.2'2 HIV 1 replicates, primarily, in the human T4+ lymphocytes.2·2• 2·5 
Replication begins with the binding of a virion to the surface of a lymphocyte.2·2• 2'5 The 
virion is internalised by the cell and its RNA genome and retroviral enzymes are 
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released.2'2' 2'5 Double stranded DNA is produced from the RNA genome by the action of 
the retroviral enzymes (including reverse transcriptase) and is incorporated into the host 
cell genome. 2'2' 2·5 Cellular enzymes then perform the expression of the viral genes, 
resulting in the synthesis of structural and enzymatic proteins which exist in immature 
forms within polyproteins.2'2' 25 These immature proteins aggregate at the cell 
membrane-which begins to bud off-and viral RNA is drawn into the nascent virion.2·2• 2·5 
Maturation of the immature viral proteins is effected by the action of a virally encoded 
enzyme, the HIV protease (HIV PR).2'2' 25 This completes the replication cycle and the 
resulting virions are able to infect an adjacent cell. 2'2' 2·5 
The genome of the virus, contained within a dimer of single stranded RNA, consists of 
three major genes-gag, pol, and env.2·1• 2·2• 25 The gag gene encodes structural proteins 
which require processing by the HIV PR.2.1. 2'2' 2·5 The pol gene contains the transcript for 
viral enzymes, including the HIV PR, and is translated as the result of a frameshift within 
gag (evasion of the termination codon of gag) to give a gag-pol polyprotein. 2.1. 2 '2' 2·5 
Autocleavage of this polyprotein releases the active HIV PR, which then processes other 
viral proteins contained within the gag-pol polyprotein and the structural proteins arising 
from the gag gene.Z·2• 2·6 Finally, the env gene encodes the surface proteins of the virion, 
responsible for binding to the host cel1.2·1 
The proteolytic processing by the HIV PR is vital to viral replication.2.1· 2·2 Abolition of 
the activity of the HIV PR by site directed mutagenesis produces mutant virions with 
unprocessed polyproteins, incapable of infecting new cells.2·1 This crucial role of the 
HIV PR makes it a prime target for chemotherapeutic intervention.2.1. 2·2• 2·5 Consequently, 
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the HIV PR has been the subject of intense research, culminating in the recent marketing 
of HIV PR inhibitors, such as Saquinavir, discussed later.2·1• 2·2• 2.4 
Part 2. Structural Properties of the HIV PR 
The HIV PR belongs to the family of aspartic acid proteases, named for the pair of 
aspartic acid residues which constitute the catalytic groups in their active sites.2.2 The 
family includes some well known non-viral proteases such as pepsin and renin?·2 
Although there is minimal sequence homology between the retroviral and the classical 
(non-viral) proteases, the catalytic triad, Asp-Thr(Ser)-Gly, is highly conserved.2.1' 2'2 The 
crystal structure of the HIV PR, shown in Figure 2.1, reveals that it exists as a homodimer 
with the active site located at the interface of the monomers. 2.7. 2'8 The monomers, each 
composed of 99 amino acids, are related by a strict two fold axis of rotational symmetry, 
in which each monomer contributes one catalytic triad to a truly symmetric active 
site.n 2'8 The axis of symmetry is perturbed upon the binding of a non-symmetrical 
inhibitor or substrate.2·2 In contrast, other aspartic acid proteases exist as monomers of 
approximately 325 residues. They contain two homologous domains, each of which 
contributes a catalytic triad to a pseudosymmetrical active site.2·8 
The HIV PR is characterised by two conformationally flexible loops, one contributed by 
each monomer (referred to as the "flaps").2·9 The "flaps" close around the substrate in the 
cylindrical substrate binding groove, which accommodates six to seven residues of a 
substrate or inhibitor.2.1. 2·9 The amino acids lining the binding groove are symmetrically 
disposed about the catalytic aspartic acid residues (Asp 251125), centered in the 
hydrophobic active site.2·9 A water molecule, present in all the HIV PR-inhibitor crystal 
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structures solved to date, is a striking feature not known in other aspartic acid 
proteases.2·1• 2·2 This water is hydrogen bonded in a tetrahedral fashion to the amide 
hydrogens of Ile 50/150 residues in the "flap" and to the carbonyl oxygens of residues in 
the inhibitor (see Figure 2.2).2.1, 2·2 It is crucial in bringing together elements of the 
"flaps" with the inhibitor, ensuring that the inhibitor binds in an extended beta sheet-like 
conformation. 2'2 
Figure 2.1. The crystal structure of the HIV PR. 
C2 Axis of Symmetry 
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Figure 2.2. Interactions between an inhibitor and the HIV PR, showing the water bridge 
hydrogen bonded in a tetrahedral fashion to the "flap". 
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Part 3. Catalysis by the HIV PR 
The HIV PR cleaves its substrates at specific sites, spanning remarkably heterogeneous 
amino acid sequences.2·1 At least eight naturally occurring peptide cleavage sites have 
been identified on the gag and gag-pol polyproteins, with a variety of amino acids 
constituting the scissile bond.22' z.Io, z.n Consequently, determinants of substrate 
specificity remain ill-defined.2.1 However, the occurrence of an aromatic-proline 
sequence, in three of the processing sites, has been noted with interest, as hydrolysis N-
terminal to Pro is unusual in mammalian proteases?J The remaining cleavage sites (Leu-
Ala, Met-Met, Phe-Trp, and Phe-Leu) are diverse and reflect a general trend for 
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hydrophobic resides in the Pl and Pl' positions?.!, 2·2• 2.1 1 See Figure 2.3 for definition of 
PIP' ternrinology.2.1 2 
Figure 2.3. Technique for labelling positions flanking the cleavage site. 
Substrate cleavage site 
Several studies have examined the substrate specificity of the HIV PR using 
oligopeptides which contain the cleavage sites identified in the viral polyproteins.2.1. 2·2 It 
was shown that seven residues spanning P4-P3' are required for efficient cleavage.2·1• 2·2 
Small and hydrophobic residues are optimal at P4, with larger residues of variable 
polarity at P3 and P3' .2·2 Hydrophobic residues were shown to be favourable at P2 and 
P2'.2.z 
The mechanism of catalysis by the HIV PR has been investigated by a number of 
workers.Z·2 The proposed mechanism, based on isotope effects and crystallographic and 
kinetic data,2.1 3 is shown in Scheme 2.1. The scissile bond is positioned in the active site, 
such that the negatively charged Asp residue is able to activate a water molecule which 
adds to the carbonyl group of the amide to be cleaved (Scheme 2.1, Step 1).2·5• 2·13 The 
resulting tetrahedral intermediate (2.1) is stabilised by protonation by the other Asp 
residue. Disassembly of the tetrahedral intermediate (2.1), shown in Step 2, releases the 
cleaved substrate. z.s, 2.1 3 
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Scheme2.1 
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Part 4. Inhibition of the HIV PR 
Step 1 
-
Step 2 
Inhibition of the HIV PR represents a viable strategy for developing antiviral agents.2.1 
In fact, the HIV PR is an ideal target for chemotherapeutic intervention for the following 
reasons:2·6 
-The HIV PR is essential to viral replication. 
-Cleavages performed by the HIV PR are not mediated by cellular proteases, such that 
the HIV PR is sufficiently distinct from cellular proteases to allow selective inhibition. 
-The solid knowledge base on other aspartic acid proteases has been extrapolated to 
studies on the HIV PR. 
-The HIV PR has been characterised and can be produced by chemical synthesis or by 
expression of the cloned gene. Rapid assays exist to screen potential inhibitors. 
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The new combination therapies, which attack the virus on several different fronts, 
including by inhibition of the HIV PR, have worked well, even reducing the level of the 
virus to undetectable levels in some patients.2.4 However, administration of a 
combination therapy involves a complicated schedule of drug taking, together with 
dreadful side effects, making it impractical for many HIV patients.2.4 Further, failure of 
patients to adhere to the complex treatment, gives the virus a perfect opportunity to 
develop resistance.2.4 Therefore, there is still a very real need for the development of new 
HIV drug therapies, including improved HIV PR inhibitors, to combat this deadly virus?A 
A classical approach to enzyme inhibition, the incorporation of non-hydrolysable 
transition state mimics into substrate analogues, has generated a number of potent HIV 
PR inhibitors.2·1• 2·2 Such peptidomimetics possess sp3 hybridisation at the central carbon, 
posing for the scissile carbonyl of the substrate, thereby mimicking the tetrahedral 
intermediate (2.1, Scheme 2.1)?·2 An early example, pepstatin A (a known inhibitor of 
the aspartic acid protease renin) was shown to be an inhibitor of the HIV PR (Ki=400-
1400 nM).2.t· 2·2 Pepstatin A (N-isoValeryl-Val-Val-Sta-Ala-Sta) possesses the unusual 
amino acid statine (Sta) which mimics the tetrahedral intermediate (2.1).2.1. 2·2 
OH 0 
H2N~ 
~ OH y Statine (Sta) 
To date, hydroxyethylene-based peptidomimetics have been used extensively, resulting in 
some potent inhibitors of the HIV PR.2'2 Two examples, the tripeptide mimics Ro-31-
8588 (2.2) and L-689,502 (2.3) are notable for their subnanomolar inhibition constants 
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(Ki=0.3 and 0.45 nM, respectively).2.10 The crystal structures of each of these inhibitors 
(2.2 and 2.3) complexed with the HIV PR have been solved.2.1° In both cases, the 
hydroxyl group of the inhibitor is centered about the two active site Asp carboxylates of 
the enzyme?·10 Interestingly, the tert-butoxy groups at theN-termini of the inhibitors (2.2 
and 2.3) occupy the S2 subsite of the enzyme and are critical for potency (see Figure 2.3 
for definition of S terminology2.1 2)_2.1° 
0 
H ~~ XOYN : N H 
0 D 0 -I 2.2 
'-._Ph 
0 
2.3 
In 1990 Roberts and co-workers reported the design of very potent and selective 
inhibitors of the HIV PR containing a hydroxyethylamine transition state mimic.2·2 One 
such compound Ro-31-8959 (2.4) was the first protease inhibitor to be administered to 
humans. Compound 2.4 is known as Saquinavir and is now in clinical use for the 
treatment of HIV infection (IC50<0.4 nM).2.10 In contrast to other hydroxyl containing 
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inhibitors, such as 2.2 and 2.3, the R -stereoisomer of the secondary alcohol of 2.4 
provides the more potent inhibitor.2·2• 2.1° The decahydro-isoquinoline group of 2.4 
substitutes for the proline associated with the S 1' binding pocket and contributes 
considerably to potency.2·2• 2·9• 2'10' The corresponding derivative containing proline in this 
position is 50-fold less potent, suggesting that the decahydro-isoquinoline group 
encourages the inhibitor into a conformation recognised by the enzyme.2·2 Further, 
structure-activity correlations suggest that Phe occupies the S 1 subsite of the enzyme, 
Asn occupies the S2 subsite, the tert-butylamide occupies S2', and the terminal quinoline 
fills the S3 subsite.2·9 
0 
~0 
. N 
a H 
0 = OH 
tert-BuHNOC 2.4 
A further class of HN PR inhibitors possess elements of C2 rotational symmetry, 
capitalising on the unique symmetry of the dimeric enzyme?·'· 2·2• 2·10• 2·14 
Pseudosymmetric inhibitors represent an important advance in HN PR inhibition since 
they are of diminished peptide character, leading to greater metabolic stability.2·2•2·14 
Further, they confer high specificity for retroviral proteases, over mammalian aspartic 
acid proteases, whose binding sites are less symmetric.2'2' 2·14 In an example of a 
pseudosymmetric inhibitor, A-74704 (2.5) (IC50=3 nM), the C-0 bond of the central 
alcohol comprises the C2 axis of symmetry.2·2 A crystal structure reveals that 2.5 binds to 
the HIV PR in a symmetrical fashion. 2J 5 A water molecule (present in all the HIV PR-
inhibitor crystal structures solved to date2·'· 2 '2) is hydrogen bonded to the carbonyl 
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oxygens of the Val residues of 2.5 and to the amide hydrogens of the lle 50/150 residues 
in the "flap" region of the protease?Js The S 1 and S2 subsites of the enzyme bind the 
benzyl (Phe) and the isopropyl (Val) groups of the inhibitor (2.5).2.15 A second example 
of a pseudosymmetrical inhibitor is provided by the diol (2.6), where the C2 axis bisects 
the carbon-carbon bond of the diol.2.14 Diol inhibitors, such as 2.6, are approximately an 
order of magnitude more potent than inhibitors of the type 2.5.2'14 Surprisingly, the 
activity of compound 2.6 is reasonably insensistive to the stereochemistry of the hydroxyl 
groups (IC50=0.22-0.38 nM).2'14 As predicted, the inhibitory activity of compounds 2.5 
and 2.6 is selective for the retroviral proteases.2•14• 2·15 
OH '-...../ 
H H -
N N . ~NHCb, 
0 
Ph/ 0 Ph 2.5 
OH 
/Ph 
0 
H 
N 
N 
H 
0 
Ph/ 
OH 
2.6 
As discussed in the introduction to this thesis, a major strategy to reduce pharmacological 
problems is the development of inhibitors which mimic bioactive peptides but have either 
reduced or no peptide character?·9 The dicarboxylate (2.7) was among the first reported 
non-peptide inhibitors of the HIV protease (IC50=12J.LM).2'16 The result is significant 
since only two potential enzyme binding sites are present.2'16 It is proposed that the 
carboxylate side chains of 2.7 engage the two Arg residues located at either end of the 
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substrate binding groove of the enzyme.Z.I6 This is supported by the importance of the 
C~ chain length. Compounds analogous to 2.7, but with an insufficient chain length for 
the C02H groups to interact with the Arg residues, are significantly less active.Z.
16 
A number of epoxide containing peptidomimetics have been shown to inactivate the HIV 
PR.2·1• 2·2• 2.17, 2.18, 2·19• 2·20• 2·21• 2·22 For example, cerulenin (2.8, Figure 2.4), a naturally 
occurring antibiotic, weakly inhibits the HIV (IC50=2500 J.LM) and other aspartic acid 
proteases.2.1 7 Structure-activity studies, performed on 2.8, suggest that inhibitory action 
occurs at the active site of the enzyme.Z.l7 Modelling studies demonstrated that the 
terminal amide of 2.8 can form hydrogen bonds to the enzyme, which position the 4-oxo 
group in the place of the carbonyl group of the scissile bond of the substrate.2·17 This 
places the epoxide close to the position occupied by the amide nitrogen of the substrate 
(Figure 2.4).2.1 7 Catalytic action on the inhibitor, thus placed, would lead to esterification 
of one of the active site residues and hence enzyme inactivation.2·17 
Figure 2.4 
0 
0 0 
I 
I 
yly 127 
• I 
I 
. 
NH2 
Ile 150 (flap) 
Cerulenin (2.8) is cytotoxic and therefore unsuitable for clinical use.Z.1 7 However, 2.8 has 
provided a lead structure for development of HIV inhibitors of potential therapeutic use. 
For example, Blunenstein et aP· 18 studied related analogues of 2.8, such as 2.9, and 
suggested that the length of the hydrophobic residue is important.2·18 Compound 2.9 
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(n=8), having the same chain length as cerulenin (2.8), was found to be a weak inhibitor, 
whereas longer chain lengths led to diminished activity.2·18 Further, the epoxide was 
shown to be essential for inhibitory activity .2·18 Compounds analogous to 2.9 lacking the 
epoxide function were inactive.2 ·18 
0 
OH 
0 2.9 
Another epoxy-containing peptidomimetic, 1,2-epoxy-3-(p-nitrophenoxy)propane (ENP) 
(2.10, Scheme 2.2), is an irreversible inhibitor of aspartic acid proteases, including the 
HIV 1 PR (Ki=9.9 mM).Z·2• 2"19 The crystal structure of 2.10 bound to the Simian 
Immunodeficiency Virus protease (SIV PR) has been determined (SIV is a retrovirus 
closely related to HIV).Z· 19 This was the first reported structure of a retroviral protease 
bound to a covalent inhibitor. 2'19 The major interaction between the protease and the 
inhibitor (2.10), the covalent bond to one of the active site Asp residues, is shown in 
Scheme 2.2.2.1 9 Scheme 2.2 details the proposed mechanism of inactivation, where the 
negatively charged Asp residue attacks the epoxide to form an ester linkage.2.1 9 Further, 
the crystal structure revealed that the phenyl group of 2.10 occupied the S 1 sub site of the 
enzyme and that the nitro group interacted with the "flap".2.1 9 The conserved water 
molecule was hydrogen bonded to amide hydrogens in the "flap".Z·19 
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Scheme2.2 
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Compound 2.10 provides a lead structure for the design of irreversible inhibitors of the 
HIV PR. For example, salient structural features of 2.10 were incorporated into a 
tripeptide analogue (containing residues typically found in substrates) giving compound 
2.11, an irreversible inhibitor of the HIV PR (Ki=20 J.LM).2.2° Inactivation by 2.11 is 
thought to result from specific alkylation of a single active site Asp residue, analogous to 
the mode of action of compound 2.10 (Scheme 2.2).2'20 It is presumed that the P3-Pl' 
groups of2.11 occupy the 83-Sl' substrate binding sites of the enzyme.2·2° Compound 
2.12 provides a further example of a potent and selective irreversible inhibitor of the HIV 
PR (K=1.32 J.LM).2'21 The cis stereochemistry of the epoxide was critical to the potency 
of compound 2.12.2'21 An analogous compound with a trans epoxide demonstrated much 
poorer activity .Z·21 Both compounds 2.11 and 2.12 contain the (R,S)-isomer of the cis 
epoxide. 2.21, 2.2o 
62 
Chapter 2 
2.12 
A recent paper details the investigation of a number of mono, di and tri substituted, non 
peptidic, epoxides of which the cis-1 ,2-disubstituted epoxide (2.13) proved to be the most 
effective inhibitor (Ki=65 J.lM).2'22 Inhibition is irreversible and results from covalent 
attachment of compound 2.13 to a catalytic Asp residue (shown by mass spectrometric 
sequencing oflabelled protolytic peptides).2'22 Interestingly, similar trans-1,2-
disubstituted epoxides did not detectably inhibit the HIV PR and it was suggested that 
this was due to steric hindrance to backside attack at the epoxide, by the unprotonated 
Asp residue of the enzyme (see Scheme 2.2 for the proposed mechanism of inactivation 
by irreversible epoxide inhibitors such as compound 2.10).2·22 
2.13 
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Results and Discussion 
Part 1. Pseudosymmetrical Potential Inhibitors of the HIV PR 
This section presents a series of compounds (2.14a-g) designed as potential inhibitors of 
the HIV PR. Compounds 2.14a-g incorporate, in a pseudosymmetric compound, the 
elements of cerulenin (2.8) considered to be important for inhibition (the amide and 
epoxide moiety). As discussed in the introduction to this chapter, a number of epoxy 
containing peptidomimetics, such as 2.8, have been shown to be inhibitors of the HIV 
PR.2·17• 2.1 8• 2·19• 2·20• 2·21• 2·22 Further, peptidomimetics possessing elements of C2 rotational 
symmetry, such as 2.5 (discussed in the introduction to this chapter), have proved to be 
potent and selective inhibitors of the HIV PR.2'1' 2'2' 2.14• 2'15 In an attempt to develop 
epoxide-containing inhibitors, this concept of symmetry was utilised to design the novel . 
structures (2.14a-g). Interestingly, a similar approach was adopted independently by 
Park and co-workers to give compound 2.15, an epoxy-containing pseudosymmetrical 
inhibitor ofthe HIV PR (Ki=75 nM).Z·23 
H 
Et02C'-..,/N 
0 
0 
0 2.14a 0 
H 
N~C02Et 
64 
Chapter 2 
0 
H H 
N N~C02Me 
-
-0 0 y 2.14b 
0 
H H 
~~C)N N~C02Me 
-0 2.14c 0 
"-..,Ph Ph 
0 0 0 Et02c'/'-..,.N~~ ~0N~COEt H H 2 
0 0 
"-.../ 0 0 ~~x = - H ~ N PhCH20 2C N ~ ~ C02CH2Ph H 
0 0 -y 2.14e 
0 
H H 
H02C, ,..N N, ,..C02H (CH2)n (CH2)n 
0 0 
2.14f n=6 
2.14g n=7 
0 
"-.../ 
H H . 
N N . ~NHCb2 
= 0 
Ph/ 2.15 
0 
Ph 
65 
Chapter 2 
It was anticipated that the configuration of the epoxide would be important to the design 
of the peptidomimetics (2.14a-g). The cis stereochemistry was adopted, since other 
epoxides shown to be inhibitors of the HIV PR, such as 2.11, 2.12, and 2.13 (discussed in · 
the introduction to this chapter) all contain cis epoxides.2·20' 2·21 ' 2·23 In fact the cis 
configuration of the epoxide was shown to be critical to the potency of compound 
2.12.2'21 Consideration of appropriate elements to enhance enzyme recognition led to a 
series of peptide-based compounds (14a-e ), which contain a pair of amino acids or 
dipeptides, similar to known inhibitors such as 2.15.2'14' 2.15, 2·23 A pair of non-peptide 
compounds (2.14f and 2.14g), which contain a long CH2 chain, arose from consideration 
of the dicarboxylate (2.7), also discussed in the introduction to this chapter.2.16 
Peptide-Based Potential Inhibitors of the HIV PR 
As discussed in the introduction to this chapter, a number of peptide-based molecules 
have been reported as inhibitors of the HIV PR.Z·14• 2·15 Since the enzyme forms a network 
of hydrogen bonds and hydrophobic interactions to a substrate sequence, inhibitors 
containing appropriate amino acid residues enhance recognition and binding affinity. 2.1 
Here, a series a novel peptide-based epoxides (2.14a-e) are reported. 
Initial work in this area concentrated on the introduction of a single amino acid to give 
compound 2.14a (Scheme 2.3). As shown in Scheme 2.3, this was achieved by the 
dicyclohexylcarbodiimide (DCC) mediated coupling2·24 of Gly ethyl ester hydrochloride 
with compound 2.16 (synthesised by a literature procedure2·25). Compound 2.14a was 
regarded as a model to demonstrate the feasibility of coupling a pair of amino acids with 
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2.16 in a single step. An appropriate hydrophobic amino acid was required to enhance 
enzyme recognition and binding affinity. 
Scheme 2.3 
0 
H02C 2.16 
0 
2.14 
E~N/DCC/HOBT 
CH2CI2 /r.t. 
H 
N'-..,/COR1 
o R' 
2.14a R=H, R 1=0Et 
The consideration of an appropriate amino acid for incorporation into compound 2.14 
involved some speculation as to the potential binding mode of 2.14 to the HIV PR. 
Modelling studies on cerulenin (2.8) indicated that the amide is hydrogen bonded to lle 
150 in the "flap" and to Gly 127, and that the 4-oxo group is close to the catalytic Asp 
residues-(see Figure 2.4)_2.17 This suggests that compounds ofthe type 2.14 could bond 
to the enzyme in a similar fashion to that shown in Figure 2.5. Here the proposed 
interactions (with the catalytic Asp residues, Ile 150, and Gly 127) are identical to those 
proposed for cerulenin (2.8).2.17 Crystallographic data2·1• 2·9 on HIV PR-inhibitor 
complexes suggests that this would place the P2' group in a position to bind in the S2' 
subsite. Further, the amide between the Pl and P2 residues may coordinate to Ile 50 and 
Gly 27, thus positioning the Pl and P2 groups to bind in the Sl and S2 subsites. 
However, a symmetrical binding mode may be adopted since it has been demonstrated 
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that symmetric inhibitors, such as compound 2.5 (discussed in the introduction to this 
chapter) generally interact with the enzyme in a symmetric fashion.2·15• 2·26 
Figure 2.4 
Figure 2.5 
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To enhance enzyme recognition, suitable Pl, P2, and P2' amino acids were investigated. 
L-Leu methyl ester hydrochloride was coupled2'24 with 2.16 to give compound 2.14b (see 
Scheme 2.3 for a general scheme). L-Leu methyl ester hydrochloride was chosen since 
naturally occurring peptide cleavage sites with Leu in the Pl position have been 
identified2'2 and further Leu is a acceptable residue at both P2' and at P2. Thus, for the 
mode of binding suggested in Figure 2.5, Leu is an suitable residue to enhance enzyme 
recognition. Further work in this area involved the coupling2·24 ofL-Phe methyl ester 
hydrochloride with 2.16 to give compound 2.14c (see Scheme 2.3 for a general scheme). 
HIV PR catalysed cleavage of peptides with Phe in the Pl position is extremely 
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common.2.1. 2·2 Phe is also known to occur in the P2 position2·2 and is, therefore, also an 
acceptable residue to enhance enzyme recognition. 
Scheme 2.3 
0 
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R
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R 0 2.14 0 
2.14bR=CH2CH(Me)z R1=0Me 
2.14c R=CH2Ph R 1=0Me 
2.14d R=H R 1=Gly ethyl ester 
-
'R 
In an attempt to further enhance enzyme recognition, the coupling2·24 of a dipeptide with 
compound 2.16 was investigated. The enhanced activity of the "tetrapeptide" (2.5) over 
an equivalent "dipeptide" analogue (discussed in the introduction to this chapter) attests 
the importance of extra residues to enhance recognition and binding affinity.Z·2 Gly-Gly 
ethyl ester hydrochloride, chosen for initial investigations as it was commercially 
available, was coupled2'24 with 2.16 giving a compound, tentatively assigned to the 
structure 2.14d (see Scheme 2.3 for a general scheme). Although purification of 2.14d 
proved difficult due to its solubility properties (discussed later), the reaction 
demonstrated the feasibility of the coupling of a dipeptide with compound 2.16. 
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Suitable residues for incorporation into a "tetrapeptide" example of compound 2.14 were 
selected on the basis of known substrate specificity of the HIV PR2'2 and the possible 
binding mode of compounds of the type 2.14, shown in Figure 2.5. As discussed above, 
Leu is a suitable Pl and P2' amino acid. z.1, 2'2 Further Val is a suitable residue at the P2 
and P3' positions.2.1' 2'2 L-Leu-L-Val benzyl ester (2.17) was coupled2'27 with 2.16 to give 
compound 2.14e as shown in Scheme 2.4. The coupling was performed on the free amine 
(2.17), as this resulted in a cleaner product than that obtained from the coupling of the 
formate salt of 2.17 with compound 2.16. 
Scheme 2.4 
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Non-Peptide-Based Potential Inhibitors of the HIV PR 
Since peptide inhibitors are traditionally associated with problems of low bioavailability, 
the development of non-peptide inhibitors of the HIV PR is of considerable therapeutic 
importance?·16 As discussed in the introduction to this chapter, the dicarboxylate (2.7) 
has been reported as a weak non-peptide inhibitor of the HIV PR.2.16 Binding to the HIV 
PR is thought to occur between the carboxylate groups of compound 2.7 and the Arg 
8/108 residues located at the end of the substrate binding groove of the enzyme?-16 The 
potential inhibitors (2.14f and 2.14g, Scheme 2.5) were designed to incorporate 
carboxylate groups of appropriate separation to engage the Arg residues (20 or 22 bonds, 
since in compound 2.7 the carboxylates are separated by 21 bonds2·16). 
As shown in Scheme 2.5, coupling2'24 ofthe amines (2.18, n=617) (synthesised by a 
literature procedure2·28• 2·29) with compound 2.16 gave compounds 2.14h and 2.14i. Base 
catalysed hydrolysis of the methyl esters of 2.14h and of 2.14i gave the target compounds 
(2.14f and 2.14g, Scheme 2.5). 
Further work in this area involved the coupling2·24 of 2.16 with the amines (2.19, n=617) 
to give compounds 2.14j and 2.14k (Scheme 2.6). Compounds 2.14j and 2.14k do not 
have carboxylate groups (as in 2.14f and 2.14g) to enhance inhibitor activity by binding 
to the Arg residues. They would, therefore, be expected to be weaker inhibitors than 
2.14f and 2.14g, acting as "controls" to demonstrate the role of the carboxylate groups in 
binding to the enzyme. However, since compounds 2.14f and 2.14g were inactive 
(discussed later) the possible role of the carboxylates was unable to be elucidated. 
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Scheme 2.6 
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Finally, compound 2.20 (Scheme 2.7) was designed to investigate the importance of the 
symmetrical nature of compounds such as 2.14j and 2.14k. Compound 2.20 is a non-
symmetrical analogue of compound 2.14j. A comparison of the in vitro activities of 
compound 2.20 and compound 2.14j is presented in Part 3 of this chapter. Compound 
2.20 was synthesised as shown in Scheme 2.7. The half ester (2.21), synthesised by a 
literature procedure,2'30 was coupled2'27 with heptylamine (2.19, n=6) to give the 
intermediate (2.22). Base catalysed hydrolysis of 2.22 gave compound 2.20. 
Scheme 2.7 
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Structure Assignment of Compounds 2.14a-k 
COMPOUND 2.14a 
Compound 2.14a was purified by recrystallisation to give white crystals. In the 1H NMR 
spectrum of 2.14a, the resonances due to the C!;kNH protons appeared as separate 
doublets of doublets at 8 4.14 and 8 3.97, while the epoxide protons gave rise to a singlet 
at 8 3.76. The 13C NMR spectrum of 2.14a was assigned by comparison to that of the 
Gly ethyl ester cation.2'31 A mass spectrum and micro analysis were consistent with the 
proposed structure of 2.14a. 
COMPOUND 2.14b 
Compound 2.14b was purified by column chromatography to give a colourless oiL Due 
to the presence of two stereocentres, compound 2.14b does not contain a plane of 
symmetry and therefore magnetic non-equivalence is observed in its NMR spectra. For 
example, in the 1H NMR spectrum of 2.14b, separate signals were observed for each 
methyl ester (8 3.73 and 8 3.72) and for each of the NH groups (o 6.65 and o 6.58). In the 
13C NMR spectrum of 2.14b most carbons gave separate signals. For example, the 
epoxide carbons appeared at 8 55.0 and 8 54.9 and the CONH signals at 8 165.1 and 
8 165.0. These signals were assigned by comparison to the 13C NMR spectrum of 2.14a. 
Other 13C NMR signals were assigned by comparison to the 13C NMR spectrum of the 
Leu methyl ester cation.231 
COMPOUND 2.14c 
Compound 2.14c was purified by radial chromatography to give a colourless oil. 
Attempts to initiate crystallisation were unsuccessful. Compound 2.14c does not contain 
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a plane of symmetry and thus magnetic non-equivalence is evident in its NMR spectra. 
For example, in the 1H NMR spectrum of 2.14c, separate signals were observed for the 
methyl esters at 8 3.70 and 8 3.66 and in the 13C NMR spectrum most carbons gave rise to 
separate resonances. A heteronuclear multiple quadrapole correlation (HMQC) 
experiment was performed to distinguish between the CHCH2 and the OMe carbons. The 
signals at 8 52.4 and 8 52.3 correlated to the 1H NMR methyl ester signals, while the 
signals at 8 53.4 and 8 53.3 correlated to the 1H NMR CHCH2 multiplet. Other 13C NMR 
signals were assigned by comparison to those of 2.14a, 2.14b, and the Phe methyl ester 
cation, 2'31 as appropriate. 
COMPOUND 2.14d 
The poor solubility properties of 2.14d in organic solvents made isolation and 
purification difficult. This compound proved to be soluble in water and methanol, and 
insoluble in organic solvents. Thus, the standard work-up procedure2·24 was not feasible. 
Instead, the evaporated reaction mixture was adsorbed onto silica and eluted with ethyl 
acetate. Further purification by recrystallisation was unsuccessful. The structure of 
2.14d was suggested on the basis of NMR data. Homonuclear decoupling experiments 
were performed to assign the 1H NMR spectrum of 2.14d. The signals at 8 4.18 and 
8 1.26 were shown to be coupled by irradiation and were assigned to the ethyl ester. One 
of the CH2NH groups was assigned on the basis of an irradiation at 8 4.71 (C!:kNH), 
which led to collapse at 8 7.25 (CH2NH) (to a broad singlet). The other CH2NH group 
was tentatively assigned to signals at 8 7.73 (CH2NH) and the multiplet at 8 4.00 
(CH2NH). Irradiation of these signals was inconclusive. The epoxide protons appeared 
as a singlet at 8 3.96. The 13C NMR spectrum of 2.14d was readily assigned by 
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comparison to that of 2.14a. Attempts to obtain a mass spectrum on 2.14d were 
unsuccessful. 
COMPOUND 2.14e 
Table 2.1. Homonuclear Decoupling Experiments on 2.14e 
Signal Irradiated (o) 
1.59-1.93 (NHCHCH2CID 
2.10 (NHCHCH) 
2.29 (NHCHCH) 
4.46 (NHCHCH) 
4.64 (NHCHCH2 and NHCHCH) 
Signal Collapsed (o) 
4.92 to d (J=8.8 Hz) (NHCHCH2) 
4.64 to m (NHCHCH2) 
0.87 tom (CH2CH(Me)2) 
4.46 to d (J=8.3 Hz) (NHCHCH) 
0.87 tom (CHCH(Me)2) 
4.64 to m (NHCHCH) 
0.87 tom (CHCH(Me)2) 
2.10 tom (NHCHCH) 
7.55 to s(br) (NHCHCH) 
2.29 to m (NHCHCH) 
1.59-1.93 to m (NHCHCI:k) 
7.99 to s(br) (NH) 
6.61 to s(br) (NID 
1.59-1.93 to m (NHCHCH2) 
7.67 to s(br) (NHCHCH2) 
Compound 2.14e was purified by radial chromatography to give a colourless oil. 
Attempts to initiate crystallisation were unsuccessful. Compound 2.14e does not contain 
a plane of symmetry and thus magnetic non equivalence is evident in its NMR spectra. 
The results of homonuclear decoupling experiments, performed to assign the complex 
1 H NMR spectrum of 2.14e, are displayed in Table 2.1. These enabled the assignment of 
the protons in the NHCHCH2CH and the NHCHCH moieties. Assignment of the 
CHCH2CH and the NHCHCH protons was also aided by published 1H NMR data on Leu 
methyl ester hydrochloride and Val ethyl ester hydrochloride.232• 2·33 The 13C NMR 
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spectrum of 2.14e was assigned by comparison to those of the Leu methyl ester cation2·31 
and the Val methyl ester cation.2·31 The carbons of the epoxide group were assigned to 
signals at o 54.8 and o 54.3 by comparison to the 13C NMR spectra of other compounds in 
this series such as 2.14b and 2.14c. 
COMPOUNDS 2.14f and 2.14g 
The 1H NMR spectra of 2.14f and 2.14g were assigned by comparison to those of 2.14h 
and 2.14i (discussed below). A HMQC experiment was performed to assign the 
13C NMR spectrum of 2.14g. The correlations are presented in Table 2.2. The 13C NMR 
spectrum of 2.14f was then assigned by comparison to that of 2.14g. 
Table 2.2. HMQC Data on 2.14g and 2.14i 
Compound 1HNMR(o) 13CNMR(o) Assignment 
2.14g 3.00 40.5 NHCH2 
2.09 35.2 CH2C02 
1.41 26.3 CH2CHzCOz 
1.29 30.6 NHCHzCH2 
1.15 30.4, 30.4, 28.0 NH(CHz)z(CH2)3 
2.14i 3.60 54.9 CH( epoxide) 
3.63 51.5 OMe 
3.19 39.4 NHCHz 
2.27 34.0 CH2COz 
1.58 24.8 CH2CHzCOz 
1.45 29.2 NHCHzCHz 
1.27 28.9, 28.8, 26.5 NH(CHz)2(CH2)3 
COMPOUNDS 2.14h and 2.14i 
Both 2.14h and 2.14i were purified by recrystallisation to give white solids. The 
1H NMR spectrum of 2.14h was assigned with the aid of homonuclear decoupling. 
Irradiation of the quartet at 6 3.20 (NHCH2CH2) led to collapse of the NH triplet at 6 6. 70 
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(to a broad singlet) and to collapse at o 1.47 (to a triplet, 1=6.8 Hz), thus assigned to the 
NHCH2Cfu group. Further, irradiation showed that the triplet at o 2.28 (CH2CH2C02) 
and the multiplet at o 1.59 (C.I:IzCH2C02) were mutually coupled. The 1H NMR spectrum 
of 2.14i was assigned by comparison to that of 2.14h. In the 13C NMR spectrum of 2.14i, 
the CH2 chain was assigned with the aid of a HMQC experiment (see Table 2.2). The 
13C NMR spectrum of 2.14h was assigned by comparison to that of 2.14i. 
COMPOUNDS 2.14j and 2.14k 
Both 2.14j and 2.14k were purified by recrystallisation to give white solids. The 
1H NMR spectrum of 2.14k was assigned with the aid of homonuclear decoupling. This 
showed the signals at o 3.21 (NHCfu) and at o 6.50 (NH) to be mutually coupled and 
further the signals o 3.21 (NHCfu) and o 1.46 (NHCH2Cfu) to be mutually coupled. The 
1H NMR spectrum of 2.14j was assigned by comparison to that of 2.14k. The 13C NMR 
spectra of2.14j and 2.14k was assigned by comparison to that of other compounds in this 
series such as 2.14f and 2.14g. 
COMPOUND 2.20 
Compound 2.20 was purified by recrystallisation to give a white solid. In the 1H NMR 
spectrum of 2.20, the epoxide protons appeared as an AB quartet at o 3.75 and o 3.68. 
Other 1H NMR signals were assigned by comparison to those of compound 2.14j. 
Similarly 13C NMR signals were assigned by comparison to those of2.14j. 
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Part 2. 1 ,2-Epoxy-3-(p-nitrophenoxy)propane (ENP) Inspired Inhibitors of the HIV PR 
The Synthesis of ENP Inspired Inhibitors 
As discussed in the introduction to this chapter, 1,2-epoxy-3-(p-nitrophenoxy)propane 
(ENP) (2.10) is an irreversible inhibitor of aspartic acid proteases, including the HIV 
PR.2·2• 2·19 The crystal structure of 2.10 bound to the Simian Immunodeficiency Virus 
Protease (SIV PR) revealed the major interaction between the protease and compound 
2.10 to be a covalent bond to one ofthe active site Asp residues.2.19 Further interactions 
with the enzyme include the occupation of the S 1 subsite by the phenyl group of 2.10 and 
weak interactions with the nitro group and the phenoxy oxygen of 2.10?.19 Compound 
2.10 provided a lead structure for the design of irreversible inhibitors of the HIV PR, 
such as compounds 2.11 and 2.12, where salient structural features of 2.10 have been 
incorporated into peptide analogues.2.20' 2'21 Inactivation by 2.11 and 2.12 is thought to 
result from alkylation of an active site Asp residue, analogous to 2.10.2·20 
N02 
o-P 2.10 2.11 
0 0 X Htt"' F\ _,,,,n II 
CbzHN~ 
~ ~ C02H 
2.12 
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This section presents the synthesis of inhibitors of the HIV PR (compounds 2.23 and 
2.24), which incorporate the important structural features of compound 2.10 into a 
peptide analogue. The target peptidomimetic (2.24) combines the epoxide, (essential for 
irreversible inhibition2.19, 2'20' 2"21) and the p-nitrophenoxy moiety of 2.10 with a suitable 
amino acid to enhance enzyme recognition. Compound 2.23 was considered as a model 
to demonstrate the feasibility of the synthesis and to probe the importance of the nitro 
group and phenoxy oxygen. The (R,R)-configuration was adopted for the epoxide of 
compounds 2.23 and 2.24 since studies on compounds 2.11 and 2.12 showed the (R,S)-
form (note the priority change) of the epoxide resulted in the most potent inhibitor. 2·20• 2·21 
Further, as discussed in the introduction to this chapter, the cis configuration of the 
epoxide was critical to the potency of compound 2.12.2·21 
H 
N~C02Me 
H 
N~C02Me 
o [ 
The five step synthetic route to compounds 2.23 and 2.24 is shown in Scheme 2.8. 
Fortunately, each step was achieved readily in good yield. Step 1 involved a "Homer-
Wadsworth-Emmons" (HWEi34 reaction on the aldehydes (2.25a and 2.25b) to give the 
olefins (2.26a and 2.26b). The aldehyde (2.25a) was purchased from Aldrich® and 
2.25b was synthesised by a literature procedure.235 Appropriate HWE conditions were 
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chosen to promote the formation of the Z olefin and an excess of the Z olefin was formed 
(the E:Z ratio was 1:6.4 for 2.26a and 1:3.4 for 2.26b ). In both cases the Z olefin was 
separable by chromatography. A detailed study of the HWE reaction, presented in 
Chapter 3, demonstrated that an excess of the Z olefin was obtained for reactions with 
methyl diphenylphosphonoacetate, at -78 °C, in tetrahydrofuran (THF). In step 2, the 
olefins (2.26a and 2.26b) were reduced with diisobutylaluminiumhydride (DIBALi'36 to 
give the allylic alcohols (2.27a and 2.27b). The reaction was performed with 2.5 
equivalents of DIBAL to ensure complete conversion to the alcohol (the potential existed 
for incomplete reduction to give an aldehyde). 
A Sharpless epoxidation237 on 2.27a and 2.27b (step 3, Scheme 2.8) gave the epoxy 
alcohols (2.28a and 2.28b). This reaction had already been demonstrated on compound 
2.27a?·37 The reaction used L-(+)-diisopropyltartrate (DIPT) to give the desired (2S,3R)-
enantiomer in >95:5 excess (note that the (2S) stereochemistry (compound 2.27) becomes 
(2R) in compounds 2.23, 2.24, and 2.29 due to a priority change at Cl). 
As shown in step 4 (Scheme 2.8), oxidation of the epoxy alcohols (2.28a and 2.28b) was 
achieved by periodoic acid (H5I06) with a catalytic amount of ruthenium trichloride 
hydrate (RuCb),2·38 to give the epoxy acids (2.29a and 2.29b). Finally, in step 5 (Scheme 
2.8), the benzotriazolyloxy-tris-( dimethylamino )phosphonium hexafluorophosphate 
(BOP) mediated coupling239 of an amino acid residue with 2.29a or 2.29b gave the target 
compounds (2.23 and 2.24, respectively). Initially L-Leu methyl ester hydrochloride was 
coupled giving compounds 2.23a and 2.24a. Leu was chosen since it was unknown 
whether a Pl' or P2' residue would best enhance enzyme recognition and Leu is an 
acceptable residue at either position.2·2 Further, L-Val methyl ester hydrochloride was 
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coupled with the epoxy acids (2.29a and 2.29b) to give the inhibitors (2.23b and 2.24b). 
Val is a well known residue at the P2' position but not at the Pl' position.2·1' 2·2 A 
discussion on relative activities of compounds 2.24a and 2.24b (and thus whether Leu or 
Val is a better residue to enhance enzyme recognition for this system) is presented in part 
3 of this chapter. 
Scheme 2.8 
Step la )lliaro 
2.28a R 1=PhCH2CH2 
2.28b R 1=4-nitroC6H40CH2 j Srep4' 
Step 5e 
C02H 
F\ 
R 1 C02Me 
2.26a R 1=PhCH2CH2 
2.26b R 1=4-nitroC6H4 OCH2 
R~OH 
2.27a R 1=PhCH2CH2 
2.27b R 1=4-nitroC6H40CH2 
H 
N'-...._/C02Me 
= 
o R' 
a.
234 
n-BuLi, (Ph0)2POCH2C02Me, THF, -78 °C. b.2.36 DIBAL, CH2Ch, -78 °C. c.237 
4A molecular sieves, Ti(OiPr)4 , L+ DIPT, TBHP. d.238 RuC13, H5106, 
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2.23a y 
0 y 2.24a 
Analysis, by 1H NMR, of their crude reaction mixtures revealed that compounds 2.23a, 
2.23b, 2.24a, and 2.24b were each obtained as single isomers. This demonstrates the 
stereoselectivity of the Sharpless epoxidation (step 3, Scheme 2.8). Further evidence for 
this was obtained by the determination of the enantiomeric excess of the reaction. This 
was achieved, as described by Sharpless et al., by conversion of the epoxides (2.28a and 
2.28b) to the corresponding acetates (2.30a and 2.30b, Scheme 2.9) followed by shift 
analysis.2.4° This analysis involved sequential addition of the shift reagent, europium 
(111) tris[3-(heptafluoropropylhydroxymethylene)-d-camphorate], to a solution of 2.30a 
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or 2.30b and observation of the acetate Me by 1 H NMR. 2.4° When a second resonance for 
the acetate Me was not observed, it was concluded that the enantiomeric excess was 
greater than the limit of detection by NMR (>95:5). 
Scheme 2.9 
OH 
DMAP!Et3N/AcCl H1111 ------------~--~ ·~·--~ 
Rl OYMe 
2.30a R 1=PhCH2CH2 0 
2.30b R 14-nitroC6H40CH2 
2.28a R 1=PhCH2CH2 
2.28b R1=4-nitroC6H40CH2 
Finally, compound 2.31 (Scheme 2.10) was designed to probe the importance of the p-
nitrophenoxy group in compounds of the type 2.24. Compound 2.31 is an analogue of 
compound 2.24b containing a simple alkyl chain place of the p-nitrophenoxy group. 
Similar compounds, such as 2.82·17 and 2.9,2.18 also containing a nine carbon chain, have 
been shown to be inhibitors of the HIV PR and are discussed in the introduction to this 
chapter. A comparison of the in vitro activities of compounds 2.24b and 2.31 is 
presented in part 3 of this chapter. Compound 2.31 was synthesised from compound 2.32 
via the acid chloride (2.33) as shown in Scheme 2.10. Compound 2.32 was synthesised 
by a literature procedure.2.1 8 
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Scheme 2.10 
(CO Cl)2/DMF 
OH )ll1lo 
Benzene 
0 
Cl 
0 
HCl H2N~C02Me 
0 
H 
N~C02Me 
A further series of inhibitors of the HIV PR included compounds 2.34a and 2.34b. The 
diethyl azodicarboxylate (DEAD) mediated coupling2.41 of the epoxy alcohols (2.28a and 
2.28b) with N-CBz-L-Val, to give compounds 2.34a and 2.34b, is shown in Scheme 2.11. 
Compounds 2.34a and 2.34b are peptidomimetics based on the tripeptide, Phe-Gly-Val, 
similar to the known inhibitor (2.12) (discussed in the introduction to this chapter).2.21 
The potential advantage of compounds 2.34a and 2.34b, over inhibitors of the type 2.24, 
is the presence of a methylene (between the epoxide and the C02). Studies on 2.12 have 
shown a methylene group, alpha to the epoxide group, to be essential to its activity.2'21 
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Scheme 2.11 
HI/, 
';.;.-'• ""--.:..:. OH 
Rl 
2.28a R 1=PhCH2CH2 
2.28b R 1=4-nitro~H40CH2 
/"-... 0 2C NHC02CH2Ph 
0 . 
lfNHco2cH2Ph 
0 
Further, the inhibitor (2.35) was synthesised by the DEAD mediated coupling of the 
epoxy alcohol (2.28b) with N-CBz-L-Val-L-Val (Scheme 2.11). Compound 2.35 is a 
"tetrapeptide" analogue with Val a suitable residue to enhance enzyme recognition,2.1, 2·2 
at the P2' and P3' positions. 
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An Alternative Approach to the Synthesis of ENP Inspired Inhibitors 
Initially, the synthesis of peptidomimetics of the type 2.23 was attempted via the 
proposed synthetic pathway shown in Scheme 2.12. However, due to problems 
encountered in step b (discussed below), this synthetic pathway was abandoned in favour 
of the efficient and stereoselective synthesis shown in Scheme 2.8. 
Scheme2.12 
0 
~CHO a Ph~O,Et ... Ph 
2.36 2.37 trans epoxide 2.39 cis epoxide 
~b 
0 0 
H "''IIII( c,d Ph~02Et N "'-../C02Me Ph 
'R 2.41a 
a.Z·42 Lithium bis(trimethylsilyl)amide/ethyl bromoacetate/THF. b. H2/Pd on C2.43 or 
rhodium on alumina.2.44 c. NaOH/MeOH. d.239 CIH3NCHRC02Me, BOP, Et3N, 
The investigations into step a (Scheme 2.12) gave an interesting and potentially useful 
synthetic result. Step a, the treatment of cinnamaldehyde (2.36) with ethyl bromoacetate 
under Darzens conditions2.42 (with an excess of base), gave a mixture of two compounds-
the trans epoxide (2.37) and the bromohydrin (2.38). Compounds 2.37 and 2.38 were 
separable by chromatography. Further treatment of compound 2.38 to Darzens 
conditions effected approximately 50% conversion to the cis epoxide (2.39) (shown by a 
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1H NMR spectrum of the crude reaction mixture). However, complete conversion to 2.39 
was effected by the action of potassium tert-butoxide in tetrahydrofuran.Z.45 Therefore, 
the trans and cis epoxides (2.37 and 2.39) were obtained separately (they were not able to 
be separated directly by chromatography). 
OH 
Ph 
Br 2.38 
Although a mixture of the trans and cis epoxides is the usual outcome of the Darzen 
reaction, halohydrins of the type (2.38) have also been obtained previously?A6 
Reportedly, halohydrins are formed by protonation of the intermediate species (2.40a and 
2.40b, Scheme 2.13) during the aqueous work-up.2.46 It has been observed that the 
intermediate (2.40a) cyclised more readily to the trans epoxide than did the intermediate 
(2.40b), which in some cases did not cyclise at all (thereby giving a mixture of a trans 
epoxide and a halohydrin similar to that reported above (compounds 2.37 and 2.38))_2.46 
Scheme 2.13 
trans epoxide cis epoxide 
Note: one enantiomer only of 2.40a and 2.40b is shown. 
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Finally, hydrogenation (palladium on carbon) of the trans epoxide (2.37) gave a mixture 
of the desired epoxide (2.41) and the ring opened compound (2.42), separable by 
chromatography (Scheme 2.14). Hydrogenation of the cis epoxide (2.39) gave a complex 
mixture. Hydrogenation over rhodium on alumina, reported to selectively saturate olefins 
in the presence of epoxides,2.44 was also unsuccessful. 
Scheme 2.14 
O C02Et O C02Et I\/ H2/Pdon~ I\/ 
Ph~ ethyl acetate Ph~ 
+ 
C02Et 
Ph 
2 
OH 
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Structure Assignment 
COMPOUNDS 2.23a and 2.23b 
The 1H NMR spectra of the crude reaction mixtures revealed that each compound (2.23a 
and 2.23b) was obtained as a single diastereoisomer. The reaction products were purified 
by radial chromatography. Compounds 2.23a and 2.23b are previously unreported and 
were fully characterised. The 1H NMR spectrum of 2.23a revealed the epoxide protons 
as a doublet at() 3.53 (J=4.9 Hz) (assigned to the CHCO epoxide) and a doublet of 
triplets at() 3.21 (J=4.9, 6.4 Hz) (assigned to the CH2CH epoxide). In the 1H NMR 
spectrum of 2.23a, the PhCfuCHz protons were distinguished by comparison to those of 
compound 2.28a. For both compounds (2.23a and 2.23b ), the amino acid moiety was 
assigned by comparison to published 1H NMR spectra.2·32•233 A HMQC experiment was 
performed on both 2.23a and 2.23b to assign their Be NMR spectra. The correlations are 
displayed in Table 2.3. 
COMPOUNDS 2.24a and 2.24b 
The 1H NMR spectra of the crude reaction mixtures revealed that each compound (2.24a 
and 2.24b) was obtained as a single diastereoisomer. The reaction products were purified 
by radial chromatography. Compounds 2.24a and 2.24b are both previously unreported 
and were fully characterised. Where appropriate, the 1 H NMR spectra of 2.24a and 2.24b 
were assigned by comparison to that of 2.23a and 2.23b. A HMQC experiment was 
performed to assign the 13C NMR spectrum of compound 2.24a and the correlations are 
shown in Table 2.3. The Be NMR spectmm of compound 2.24b was assigned by 
comparison to those of 2.23a, 2.23b, and 2.24a. 
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Table 2.3. HMQC Data on 2.23a, 2.23b, and 2.24a 
Compound 1HNMR(o) 13C NMR(o) Assignment 
2.23a 4.66 57.7 NHCH 
3.63 54.6 OMe 
3.53 51.7 CHCO( epoxide) 
3.21 49.4 CH2CH( epoxide) 
2.82 31.7 PhCH2 
1.99 28.4 PhCH2CHz 
1.55-1.70 24.2, 40.7 CHzCH(Me)z 
0.95 21.1, 22.3 CH(Meh 
2.23b 4.57 57.6 NHCH 
3.64 55.9 OMe 
3.55 54.6 CHCO( epoxide) 
3.22 51.6 CH2CH( epoxide) 
2.81 31.7 PhCH2 
2.21 30.4 CH(Me)2 
1.95 28.5 PhCH2CH2 
2.24a 4.64 55.2 NHCH 
3.72 52.0, 52.8 COCH(epoxide) and OMe 
3.67 49.7 CH2CH( epoxide) 
1.52-1.71 24.3, 40.0 CH2CH(Me)2 
0.95 20.8, 22.3 CH(Me)2 
COMPOUNDS 2.26a and 2.26b 
Compounds 2.26a and 2.26b were fully characterised. The Z stereochemistry was 
assigned to 2.26a and 2.26b on the basis of 1H NMR evidence. The coupling constants 
of the olefin protons (J= 11.7 Hz) was consistent with literature data for other Z ole fins. 2.47 
Further, the downfield position of the CfuCH signals, due to the deshielding effect of the 
carbonyl group/.48 was diagnostic of the Z isomer. For example, the CH2CH signal of 
2.26b appeared at o 5.25, compared too 4.80 for theE isomer (2.26d) (this phenomena is 
discussed further in Chapter 3). Homonuclear decoupling experiments, performed to 
assign the CH2CH signal of 2.26a, showed that the signals at o 6.26 (CH2CH) and at 
o 2.98 (CH2CH) were mutually coupled. The presence of allylic coupling was noted in 
the 1H NMR spectra of both 2.26a and 2.26b (J=2.0 and 2.4 Hz, respectively). The 
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assignment of the 13C NMR spectra of 2.26a and 2.26b was aided by comparison to those 
of the olefins (3.5), discussed in Chapter 3. A satisfactory micro analysis was obtained 
on compound 2.26b. 
COMPOUNDS 2.27a and 2.27b 
Compounds 2.27a and 2.27b were purified by radial chromatography and were fully 
characterised. In the 1H NMR spectra of 2.27a and 2.27b, the assignment of the CfuOH 
protons was confirmed by homonuclear decoupling experiments. For example, in the 
1H NMR spectrum of 2.27b, irradiation of the signal at o 4.32 (CfuOH) lead to collapse 
of the CHCH20H signal (to a doublet at o 5.91, 1=11.7 Hz) and of the OH triplet at o 1.51 
(to a singlet). A HMQC experiment, performed to assign the 13C NMR spectrum of 
2.27b, distinguished the C6~0CH2 signal at o 64.1 and demonstrated that the 13C NMR 
signal at o 125.4 was due to two carbons (one of the olefms and the N02CCH carbon). 
The 13C NMR spectrum of 2.27a was assigned by comparison to those of 2.27b and 
2.26a. 
COMPOUNDS 2.28a and 2.28b 
Compounds 2.28a and 2.28b, purified by radial chromatography, were fully 
characterised. All signals in the 1H NMR spectrum of 2.28a appeared as multiplets and, 
therefore, the direct assignment of signals on the basis of their coupling was not feasible. 
Instead, the spectrum was assigned on the basis of homonuclear decouplings experiments 
(see Table 2.4). Interestingly, the PhCH2CH2 protons appeared as four separate 
multiplets between o 1.81 and o 2.88. Homonuclear decoupling experiments were also 
employed to assign the 1H NMR spectrum of 2.28b (see Table 2.4). The C6RtOCH2 
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signal appeared as two separate doublets of doublets, as did the CH20H signal after 
irradiation of either the OH triplet or the CHCH20H signal (see Table 2.4). To assign the 
13C NMR spectrum of 2.28a, a distortionless enhancement by polarisation transfer 
(DEPT) experiment was performed to distinguish the epoxide carbons at o 56.6 and 
o 56.1 from the CH20H carbon at o 60.0 (the olefins were used as the reference carbons). 
The 13CNMR spectrum of 2.28b was assigned by comparison to those of 2.28a and 
2.27b. 
Table 2.4. Homonuclear Decoupling Experiments on 2.28a and 2.28b 
Compound Signal Irradiated (o) 
2.28a 3.57 (C!kOH) 
3.11 (epoxide) 
2.88 (PhC!k) 
2.73 (PhC!k) 
2.01 (PhCH2Clli) 
1.81 (PhCH2Clli) 
1.34 (OH) 
2.28b 3.98 (CfuOH) 
3.87 (CfuOH) 
3.34 (CHCH20H) 
1.77 (OH) 
Signal Collapsed (o) (coupling constant (Hz)) 
1.34 to s (OH) and 3.11 (epoxide) 
3.57 (CfuOH) and 1.81, 2.01 (PhCH2Clli) 
1.81, 2.01 (PhCH2Clli) and 2.73 (PhClli) 
1.81, 2.01 (PhCH2Cfu) and 2.88 (PhCfu) 
1.81 (PhCH2Cfu) and 2.73, 2.88 (PhClli) 
2.01 (PhCH2Cfu) and 2.73, 2.88 (PhClli) 
3.57 to d (J=5.9) (ClliOH) 
1.77 (OH), 3.34 (CHCH20H), and 
3.87 (CfuOH) 
1.77 (OH), 3.34 to t (J=4.9) (CHCH20H), and 
3.98 (CfuOH) 
3.34 (CHCH20H) and 4.28, 4.37 to ABq 
(J=11.7) (C6~0Clli) 
3.47 (C6~0CH2CH), 3.98 todd (1=5.4, 
12.7), and 3.87 todd (J=5.9, 12.7) (ClliOH) 
3.98 todd (1=3.9, 12.7) and 3.87 todd 
(1=4.9, 12.7) (ClliOH) 
Note: unless otherwise stated, signals did not collapse to a recognisable shape. 
COMPOUNDS 2.29a and 2.29b 
The 1H NMR spectra of 2.29a and 2.29b showed that the oxidation was complete-the 
signals due to the CH20H protons had disappeared and no signals had appeared in the 
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aldehyde region of the spectrum. The NMR spectra of 2.29a and 2.29b were assigned by 
comparison to those of 2.28a and 2.28b. 
COMPOUND 2.31 
Compound 2.31, purified by radial chromatography, was fully characterised. NMR 
spectra were assigned by comparison to similar compounds such as 2.23b as appropriate. 
COMPOUNDS 2.34a, 2.34b and 2.35 
The 1H NMR spectra of the crude reaction mixtures revealed that each compound (2.34a, 
2.34b, arid 2.35) was obtained as a single diastereoisomer. The reaction products were 
purified by radial chromatography and were fully characterised. In the 1H NMR 
spectrum of 2.34a, the ClhO signal appeared as two separate doublets of doublets at 
o 4.19 and o 4.05. Irradiation of these signals collapsed the epoxide (CHCH20) signal at 
o 3.14 (to a doublet, J=3.6 Hz). Further homonuclear decoupling experiments showed 
that the signals at o 3.06 ((CH2CH2CID and at o 1.87 (CH2CfuCH) were mutually 
coupled. In the 1H NMR spectra of 2.34b and of 2.35, both OCH2 signals appeared as a 
single multiplet, shown by homonuclear decoupling experiments to be coupled to the 
epoxide signals (which appeared at o 3.36 and o 3.45 for both compounds). A HMQC 
experiment, performed to assign the 13C NMR spectrum of 2.34a, is shown in Figure 2.6. 
This distinguished the PhCH2CH2 signals (at o 32.1 and o 29.7) from each other and from 
the CH(Me)2 signal at o 30.7 and further enabled the assignment of the epoxide carbons 
(o 55.3 and o 53.1) and the CHCH(Me)2 carbon (o 58.5). A HMQC experiment was also 
petformed to assign the 13C NMR spectrum of 2.35, particularly to distinguish the 
epoxide carbons (o 52.3 and 8 53.3) and both the CHCH(Me)2 carbons (o 56.7 and 
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o 59.9). The 13C NMR spectrum of 2.34b was assigned by comparison to those of 2.34a 
and 2.35. 
Figure 2.6. The HMQC of Compound 2.34a 
<I 
• 
• 
j l l 
•• 
70 65 60 55 50 45 40 35 30 25 20 15 
fl (ppm) 
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COMPOUNDS 2.37 and 2.39 
The configuration of the epoxide was assigned on the basis of the coupling constants of 
the epoxide protons in the 1H NMR spectra of compounds 2.37 and 2.39. For 2.37, the 
epoxide protons appeared as a doublet at b 3.49 (J=2.0 Hz) and a multiplet at b 3.76 
(which collapsed to a doublet (J=2.1 Hz) on irradiation at 8 5.88 (PhCHCH)). These 
coupling constants are consistent with trans epoxides.2·47 Further, nuclear Overhauser 
enhancement (nOe) experiments were performed on compound 2.37 to confirm the trans 
assignment of the epoxide. Irradiation at b 3.49 (CHCO) gave enhancement at o 5.88 
(PhCHCH) and vice versa. These protons are close (in space) in the trans epoxide (2.37) 
but not in the cis epoxide (2.39) (see Figure 2.7). As expected for an trans epoxide, a 
nOe was not obtained between the epoxide protons of compound 2.37. For compound 
2.39 the cis configuration was assigned to the epoxide on the basis of the 1H NMR 
coupling constants of the epoxide protons. The epoxide protons appeared as a multiplet 
at o 3.78 which collapsed to a doublet at 8 3.80 (J=4.4 Hz) and a doublet at 8 3.76 
(J=4.4 Hz), after irradiation at 8 6.15 (PhCHCH). These coupling constants are 
consistent with cis epoxides?.47 The 13C NMR spectra of compounds 2.37 and 2.39 both 
required a HMQC experiment to distinguish the olefin carbons from the aromatic carbons 
and the epoxide carbons from the OCH2 carbon. The correlations are shown in Table 2.5. 
Figure 2. 7. Protons (in bold) which are close (in space) in 2.37 but not in 2.39. 
0 
Ph Ph C02Et 
H trans-epoxide 2.37 H cis-epoxide 2.39 
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Table 2.5. HMQC Data on 2.37 and 2.39 
Compound 1HNMR(3) 13C NMR(3) Assignment 
2.37 6.87 136.4 PhCH 
5.88 129.9 PhCHCH 
4.28 61.8 OCH2 
3.76 58.3 CHCHCO 
3.49 55.1 CHCO 
2.39 6.91 137.9 PhCH 
6.15 121.5 PhCHCH 
4.29 61.6 OCH2 
3.78 54.6, 57.9 CHCH( epoxides) 
COMPOUND 2.38 
The molecular formula determined by mass spectrometry was consistent with the 
proposed structure, and the infrared spectrum indicated the presence of an OH group 
(assigned to a broad peak at 3459 cm-1).2.47 To assign the 1H NMR spectrum of 2.38, 
homonuclear decoupling experiments were performed. The signals at 3 6.18 (PhCHCH) 
and at 3 4.70 (later assigned CHOH) were found to be mutually coupled and further the 
signals at 3 4.70 and at 3 4.35 (later assigned CHBr) were found to be mutually coupled. 
A HMQC experiment correlated the 1H NMR signal at 3 4.70 to the 13C NMR signal at 
3 72.5 (assigned CHOH on the basis of the chemical shift of the carbon2.47) and the 
1H NMR signal at 3 4.35 to the 13C NMR signal at 3 51.5 (assigned CHBr on the basis of 
the chemical shift of the carbon2A7). NMR data indicated the presence of a single 
diastereoisomer, which was confirmed since 2.38 was converted stereoselectively to the 
cis epoxide (2.39) (see Scheme 2.13 for a general scheme). 
COMPOUND 2.41 
The NMR spectra of compound 2.41 was assigned by comparison to similar compounds 
such as 2.37 and 2.29a. 
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COMPOUND 2.42 
The structure (2.42) was determined by examination of NMR data. A mass spectrum was 
consistent with the proposed structure. In the 1H NMR spectrum of 2.42, the four proton 
multiplet at o 1.66-1.87 ((C.lli,)2CHOH) was shown by homonuclear decoupling to be 
mutually coupled to the CHOH proton at 0 4.19, which appeared as a triplet (J=4.9 Hz). 
To assign the 13C NMR spectrum of compound 2.42, a HMQC experiment was performed 
to distinguish the PhCH2 carbon at o 35.5 from the PhCH2(QH2)2 carbons at a 33.9 and at 
a 26.5. The CHOH carbon was assigned on the basis of its chemical shift to the signal at 
a 70.3. 
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Part 3. In Vitro Testing against the HIV-1 PR 
In Vitro Testing of compounds 2.14b-g, 2.14j, 2.20, 2.23a, 2.24a, 2.24b, 2.29b, 2.31, 
2.34b, and 2.35 against the HIV-1 PR was performed by Drs. D. Fairlie and D. Bergman 
of the Centre for Drug Design and Development, University of Queensland, according to 
a published procedure.2.49 The results are displayed in Table 2.6. 
Table 2.6 Inhibition Data for Epoxide-Based Compounds 
Compound ICso % Inhibition (at 200 }.1M) 
2.14b, 2.14c, and 2.14e inactive 
2.14f, 2.14g, and 2.14j inactive 
2.20 9.8 
2.23a 19.1 
2.24a 30.2 
2.24b 710 }.1M 210 }.1M 
2.29b 15.1 
2.31 inactive 
2.34b 800nM 200nM 
2.35 6}-lM l.7J1M 
As shown in Table 2.6, the peptide-based pseudosymmetrical epoxides (2.14b, 2.14c, and 
2.14e, Part 1) were inactive (at 200 }.1M). Further, the symmetrical epoxides (2.14f, 
2,14g, and 2.14j, Part 1) were also inactive. Interestingly, however, the non-symmetrical 
THE LIBRARY 
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epoxide (2.20, Part 1) showed modest activity (9.8% at 200 JlM). Compound 2.20 was 
designed as an analogue of compound 2.14j to probe the importance of the symmetrical 
nature of such compounds. A comparison of the in vitro results for 2.20 and 2.14j (Table 
2.6) suggests that the symmetrical nature of compound 2.14j may contribute to its 
inactivity. This suggestion is supported by literature on the pseudosymmetrical epoxide 
(2.15)?·23 Compound 2.15 is a reversible inhibitor of the HIV PR (Ki=75 nM), whereas 
non-symmetrical analogues of 2.15, such as compound 2.43, exhibited irreversible 
inactivation of the enzyme (K1=0.1 nM).Z·23 The authors suggested that the rigidity of the 
epoxide (together with Phe at the Pl' position) did not allow 2.15 to adopt the 
conformation required for irreversible inactivation. 
0 0 
0 
H . N . '~NHCbz 
0 
Ph 
~ 
H /
0
\ H ~ 
N~N . ~ ~NHCbz 
0 - 0 
Ph/ 2.43 
The ENP inspired peptidomimetics (2.23a, 2.24a, 2.24b, 2.29b, 2.34b, 2.35, Part 2) were 
tested against the HIV-1 PR and were found to be active (Table 2.6). Notably, compound 
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2.34b stood out with a K1 value of 200 nM. Such activity is superior to the epoxide-based 
inhibitors 2.10 (K1=9.9 mM),2'19 2.11 (K1=20 J.LM),2·20 and 2.12 (1.32 J.LM)2'21 which served 
as lead structures (see Part 2 of this chapter). Exhaustive dialysis failed to restore enzyme 
activity, indicating that inactivation by compound 2.34b was irreversible, as predicted. 
Further, the addition of a reversible competitive inhibitor protected the enzyme from 
inactivation by 2.34b, indicating that compound 2.34b reacts with an active site residue. 
It is noteworthy that compounds 2.34b and 2.35 were considerably more active than 
compounds of the type 2.24. This is perhaps due to presence of the methylene (between 
the epoxide and the C02) in compounds 2.34b and 2.35. Studies on the known inhibitor 
(2.12) have shown a methylene group, alpha to the epoxide group, to be essential to its 
activity.2·21 Note further, that in compounds 2.34b and 2.35 the amino acid sequence is 
inverted (at the Val residue of compound 2.34b and at the Val-Val moiety of 2.35). 
Unexpectedly, the "tetrapeptide" (2.35), which contains Val at the P3' position, is less 
active than the "tripeptide" (2.34b). 
0 ~ r('Y0~00NHC02CH2Ph )V 0 2.34b 
0 2N 
0 
0~~ NHC02CH2Ph 
0 2.35 
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N02 
0~ 2.10 2.12 
Compounds 2.23a (19.1% inhibition at 200 J.!M), 2.24a (30.2% inhibition at 200 J.!M), 
and 2.24b (K1=210 J.!M) displayed moderate activity. They were, in fact, considerably 
more active than ENP (2.10) (K1=9.9 mM),2.1 9 which served as a lead structure (see Part 2 
of this chapter). A comparison of the activities of compounds 2.24a and 2.24b 
demonstrates that Val, rather than Leu, is the better residue to enhance enzyme 
recognition in this system. Since Val is well known at the P2' position but not at 
Pl' ,2·1• 2·2 this result suggests the amino acid moiety may bind in the S2' subsite of the 
enzyme. Further, a comparison of the activities of compounds 2.23a and 2.24a 
demonstrates that a p-nitrophenoxy moiety rather than a phenylmethylene group leads to 
a superior inhibitor (in this system). This suggests interactions between the nitro group 
and phenoxy oxygen of 2.24a and the enzyme. The crystal structure of the known 
inhibitor (2.10) bound to the SIV PR revealed weak interactions between the nitro group 
and phenoxy oxygen of2.10 and the enzyme.2.1 9 
H 
N~C02Me 
R 2.23a R=CHCH2(Me )z 
0 
2.24a R=CHCH2(Me)z 
2.24b R=CH(Me h 
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A comparison of the activity of the parent acid (2.29b) with 2.24a or 2.24b suggests that, 
as expected, the addition of an amino acid residue increases inhibitor activity, presumably 
by enhancing enzyme recognition and binding affinity. Further, the superior activity of 
2.24a and 2.24b, over 2.29b, indicates that enzymatic hydrolysis of the amide bond alpha 
to the epoxide is unlikely to occur to a significant extent (enzymatic hydrolysis of 
2.24a/2.24b would give 2.29b and therefore 2.24a/2.24b would give a similar in vitro 
result to 2.29b ). 
OH 
0 
Finally, compound 2.31, designed to probe the importance of the p-nitrophenoxy group in 
compounds of the type 2.24, proved to be inactive at 200 JlM. Compound 2.31 is an 
analogue of compound 2.24b containing a simple alkyl chain in place of the 
p-nitrophenoxy group. This result demonstrates that the p-nitrophenoxy group is critical 
to the activity of 2.24b. 
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Experimental 
General Procedure 
Melting points (m.p.) were taken on a Reichert hot-stage microscope and are uncorrected. 
Nuclear Magnetic Resonance (NMR) spectra were recorded on either a Varian CFT300 
or a XL300 spectrometer. Mass spectra (MS) were obtained on a Kratos MSSORFA 
spectrometer. Infrared (IR) spectra were recorded on a Shimadzu FTIR-8201PC 
spectrophotometer. Optical rotations were measured on a JASCO J-20C recording 
spectropolarimeter and [ a]n values are given in units of 10-1 degrees cm2 g-1, with the 
concentration (c) given in units of mg cm-3• Radial chromatography was performed on a 
Chromatotron (Harrison and Harrison) using Merck type 60 PF254 silica gel. The amino 
acids (glycine ethyl ester hydrochloride, L-leucine methyl ester hydrochloride, L-
phenylalanine methyl ester hydrochloride, glycinylglycine ethyl ester hydrochloride, N-
Boc-L-leucine, L-valine benzyl ester hydrochloride, L-valine methyl ester hydrochloride, 
N-CBz-L-valine, and N-CBz-L-valinyl-L-valine), the amines (2.19, n=617), and the 
aldehyde (2.25a) were commercially available. 
Preparation2·24 of (2S,3R)-N,N-Ethylglycinyl-2,3-epoxybutandiamide (2.14a) 
To a stirring solution of 100 mg (0.76 mmol) of 2.16 (synthesised by a literature 
procedure2'25) in dichloromethane (CH2Cb) (5.0 ml), at 0 °C, were added two equivalents 
(1.5 mmol) of each glycine ethyl ester hydrochloride (209 mg), triethylamine (Et3N) 
(152 mg), dicyclohexylcarbodiimide (DCC) (309 mg), and 1-hydroxybenzotriazole 
(HOBT) (203 mg). The resultant solution was stirred at room temperature (r.t.) overnight 
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after which the solvent was evaporated under reduced pressure. Ethyl acetate was then 
added to the residue to precipitate the dicyclohexylurea (DCU) byproduct, which was 
removed by filtration. The filtrate was washed (3x) with saturated sodium bicarbonate 
(NaHC03), dried with magnesium sulfate (MgS04), and the solvent was evaporated under 
reduced pressure. The resultant solid was recrystallised from ethyl acetate/petroleum 
ether to give white crystals (146 mg, 63%) m.p. 129-130°C. 
Spectral data for 2.14a: 
1H NMR (CDCh) o 6.75 (t (br), 2H, 1=5.8 Hz, NH); 4.20 (q, 4H, 1=6.9 Hz, OCH2); 4.14 
(dd, 2H, 1=5.8, 18.0 Hz, NHC_fu); 3.97 (dd, 2H, 1=5.8, 18.0 Hz, NHC_fu); 3.76 (s, 2H, 
CH(epoxide)); 1.28 (t, 6H, 1=7.4 Hz, Me). 13C NMR (CDCh) o 169.2 (C02); 164.9 
(CONH); 61.6 (OCH2); 55.0 (C(epoxide)); 41.0 (NHCH2); 14.1 (Me). HRMS Calculated 
for Ct2H19N207 (W+H): 303.11921. Found: 303.11930. FTIR (KBr) 3332; 2924; 1743; 
1681; 1556 cm·1• Anal. Calculated for C12H18N20 7: C 47 7, H 6.0, N 9.3. Found: C 47.4, 
H 6.1, N 9.2. 
Preparation2·24 of (2S.3R)-N.N-(Methyl-L-leucinyl)-2,3-epoxybutandiamide (2.14b) 
To a stirring solution of 500 mg (3.8 mmol) of 2.16 (synthesised by a literature 
procedure2"25) in CH2Ch (10 ml), at 0 °C, were added two equivalents (7.6 mmol) of each 
L-leucine ethyl ester hydrochloride (1.381 g), Et3N (769 mg), DCC (1.568 g), and HOBT 
(1.027 g). The resultant solution was stirred at r.t. overnight after which the solvent was 
evaporated under reduced pressure. Ethyl acetate was then added to the residue to 
precipitate the DCU byproduct, which was removed by filtration. The filtrate was 
washed (3x) with saturated NaHC03, dried with MgS04, and the solvent was evaporated 
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under reduced pressure. The crude product was purified by radial chromatography on 
silica (60% dichloromethane, 40% ethyl acetate) to give a colourless oil (903 mg, 62%). 
Spectral data for 2.14b: 
1H NMR (CDCh) () 6.65 (d, 1H, J=7.3 Hz, NH); 6.58 (d, 1H, J=7.8 Hz, NH); 4.57 (m, 
2H, NHCH); 3.73 (s, 3H, OMe); 3.72 (s, 3H, OMe); 3.70, 3.68 (ABq, 2H, J=7.3 Hz, 
CH(epoxide)); 1.57 (m, 6H, CfuCH(Me)z); 0.92 (m, 12H, CH(Me)2). 13C NMR (CDCh) 
() 172.6 (C02); 165.1, 165.0 (CONH); 55.0, 54.9 (C(epoxide)); 53.2, 52.2 (NHCH); 50.8 
(OMe); 41.2, 41.1 (CH2); 24.7, 24.5 (CH(Me)2); 22.6, 21.9 (CH(Me)2). HRMS 
Calculated for C18H31N20 7 (M++H): 387.21311. Found: 387.21360. FTIR (thin film) 
3304; 3075; 2958; 2872; 2252; 1742; 1682; 1651; 1538 cm-1• 
Preparation2·24 of (2S,3R)-N,N-(Methyl-L-phenylalaninyl)-2,3-
epoxybutandiamide (2.14c) 
To a stirring solution of 100 mg (0.76 mmol) of 2.16 (synthesised by a literature 
procedure2.25) in CH2Ch (5.0 ml), at 0 °C, were added two equivalents (1.5 mmol) of each 
L-phenylalanine methyl ester hydrochloride (324 mg), Et3N (152 mg), DCC (309 mg), 
and HOBT (203 mg). The resultant solution was stirred at r.t. overnight after which the 
solvent was evaporated under reduced pressure. Ethyl acetate was then added to the 
residue to precipitate the DCU byproduct, which was removed by filtration. The filtrate 
was washed (3x) with saturated NaHC03, dried with MgS04, and the solvent was 
evaporated under reduced pressure. The crude product was purified by radial 
chromatography on silica (80% dichloromethane, 20% ethyl acetate) to give a colourless 
oil (172 mg, 50%). 
106 
Chapter 2 
Spectral data for 2.14c: 
1H NMR (CDCb) o 7.27 (m, 6H, ArH); 7.12 (m, 4H, ArH); 6.65 (m(br), 2H, NH); 4.67 
(m, 2H, CHCH2); 3.70 (s, 3H, Me); 3.66 (s, 3H, Me); 3.64, 3.62 (ABq, 2H, J=7.8 Hz, 
CH(epoxide)); 3.08 (m, 4H, CHC!L). 13C NMR (CDCb) o 171.0 (C02); 164.4 (CONH); 
135.8, 135.4, 129.2, 129.2, 128.7, 128.6, 127.3, 127.1 (Ar); 54.8, 54.7 (C(epoxide)); 53.4, 
53.3 (CHCH2); 52.4, 52.3 (Me); 37.7, 37.7 (CH2Ph). HRMS Calculated for C24H26N20 7K 
(M+ +K): 493.13770. Found: 493.13770. FTIR (thin film) 3341; 3028; 2953; 1744; 
1682; 1536 cm-1• 
Preparation2·24 of (2S,3R)-N,N-(Ethylglycinylglycinyl)-2,3-epoxybutandiamide (2.14d) 
To a stirring solution of 100 mg (0.76 mmol) of 2.16 (synthesised by a literature 
procedure2·25) in CH2Clz (5.0 ml), at 0 °C, were added two equivalents (1.5 mmol) of each 
glycinylglycine ethyl ester hydrochloride (298 mg), Et3N (152 mg), DCC (309 mg), and 
HOBT (203 mg). The resultant solution wa;;; stirred at r.t. overnight after which the 
solvent was evaporated under reduced pressure. The crude product was purified on a 
silica plate (eluting with 100% ethyl acetate) to give a white solid, tentatively assigned to 
the structure 2.14d (35 mg, 11 %) m.p. 156-159 °C. 
Spectral data for 2.14d: 
1H NMR (CD30D) o 7.73 (m(br), 2H, NH); 7.25 (m(br), 2H, NH); 4.71 (m, 4H, NHCfu); 
4.18 (q, 4H, 1=6.8 Hz, OCfu); 4.00 (m, 4H, NHC!L); 3.96 (s, 2H, CH(epoxide)); 1.26 (t, 
6H, J=6.8 Hz, Me). 13C NMR (CD30D) o 62.7 (OCH2); 55.8 (C(epoxide)); 44.1, 43.3 
(NHCHz); 14.7 (Me). FTIR (KBr) 3310; 2847; 1760; 1634 cm-1• 
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epoxybutandiamide (2.14e) 
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To a stirring solution of 26 mg (0.20 mmol) of 2.16 (synthesised by a_literature 
procedure2'25) in THF (1.0 ml), at 0 °C, were added two equivalents (0.40 mmol) of each 
2.17 (129 mg) (also in THF (1.0 ml)) and DCC (83 mg). The resultant solution was 
stirred for 30 minutes, at 0 °C, and HOBT (54 mg, 0.4 mmol) was added. The reaction 
mixture was then stirred at r.t. overnight after which the solvent was evaporated under 
reduced pressure. Ethyl acetate was then added to the residue to precipitate the DCU 
byproduct, which was removed by filtration. The filtrate was washed (3x) with saturated 
NaHC03 followed by 10% hydrochloric acid (HCl), dried with MgS04, and the solvent 
was evaporated under reduced pressure. The crude product was purified by radial 
chromatography on silica (60% petroleum ether, 40% ethyl acetate) to give a colourless 
oil (15 mg, 10%). 
Spectral data for 2.14e: 
1H NMR (CDCh) o 7.99 (d(br), 1H, 1=9.3 Hz, NH); 7.67 (d(br), 1H, 1=8.8 Hz, 
NHCHCH2); 7.55 (d(br), 1H, 1=8.3 Hz, NHCHCH); 7.34 (m, 10H, ArH); 6.61 (d(br), 1H, 
1=10.3 Hz, NH); 5.07 (m, 4H, CH2Ph); 4.92 (q(br), 1H, 1=8.8 Hz, NHCHCH2); 4.64 (m, 
2H, NHCH); 4.46 (dd, 1H, 1=5.4, 8.4 Hz, NHCHCH); 3.75, 3.69 (ABq, 2H, 1=15.6 Hz, 
CH(epoxide)); 2.29 (m, 1H, NHCHCH); 2.10 (m, 1H, NHCHCH); 1.59-1.93 (m, 6H, 
CfuCH(Me)2); 0.87 (m, 24 H, Me). 13C NMR (CDC13) o 173 3, 171.9, 171.5, 171,3, 
164.8, 164.4 (CO); 135.2, 135.1, 128.6 128.6, 128.6, 128.4, 128.1 (Ar); 67.1, 66.9 
(hH2Ph); 57.8, 57.6 (NHCHCH); 54.8, 54.3 (C(epoxide)); 51.8, 51.5 (NHCHCH2); 42.2, 
41.8 (NHCHCH2); 32.2, 31.1 (NHCHCH); 24.8, 24.6 (CH2CH(Me)2); 23.3, 22.6, 22.2, 
21.3 (CH2CH(Me)2); 19.1, 18.9, 18.6, 17.9 (CHCH(Me)2). HRMS Calculated for 
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C40H56N409K (M++K): 775.36841. Found: 775.36895. FTIR (thin film) 3288; 2961; 
1737; 1656; 1537 cm-1• 
Preparation of (2S.3R)-N,N-(6-Carboxyhexyl)-2,3-epoxybutandiamide (2.14f) and 
(2S,3R)-N,N-(7-Carboxyheptyl)-2,3-epoxybutandiamide (2.14g) 
To a stirring solution of 30 mg (0.07 mmol) of either 2.14h or 2.14i in methanol (MeOH) 
(1.4 ml), was added 0.15 ml of a 1M solution of sodium hydroxide (NaOH). The reaction 
mixture was stirred at r.t. overnight after which the MeOH was evaporated under reduced 
pressure. Water was added to the residue and the resultant solution was extracted (3x) 
with ethyl acetate. The aqueous layer was then acidified with 10% HCl and extracted 
(3x) with ethyl acetate. The combined fractions from the second extraction were dried 
with MgS04 and evaporated under reduced pressure. The crude product was purified by 
recrystallisation from ethyl acetate to give either 2.14f (18 mg, 67%) m.p. 50-51 °C or 
2.14g (15 mg, 52%) m.p. 95-96 °C as white crystals. 
Spectral data for 2.14f: 
1H NMR (CD30D) o 7.78 (t(br), 2H, J=5.8 Hz, NH); 3.52 (s, 2H, CH(epoxide)); 3.01 (m, 
4H, NHCfiz); 2.10 (t, 4H, J=7.4 Hz, CHzCO); 1.42 (m, 4H, CfizCH2CO); 1.31 (m, 4H, 
NHCHzCfiz); 1.17 (m, 8H, NHCHzCHz(CHz)2). 13C NMR (CD30D) o 177.9 (COz); 
167.8 (CONH); 56.1 (C(epoxide)); 40.5 (NHCH2); 35.2 (hH2CO); 30.5 (NHCH2CH2); 
30.2, 27.2, (NHCH2CHz(CHz)z); 26.3 (CHzCH2CO). HRMS Calculated for C 18H30N20 7K 
~+K): 425.16898. Found: 425.16910. FTIR (thin film) 3474; 2934; 2360; 1655 cm-1• 
Spectral data for 2.14g: 
1H NMR (CD30D) o 7.77 (t(br), 2H, J=5.8 Hz, NH); 3.51 (s, 2H, CH(epoxide)); 3.00 (m, 
4H, NHCHz); 2.09 (t, 4H, J=7.3 Hz, CHzCO); 1.41 (m, 4H, CH2CH2CO); 1.29 (m, 4H, 
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NHCH2C.fu); 1.15 (m, 12H, NHCH2CH2(CH2)3). 13C NMR (CD30D) o 177.9 (C02); 
167.8 (CONH); 56.1 (C(epoxide)); 40.5 (NHCH2); 35.2 ~H2CO); 30.6 (NHCH2CH2); 
30.4, 30.4, 28.0 (NHCH2CH2~H2)3); 26.3 ~H2CH2CO). HRMS Calculated for 
C2oH35N20 7 (M++H): 415.24441 Found: 415 24450. FTIR (thin film) 3455; 2932; 2360; 
Preparation2'24 of (2S,3R)-N,N-(6-Methoxycarbonylhexyl)-2,3-epoxybutandiamide 
(2.14h) and (2S,3R)-N,N-(7-Methoxycarbonylheptyl)-2,3-epoxybutandiamide (2.14i) 
To a stirring solution of 250 mg (1.9 mmol) of 2.16 (synthesised by a literature 
procedure2·25) in CH2Ch (15 ml), at 0 °C, were added two equivalents (3.8 mmol) of each 
2.182'28' 2'29 (either n=6 (744 mg) or n=7 (797 mg)), Et3N (385 mg), DCC (784 mg), and 
HOBT (513 mg). The resultant solution was stirred at r.t. overnight after which the 
solvent was evaporated under reduced pressure. Ethyl acetate was then added to the 
residue to precipitate the DCU byproduct, which was removed by filtration. The filtrate 
was washed (3x) with saturated NaHC03, dried with MgS04, and the solvent was 
evaporated under reduced pressure. The crude product was recrystallised from ethyl 
acetate/petroleum ether to give either 2.14h ( 406 mg, 52%) m.p. 45-46 °C or 2.14i 
(451 mg, 54%) m.p. 47-48 °C as white crystals. 
Spectral data for 2.14h: 
1H NMR (CDCb) o 6.70 (t(br), 2H, J=5.8 Hz, NH); 3.64 (s, 6H, OMe); 3.61 (s, 2H, 
CH(epoxide)); 3.20 (q, 4H, J=5.8 Hz, NHCH2); 2.28 (t, 4H, J=7.4 Hz, CH2CO); 1.59 (m, 
4H, C_fuCH2CO); 1.47 (m, 4H, NHCH2CH2); 1.30 (m, 8H, NHCH2CH2(Cfu)2). 
13C NMR (CDCb) o 175.2 (C02); 165.1 (CONH); 54.9 (C(epoxide)); 51.5 (OMe); 39.3 
(NHCH2); 33.9 (CH2CO); 29.1 (NHCH2CHz); 28.6, 26.4 (NHCH2CH2(CH2)z); 24.7 
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(CHzCHzCO). HRMS Calculated for C20H34Nz07K (M++K): 453 20029. Found: 453 
20046. FTIR (thin ftlm) 3302; 2935; 2859; 1679; 1555 cm-1• Anal. Calculated for 
CzoH34Nz07: C 58.0, H 8.3, N 6.8. Found: C 57 .9, H 8.0, N 6.8. 
Spectral data for 2.14i: 
1H NMR (CDClg) 8 6.71 (t(br), 2H, 1=5.9 Hz, NH); 3.63 (s, 6H, OMe); 3.60 (s, 2H, 
CH(epoxide)); 3.19 (q, 4H, 1=5.9 Hz, NHCHz); 2.27 (t, 4H, 1=7.3 Hz, CH2CO); 1.58 (m, 
4H, CHzCHzCO); 1.45 (m, 4H, NHCHzCHz); 1.27 (m, 12H, NHCHzCHz(CHz)3). 
13C NMR (CDCh) 8174.3 (C02); 165.1 (CONH); 54.9 (C(epoxide)); 51.5 (OMe); 39.4 
(NHCHz); 34.0 (CH2CO); 29.2 (NHCHzCH2); 28.9, 28.8 26.5 (NHCH2CH2(CH2)3); 24.8 
(CHzCHzCO). HRMS Calculated for CzzH3sNz07K (M++K): 481.23159. Found: 
481.23170. FTIR (thin film) 3315; 2932; 2856; 1738; 1659; 1553 cm·1• Anal. Calculated 
for CzzH3sNz07: C 59.7, H 8.7, N 6.3. Found: C 59.6, H 8.7, N 6.4. 
Preparation2'24 of (2S,3R)-N,N-Heptyl-2,3-epoxybutandiamide (2.14j) and (2S,3R)-N,N-
Octyl-2,3-epoxybutandiamide (2.14k) 
To a stirring solution of 50 mg (0.38 mmol) of 2.16 (synthesised by a literature 
procedure2'25) in CH2Clz (15 ml), at 0 °C, were added two equivalents (0.76 mmol) of 
each 2.19 (either n=6 (88 mg) or n=7 (98 mg)), DCC (157 mg), and HOBT (103 mg). 
The resultant solution was stirred at r.t. overnight after which the solvent was evaporated 
under reduced pressure. Ethyl acetate was then added to the residue to precipitate the 
DCU byproduct, which was removed by filtration. The filtrate was washed (3x) with 
saturated NaHC03, dried with MgS04, and the solvent was evaporated under reduced 
pressure. The crude product was recrystallised from ethyl acetate/petroleum ether to give 
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either 2.14j (96 mg, 77%) m.p. 82-83 °C or 2.14k (80 mg, 59%) m.p. 83-84 °C, as white 
crystals. 
Spectral data for 2.14j: 
1H NMR (CDCh) o 6.65 (t(br), 2H, J=5.8 Hz, NH); 3.62 (s, 2H, CH(epoxide)); 3.21 (q, 
4H, J=5.8 Hz, NHCfu); 1.46 (m, 4H, NHCH2Cfu); 1.26 (m, 16H, (Cfu)4CH3); 0.86 (t, 
6H, J=6.8 Hz, Me). 13C NMR (CDCh) o 164.9 (CONH); 55.0 (C(epoxide)); 39.5 
(NHCHz); 31.7 (NHCHzCHz); 29.4, 28.9, 26.7 (NHCH2CH2~H2)3); 22.6 ~H2Me); 14.9 
(Me). HRMS Calculated for C1sH34N20g: 326.25693. Found: 326.2569. FTIR (thin 
film) 3280; 2956; 2928; 2856; 1661; 1558 cm-1• Anal. Calculated for C18H34N20 3: C 
66.2, H 10.5, N 8.6. Found: C 65.9, H 10.4, N 8.7. 
Spectral data for 2.14k: 
1H NMR (CDCh) o 6.50 (t(br), 2H, J=5.8 Hz, NH); 3.62 (s, 2H, CH(epoxide)); 3.21 (q, 
4H, J=5.8 Hz, NHCfu); 1.46 (m, 4H, NHCH2Cfu); 1.25 (m, 20H, (Cfu)5Me); 0.86 (t, 
6H, J=6.8 Hz, Me). 13C NMR (CDCh) o 165.0 (CONH); 54.9 (C(epoxide)); 39.4 
(NHCHz); 31.7 (NHCH~Hz); 29.3, 29.2, 29.1, 26.8 (NHCH2CH2~Hz)4); 22.6 ~H2Me); 
14.0 (Me). HRMS Calculated for C20H38N20 3: 354.28822. Found: 354.28885. FTIR 
(thin film) 3278; 3098; 2957; 2926; 2426; 2122; 1660; 1557 cm-1• Anal. Calculated for 
CzoH3sNz03: C 67.8, H 10.8, N 7.9. Found: C 67.8, H 10.7, N 8.0. 
Preparation2·27• 230• 250 ofL-Leucinyl-L-valine benzyl ester (2.17) 
Step 1 
To a stirring solution of 690 mg (3.0 mmol) of N-Boc-L-leucine in tetrahydrofuran (THF) 
(5.0 ml), at 0 °C, were added 3.0 mmol of each L-valine benzyl ester hydrochloride 
(730 mg), Et3N (304 mg), DCC (618 mg), and HOBT (406 mg). The resultant solution 
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was stirred at r.t. overnight after which the solvent was evaporated under reduced 
pressure. Ethyl acetate was then added to the residue to precipitate the DCU byproduct, 
which was removed by filtration. The filtrate was washed (3x) with saturated NaHC03, 
dried with MgS04, and the solvent was evaporated under reduced pressure. The crude 
product was purified by radial chromatography on silica (80% petroleum ether, 20% ethyl 
acetate) to give the intermediate, N-Boc-L-leucinyl-L-valine benzyl ester (800 mg, 63%). 
Step 2 
A solution of 400 mg (0.96 mmol) of N-Boc-L-leucinyl-L-valine benzyl ester in formic 
acid (1.6 ml) was stirred overnight, at r.t., after which the formic acid was evaporated 
under reduced pressure. Water (2.0 ml) was added to the residue and the resultant 
solution was alkalified (pH=lO) with 25% NaOH and then extracted (3x) with ethyl 
acetate. The combined organic layers were dried with MgS04 and evaporated to give 
2.17 as a colourless oil (129 mg, 42%). 
Spectral data for the intermediate, N-Boc-L-Leucinyl-L-valine benzyl ester: 
1H NMR (CDC13) 8 7.35 (m, 5H, ArH); 6.54 (d, 1H, J=8.8 Hz, NH); 5.20, 5.12 (ABq, 2H, 
1=12.2 Hz, CHzPh); 4.85 (d(br), J=7.1 Hz, NH); 4.57 (dd, 1H, J=4.9, 8.8 Hz, NHCHCH); 
4.10 (m, 1H, NHCHCH2); 2.19 (m, 1H, CHCH(Me)2); 1.63 (m, 3H, CHzCH(Me)2); 1.43 
(s, 9H, C(Me)3); 0.89 (m, 12H, Me). 
Spectral data for 2.17: 
1H NMR (CDClg) 8 7.82 (d(br), 1H, J=8.8 Hz, NH); 7.35 (m, 5H, ArH); 5.20, 5.13 (ABq, 
2H, 1=12.2 Hz, C.fuPh); 4.57 (dd, lH, 1=4.4, 7.8 Hz, NHCHCH); 3.44 (m, lH, 
NHCHCH2); 2.19 (m, 1H, CHCH(Me)l); 1.72 (m, 2H, NHCHC.fu); 1.35 (m, 1H, 
CH2CH(Me)2); 0.94 (m, 12H, Me). 
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Preparation of (2RS,3SR)-3-(Heptylcarbamoyl)-2,3-epoxypropanoic acid (2.20) 
To a stirring solution of 15 mg (0.06 mmol) of 2.22 in MeOH (1.2 ml), was added 
0.06 ml of a 1M solution of NaOH. The reaction mixture was stirred at r.t. overnight 
after which the MeOH was evaporated under reduced pressure. Water was added to the 
residue and the resultant solution was extracted (3x) with ethyl acetate. The aqueous 
layer was then acidified with 10% HCl and extracted (3x) with ethyl acetate. The 
combined fractions from the second extraction were dried with MgS04 and evaporated 
under reduced pressure. The crude product was purified by recrystallisation from ethyl 
acetate/petroleum ether to give (2.20) (7 mg, 50%) m.p. 87-89 °C as white crystals. 
Spectral data for 2.20: 
1H NMR (CDCh) () 6.43 (t(br), lH, J=5.8 Hz, NH); 3.75, 3.68 (ABq, 2H, 1=4.9 Hz, 
CH(epoxide)); 3.17 (m, 2H, NHCfu); 1.48 (m, 2H, NHCH2Cfu); 1.30 (m, 8H, 
(CH2)4Me); 0.89 (t, 3H, J=6.7 Hz, Me). 13C NMR (CDCh) () 169.7, 168.0 (CO); 55.5, 
54.6 (C(epoxide)); 40.5 (NHCH2); 33.2 (NHCH2CH2); 30.6, 30.4, 28.2 
(NHCH2CH2(CH2)3); 24.0 (CH2Me); 14.7 (Me). HRMS Calculated for C11H19N04: 
229.13140. Found: 229.1319. FTIR (thin film) 3313; 2923; 2364; 1746 cm-1. 
Preparation2'27 of (2RS,3SR)-Ethyl-3-(heptylcarbamoyl)-2,3-epoxypropanoate (2.22) 
To a stirring solution of 88 mg (0.56 mmol) of 2.21 (synthesised by a literature 
procedure230) in THF (1.0 ml), at 0 °C, was added one equivalent (88 mg, 0.56 mmol) of 
2.19 (n=6), in THF (1.0 ml), followed by DCC (112 mg, 0.56 mmol). The resultant 
solution was stirred for 30 minutes, at 0 °C, and HOBT (72 mg, 0.4 mmol) was added. 
The reaction mixture was then stirred at r.t. overnight after which the solvent was 
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evaporated under reduced pressure. Ethyl acetate was then added to the residue to 
precipitate the DCU byproduct, which was removed by filtration. The ftltrate was 
washed (3x) with saturated NaHC03, dried with MgS04, and the solvent was evaporated 
under reduced pressure. The crude product was recrystallised from ethyl 
acetate/petroleum ether to give (2.22) (56 mg, 39%) m.p. 30-31 °C as white crystals. 
Spectral data for 2.22: 
1H NMR (CDCh) o 6.44 (t(br), 1H, J=5.8 Hz, NH); 4.22 (dq, 2H, J=2.0, 4.8 Hz, CH20); 
3.70, 3.68 (ABq, 2H, J=4.9 Hz, CH(epoxide)); 3.23 (m, 2H, NHCfu); 1.48 (m, 2H, 
NHCH2Cfu); 1.29 (m, 8H, (Cfu)4Me); 1.29 (t, 3H, J=7.3 Hz, MeCH20); 0.86 (t, 3H, 
J=6.9 Hz, (CH2) 6Me). 13C NMR (CDCh) o 166.1, 164.5 (CO); 62.2 (CH20); 54.7, 53.4 
(C(epoxide)); 39.1 (NHCH2); 31.7 (NHCHzCHz); 29.3, 28.8, 26.7 (NHCHzCHz(CH2)3); 
22.5 (CH2Me); 14.0 (Me). HRMS Calculated for C13H23N04: 257.16270. Found: 
257.1624. FTIR (thin film) 3323; 2929; 2857; 2360; 2341; 1749; 1673; 1544 cm-1• 
General Procedure2·39 for the Preparation of Compounds 2.23a and 2.23b 
To a stirring solution of 15 mg (0.08 mmol) of 2.29a in CH2Clz (1.5 ml), were added 0.08 
mmol of the amino acid, of benzotriazolyloxy-tris-(dimethylamino)phosphonium 
hexafluorophosphate (BOP) (35 mg) and ofEt3N (16 mg). The resultant solution was 
stirred for 3 hours after which the solvent was removed. The residue was dissolved in 
ethyl acetate, washed with water (3x), and then washed with brine (2x). The organic 
layer was dried (MgS04) and evaporated under reduced pressure. 
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Preparation2·39 of (2R,3R, 1 'S)-N-(1-Methoxycarbonyl-3-methylbutyl)-2,3-epoxy-5-
phenylpentamide (2.23a) 
The reaction was performed as described by the general procedure, with 15 mg 
(0.08 mmol) of L-leucine methyl ester hydrochloride. Isolation by radial chromatography 
on silica (70% petroleum ether, 30% ethyl acetate) gave 2.23a as white crystals (15 mg, 
59%) m.p. 43-44 °C. 
Spectral data for 2.23a: 
1H NMR (CDCb) o 7.23 (m, 5H, ArH); 6.45 (d, 1H, J=8.8 Hz, NH); 4.66 (dt, 1H, J=4.4, 
9.3 Hz, NHCH); 3.63 (s, 3H, OMe); 3.53 (d, 1H, J=4.9 Hz, CHCHCO); 3.21 (dt, 1H, 
1=4.9, 6.4 Hz, CHCHCO); 2.82 (m, 2H, PhC.fu); 1.99 (q, 2H, J=6.8 Hz, PhCH2C.lli); 
1.55-1.70 (m, 3H, CH2CH(Me)2); 0.95 (m, 6H, CH(Me)z). 13C NMR (CDCh) o 172.2 
(C02); 166.6 (CONH); 140.1, 128.0, 128.0, 125.6 (Ar); 57.7 (NHCH); 54.6 (OMe); 51.7 
(CHCHCO); 49.4 (CHCHCO); 40.7 (NHCHCH2); 31.7 (PhCH2); 28.4 (PhCH2CH2); 24.2 
(CH(Me)z); 22.3, 22.1 (CH(Me)z). HRMS Calculated for C18H25N04: 319.17836. 
Found: 319.17807. FTIR (CHCb) 3408; 2960; 1742; 1678; 1526 cm-1• [o:]0 23 +2.8 
(c 5.0, CHCh). 
Preparation2·39 of (2R,3R, 1 'S)-N-(1-Methoxycarbonyl-2-methylpropyl)-2,3-epoxy-5-
phenylpentamide (2.23b) 
The reaction was performed as described by the general procedure, with 13 mg 
(0.08 mmol) of L-valine methyl ester hydrochloride. Isolation by radial chromatography 
on silica (70% petroleum ether, 30% ethyl acetate) gave 2.23b as a colourless oil (14 mg, 
57%). 
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Spectral data for 2.23b: 
1H NMR (CDCb) o 7.24 (m, 5H, ArH); 6.58 (d, 1H, 1=9.3 Hz, NH); 4.57 (dd, 1H, J=4.9, 
9.3 Hz, NHCH); 3.64 (s, 3H, OMe); 3.55 (d, 1H, 1=4.9 Hz, CH2CHCH); 3.22 (m, 1H, 
CH2CH); 2.81 (m, 2H, PhC!h); 2.21 (m, 1H, CH(Me)2); 1.95 (q, 2H, J=7 .8Hz, C!:LCH); 
0.97 (d, 3H, J=6.8 Hz, CH(Me)2); 0.91 (d, 3H, J=7.3 Hz, CH(Me)2). 13C NMR (CDC13) 
o 172.2 (C02); 166.7 (CONH); 140.1, 127.9, 127.9, 125.6 (Ar); 57.6 (NHCH); 55.9 
(OMe); 54.6 (CH2CHCH); 51.6 (CH~H); 31.7 (PhCH2); 30.4 (CH(Me)2); 28.5 
(CH2CH); 18.5, 17.0 (CH(Me)2). HRMS Calculated for C17H23N04: 305.16271. Found: 
305.16278. FTIR (CHCb) 3411; 2969; 1740; 1678; 1522 cm-1• [a]n23 +14.2 (c 9.0, 
CHClg). 
General Procedure for the Preparation of Compounds 2.24a and 2.24b 
To a stirring solution of 10 mg (0.04 mmol) of 2.29b in CH2Cb (1.0 ml), were added 
0.04 mmol of the amino acid, of BOP (19 mg), and of Et3N (4 mg). The resultant 
solution was stirred for 3 hours after which the solvent was evaporated under reduced 
pressure. The residue was dissolved in ethyl acetate, washed with water (3x), and then 
washed with brine (2x). The organic layer was dried (MgS04) and evaporated under 
reduced pressure. 
Preparation2'39 of (2R,3R, 1 'S)-N-(1-Methoxycarbonyl-3-methylbutyl)-2,3-epoxy-4-( 4-
nitrophenoxy)butamide (2.24a) 
The reaction was performed as desc1ibed by the general procedure, with 8 mg 
(0.04 mmol) of L-leucine methyl ester hydrochloride. Isolation by radial chromatography 
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on silica (60% petroleum ether, 40% ethyl acetate) gave 2.24a as white crystals (8 mg, 
53%) m.p. 91-92 °C. 
Spectral data for 2.24a: 
1H NMR (CDCb) 8 8.22 (d, 2H, 1=9.3 Hz, ArH); 7.06 (d, 2H, 1=9.3 Hz, ArH); 6.44 (d, 
1H, 1=9.3 Hz, NH); 4.64 (dt, 1H, 1=4.4, 9.8 Hz, NHCH); 4.39 (m, 2H, OCI:h); 3.72 (d, 
1H, 1=4.9 Hz, CH2CHCH); 3.72 (s, 3H, OMe); 3.67 (m, 1H, CH2CHCH); 1.52-1.71 (m, 
3H, CfuCH(Me)2); 0.95 (d, 6H, 1=6.4 Hz, (Me h). 13C NMR (CDCb) 8 172.5 (C02); 
165.6 (CONH); 162.7 (COCH2); 141.4 (N02C); 125.4 (N02CCH); 114.2 (CHCOCH2); 
65.9 (OCH2); 55.2 (NHCH); 52.8 (OMe); 52.0 (CH2CHCH); 49.7 (CH2CHCH); 40.0 
(CH2CH(Me)2); 23.4 (CH(Me)2); 22.3, 20.8 ((Me)2). HRMS Calculated for C17H22N201: 
366.14270. Found: 366.14204. FTIR (CHCb) 3408; 2960; 1742; 1678; 1526 cm-1• 
[a]n23 +18.0 (c 2.0, CHCl3). 
Preparation2·39 of (2R,3R, 1 'S)-N-(1-Methoxycarbonyl-2-methylpropyl)-2,3-epoxy-4-( 4-
nitrophenoxy)butamide (2.24b) 
The reaction was performed as described by the general procedure, with 8 mg 
(0.04 mmol) of L-valine methyl ester hydrochloride. Isolation by radial chromatography 
on silica (50% petroleum ether, 50% ethyl acetate) gave 2.24b as white crystals (13 mg, 
81 %) m.p. 86-88 °C. 
Spectral data for 2.24b: 
1H NMR (CDCb) 8 8.14 (d, 2H, 1=9.0 Hz, ArH); 6.97 (d, 2H, 1=9.5 Hz, ArH); 6.47 (d, 
1H, 1=8.0 Hz, NH); 4.49 (dd, 1H, 1=4.5, 9.5 Hz, NHCH); 4.29 (d, 2H, 1=4.5 Hz, OCH2); 
3.68 (d, 1H, 1=5.5 Hz, CH2CHCH); 3.65 (s, 3H, OMe) 3.60 (m, 1H, CH2CH); 2.20 (m, 
1H, CH(Me)2); 0.91 (d, 3H, 1=7.1 Hz, CHMe); 0.83 (d, 3H, 1=7.0 Hz, CHMe). 
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13C NMR (CDCh) 8171.5 (C02); 165.7 (CONH); 162.6 (COCH2); 141.4 (N02C); 125.4 
(N02CCH); 114.2 (CHCOCH2); 65.8 (OCH2); 56.1 (NHCH); 55.2 (OMe); 52.8 
(CH2CHCH); 51.9 (CH2.CH); 29.8 (CH(Meh); 18.6, 16.9 ((Me)2). HRMS Calculated for 
C16H2oN207: 352.12705. Found: 352.12720. FTIR (CHCh) 3417; 2968; 2360; 1740; 
1686, 1594, 1518 cm-1• [a]0 23 +17.1 (c 3.5, CHC13). 
General Procedure2·34 for Preparation of Compounds 2.26a-d 
A stirring solution of 2.000 g (6.6 mmol) of methyl diphenylphosphonoactetate in dry 
THF (20 ml) was cooled to 0 oc under a nitrogen atmosphere and 3.4 ml (6.6 mmol) of a 
2.0 M solution of n-butyllithium in pentane was added dropwise. After 10 minutes, the 
reaction was cooled to -78 oc and the aldehyde (5.4 mmol) was added dropwise. The 
resultant mixture was stirred for 1.5 hours and the reaction was then quenched by the 
addition of water (20 ml) and ether (40 ml). The aqueous layer was removed and the 
organic layer was washed with saturated brine, dried (MgS04), filtered, and the solvent 
was evaporated under reduced pressure. 
Preparation2.34 of (Z)-Methyl 5-phenyl-2-pentenoate (2.26a) and (E)-Methyl5-phenyl-2-
pentenoate (2.26c) 
The reaction was performed as described by the general procedure, with 736 mg 
(5.4 mmol) of the aldehyde (2.25a). The E:Z ratio of the crude product was found to be 
1 :6.4. Isolation by radial chromatography on silica (95% petroleum ether, 5% ethyl 
acetate) gave 2.26a (804 mg, 78%) and 2.26c (120 mg, 12%) as colourless oils. 
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Spectral data for 2.26a: 
1H NMR (CDCh) o 7.19-7.31 (m, 5H, ArH); 6.26 (dt, 1H, J=7.3, 11.7 Hz, CH2CH); 5.79 
(dt, 1H, 1=2.0, 11.7 Hz, CHCO); 3.70 (s, 3H, Me); 2.98 (dq, 2H, 1=2.0, 7.8 Hz, Cl:LCH); 
2.77 (t, 2H, J=7.3 Hz, PhC!L). 13C NMR (CDCb) o 166.3 (C02); 149.0 (CH2CH); 140.8, 
128.2, 128,0, 125.7 (Ar); 119.6 (CHCO); 50.7 (Me); 34.7, 30.2 (CH2). HRMS Calculated 
for C12H140 2: 190.09938. Found: 190.09937. FTIR (thin film) 3427; 3086; 3063; 3028; 
2999; 2949; 2926; 2858; 1720; 1645; 1603 cm-1• 
Spectral data for 2.26c: 
1H NMR (CDCb) o 7.17-7.32 (m, 5H, ArH); 7.01 (dt, 1H, J=6.8, 15.3 Hz, CH2CH); 5.85 
(dt, 1H, J=1.5, 15.6 Hz, CHCO); 3.72 (s, 3H, Me); 2.78 (t, 2H, J=8.3 Hz, PhC.Hz); 2.53 
(dq, 2H, J=1.9, 6.8 Hz, C.HzCH). 13C NMR (CDCh) o 166.5 (C02); 148.0 (CHzCH); 
140.4, 128.2, 128,0, 125.9 (Ar); 121.2 (CHCO); 50.0 (Me); 34.0, 33.5 (CH2). HRMS 
Calculated for C12H140 2: 190.09938. Found: 190.09980. FTIR (thin film) 3063; 3028; 
2949; 2858; 1724; 1659; 1603 cm-1. 
Preparation234 of (Z)-Methyl4-(4-nitrophenoxy)-2-butenoate (2.26b) and (E)-Methyl4-
( 4-nitrophenoxy)-2-butenoate (2.26d) 
The reaction was performed as described by the general procedure, with 990 mg 
(5.4 mmol) of the aldehyde (2.25b) (synthesised by a literature procedure2·35). The E:Z 
ratio of the crude product was found to be 1 :3.4. Isolation by radial chromatography on 
silica (80% petroleum ether, 20% ethyl acetate) gave 2.26b (1.082 g, 84%) and 2.26d 
(193 mg, 15%) as white crystals m.p. 74-75 and 120-121 °C, respectively. 
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Spectral data for 2.26b: 
1H NMR (CDCh) o 8.21 (d, 2H, J=9.3 Hz, ArH); 6.98 (d, 2H, J=9.2 Hz, ArH); 6.47 
(dt,1H, J=4.8, 11.7 Hz, CH2CID; 5.99 (dt, 1H, J=2.4, 11.7 Hz, CHC02); 5.25 (dd, 2H, 
1=2.4, 4.8 Hz, CH2); 3.78 (s, 3H, Me). 13C NMR (CDC13) o 165.9 (C02); 162.8 
(COCH2); 144.7 (CHz.CH); 140.6 (N02C); 125.6 (N02CCH); 120.3 (CHC02); 114.3 
(CHCOCH2); 66.5 (CH2); 51.3 (Me). HRMS Calculated for C11H11N05: 237.06372. 
Found: 237.06397. FTIR (thin film) 3453; 3115; 1717; 1663; 1590 cm·1• Anal. 
Calculated for C11H11N05: C 55.9, H 4.7, N 5.9. Found: C 55.6, H 4.8, N 5.8. 
Spectral data for 2.26d: 
1H NMR (CDCh) o 8.22 (d, 2H, J=9.3 Hz, ArH); 7.07 (dt, 1H, J=3.9, 16.1 Hz, CH2CID; 
6.98 (d, 2H, J=9.3 Hz, ArH); 6.19 (dt, 1H, J=l.9, 16.1 Hz, CHC02); 4.80 (dd, 2H, J=2.0, 
3.9 Hz CH2); 3.77 (s, 3H, Me). 13C NMR (CDC13) o 165.7 (C02); 162.5 (COCH2); 141.6 
(CHz.CH); 140.6 (N02C); 125.6 (N02CCH); 122.0 (CHC02); 114.3 (CHCOCH2); 66.6 
(CH2); 51.5 (Me). HRMS Calculated for C 11H11N05: 237.06372. Found: 237.06339. 
FTIR (thin film) 3084; 2912; 1713; 1651; 1609; 1593 cm-1• 
Preparation2·36 of (Z)-5-Phenyl-2-penten-1-ol (2.27a) 
A stirring solution of 600 mg (3.1 mmol) of 2.26a in dry CH2Clz (24 ml) was cooled to 
-78 °C under a nitrogen atmosphere and 7.7 ml (7.7 mmol) of a 1M solution of 
diisobutylaluminium hydride (DIBAL) in CH2Clz was added dropwise. The resultant 
solution was stirred for 3 hours at -78 °C after which water (1.0 ml) was added over 
5 minutes, followed by 10% potassium sodium tartrate (10 ml). The mixture was warmed 
to r.t. and the aqueous layer was removed. The organic layer was washed (3x) with 10% 
potassium sodium tartrate and the combined aqueous fractions were washed with 
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CHzCb (3x). The combined organic fractions were dried (MgS04) and the solvent was 
evaporated under reduced pressure. The crude product was purified by radial 
chromatography on silica (60% petroleum ether, 40% ethyl acetate) to give a colourless 
oil (470 mg, 93%). 
Spectral data for 2.27 a: 
1H NMR (CDCb) o 7.16-7.36 (m, 5H, ArH); 5.58 (m, 2H, CH(olefins)); 4.00 (d, 2H, 
J=5.4 Hz, CHzOH); 2.69 (t, 2H, J=7.8 Hz, PhCHz); 2.41 (q, 2H, J=7.3 Hz, PhCH2CHz); 
1.56 (s(br), 1H, OH). 13C NMR (CDCb) o 141.5, 128.6, 128,3, 126.0 (Ar); 131.5, 129.3 
(CH(olefins)); 58.3 (CH20H); 35.6, 29.3 (Ph(CH2) 2). HRMS Calculated for C11H140: 
162.10447. Found: 162.10451. FTIR (thin film) 3309; 3024; 2928; 2858 cm-1• 
Preparation2·36 of (Z)-4-(4-Nitrophenoxy)-2-buten-1-ol (2.27b) 
A stirring solution of 500 mg (2.1 mmol) of 2.26b in dry CH2Ch (16 ml) was cooled to 
-78 °C under a nitrogen atmosphere and 5.2 ml (5.2 mmol) of a 1 M solution of DIBAL in 
CH2Ch was added dropwise. The resultant solution was stirred for 3 hours at -78 °C after 
which water (1.0 ml) was added over 5 minutes, followed by 10% potassium sodium 
tartrate (10 ml). The mixture was warmed to r.t. and the aqueous layer was removed. 
The organic layer was washed (3x) with 10% potassium sodium tartrate and the 
combined aqueous fractions were washed with CH2Ch (3x). The combined organic 
fractions were dried (MgS04) and the solvent was evaporated under reduced pressure. 
The crude product was purified by radial chromatography on silica (50% petroleum ether, 
50% ethyl acetate) to give white crystals (257 mg, 59%) m.p. 77-78 °C. 
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Spectral data for 2.27b: 
1H NMR (CDCh) 8 8.21 (d, 2H, J=9.3 Hz, ArH); 6.97 (d, 2H, 1=9.2 Hz, ArH); 5.79-5.93 
(m, 2H, CH(olefins)); 4.74 (d, 2H, J=5.9 Hz, C6!40CH2); 4.32 (t, 2H, 1=4.9 Hz, 
CfuOH); 1.51 (t(br), 1H, J=4.4 Hz, OH). 13C NMR (CDCh) 8162.9 ~OCH2); 141.1 
(N02C); 132.5 (CH(olefin)); 125.4 (N02CCH and CH(olefin)); 114.1 ~HCOCH2); 64.1 
(C6!40CH2); 58.4 (CH20H). HRMS Calculated for C10H11N04: 209.06881. Found: 
209.06881. FTIR (thin film) 3439; 3292; 3115; 2872; 1591; 1501 cm-1• 
Preparation2·37 of (2S,3R)-2,3-Epoxy-5-phenyl-1-pentanol (2.28a) 
A stirring solution of 701 mg (2.5 mmol) of titanium tetraisopropoxide (Ti(OiPr)4 and 4A 
molecular sieves (250 mg) in dry CH2Cb (25 ml) was cooled to between -20 and -30°C 
(dry ice/carbon tetrachloride (CC4)) under a nitrogen atmosphere. A solution of 691 mg 
(3.0 mmol) ofL-(+)-diisopropyl tartrate (DIPT) in dry CH2Cb (1.0 ml) was added, 
dropwise, followed by 395 mg (2.5 mmol) of 2.27a also in dry CH2Ch (4.0 ml). The 
resultant solution was stirred for 30 minutes and 1.0 ml (4.8 mmol) of a 4.8 M solution of 
tert-butyl hydroperoxide (TBHP) in CH2Cb was added. The resultant solution was stored 
in a -20 °C freezer for 20 hours. The reaction was quenched with 10% tartaric acid 
(25 ml), the organic layer was separated, and the aqueous layer was washed with 
CH2Ch (3x). The combined organic fractions were dried (MgS04) and evaporated under 
reduced pressure. The excess peroxide wa.'> removed by azeotropic distillation with CC14 
and the crude mixture was purified by radial chromatography on silica (60% petroleum 
ether, 40% ethyl acetate) to give a colourless oil (303 mg, 68% ). 
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Spectral data for 2.28a: 
1H NMR (CDCb) & 7.27 (m, 5H, ArH); 3.57 (m, 2H, 1=5.4 Hz, CHzOH); 3.11 (m, 2H, 
CH(epoxide)); 2.88 (m, 1H, PhCHz); 2.73 (m, 1H, PhCHz); 2.01 (m, 1H, PhCH2CHz); 
1.81 (m, 1H, PhCH2CHz); 1.34 (m(br), 1H, OH). 13C NMR (CDCh) & 140.4, 128.0, 
127.9, 125.7 (Ar); 60.0 (CH20H); 56.6, 56,1 (C(epoxide)); 32.2, 29.2 (Ph(CH2)2). HRMS 
Calculated for C11H120 (M+-H20): 160.08882. Found: 160.08877. FTIR (thin film) 
3422(br); 3026; 2928; 2860; 1603 cm-1• [a]0 23 -1.9 (c 10.9, CHCb). 
Preparation2·37 of (2S,3R)-2,3-Epoxy-4-( 4-nitrophenoxy)-1-butanol (2.28b) 
A stirring solution of 266 mg (0.94 mmol) of Ti(OiPr)4 and 4A molecular sieves (94 mg) 
in dry CH2Clz (10 ml) was cooled to between -20 and -30 °C (dry ice/ CC14) under a 
nitrogen atmosphere. A solution of263 mg (1.1 mmol) ofL-(+)-DIPT in dry CH2Clz 
(0.5 ml) was added, dropwise, followed by 195 mg (0.94 mmol) of 2.27b also in dry 
CHzClz (1.5 ml). The resultant solution was stirred for 30 minutes and 0.38 ml 
(1.9 mmol) of a 4.8 M solution of TBHP in CH2Clz was added. The resultant solution 
was stored in a -20 oc freezer for 20 hours. The reaction was quenched with 10% tartaric 
acid (10 ml), the organic layer was separated, and the aqueous layer was washed with 
CHzCh (3x). The combined organic fractions were dried (MgS04) and evaporated under 
reduced pressure. The excess peroxide was removed by azeotropic distillation with CC14 
and the crude mixture was purified by radial chromatography on silica (25% petroleum 
ether, 75% ethyl acetate) to give white crystals (150 mg, 71 %) m.p. 114-116 °C. 
Spectral data for 2.28b: 
1H NMR (CDCh) & 8.21 (d, 2H, 1=9.3 Hz, ArH); 7.01 (d, 2H, 1=9.3 Hz, ArH); 4.37 (dd, 
lH, 1=3.4, 11.2 Hz, C6~0CH2); 4.28 (dd, 1H, 1=6.9, 11.3 Hz, C6~0CH2); 3.98 (m, 1H, 
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C.EkOH); 3.87 (m, 1H, CHzOH); 3.47 (m, 1H, C6~0CH2CH); 3.34 (q, 1H, 1=4.4 Hz, 
CHCHzOH); 1.77 (t, 1H, J=6.3 Hz, OH). 13C NMR (CDCb) o 167.7 (COCH2); 141.4 
(N02C); 125.4 (N02CCH); 114.1 (CHCOCH2); 66.5 (C6!40CH2); 59.8 (CH20H); 55.3, 
53.9 (C(epoxide)). HRMS Calculated for C10H11N05: 225.06372. Found: 225.06365. 
FTIR (thin film) 3454 (br); 3285 (br); 2930; 1593; 1510 cm-1• [a]n23 -13.5 (c 4.0, 
CHCb). 
Preparation2·38 of (2R,3R)-2,3-Epoxy-5-phenylpentanoic acid (2.29a) 
To a biphasic solution of CC4 (1.0 rnl), acetonitrile (CH3CN) (1.0 rnl), and water 
(1.5 ml), were added 2.28a (100 mg, 0.56 mmol), ruthenium trichloride hydrate (RuCh) 
(2.6 mg, 2.2 mol%), and periodoic acid (H5I06) (319 mg, 1.4 mmol). The resultant 
solution was stirred vigorously for 3 hours at r.t. after which CH2Cb was added and the 
organic layer was separated. The aqueous layer was washed with CH2C}z (3x) and the 
combined organic fractions were dried (MgS04) and evaporated under reduced pressure. 
The residue was taken up in ether, filtered through a celite pad, and concentrated to give 
white crystals (93 mg, 85%) m.p. 84-85 °C. 
Spectral data for 2.29a: 
1H NMR (CDCh) o 7.23 (m, 5H, ArH); 3.56 (d, 1H, J=4.4 Hz, CHC02); 3.26 (m, 1H, 
CHzCH); 2.80 (m, 2H, PhC.Ek); 2.00 (m, 2H, PhCH2C.Ek). 13C NMR (CDCb) o 173.3 
(C02); 139.8, 128.0, 127.9, 125.8 (Ar); 57.0, 52.0 (C(epoxide)); 31.8, 28.5 (Ph(CH2) 2). 
HRMS Calculated for CnH1203: 192.07864. Found:192.07889. FTIR (CHCb) 2932; 
2560; 1948; 1725; 1604 cm-1• [a]n23 -5.9 (c 16.0, CHCb). 
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Preparation2'38 of (2R.3R)-2,3-Epoxy-4-(4-nitrophenoxy)butanoic acid (2.29b) 
To a biphasic solution of CC14 (0.15 ml), acetonitrile (CH3CN) (0.15 ml), and water 
(0.21 ml), were added 2.28b (15 mg, 0.07 mmol), RuCb (0.4 mg, 2.2 mol%), and H5I06 
(41 mg, 0.18 mmol). The resultant solution was stirred vigorously for 3 hours at r.t. after 
which CH2Ch was added and the organic layer was separated. The aqueous layer was 
washed with CH2Ch (3x) and the combined organic fractions were dried (MgS04) and 
evaporated under reduced pressure. The residue was taken up in ether, filtered through a 
celite pad, and concentrated to give white crystals (12 mg, 72%) m.p. 108-109 °C. 
Spectral data for 2.29b: 
1HNMR (CDCh) ~ 8.21 (d, 2H, 1=6.9 Hz, ArH); 7.01 (d, 2H, J=6.8 Hz, ArH); 4.38 (m, 
2H, OCHz); 3.73 (d, 1H, J=4.4 Hz, CHC02); 3.68 (q, 1H, J=5.3 Hz, CH2CH). 13C NMR 
(CD30D) ~ 171.9 (C02); 166.0 (COCH2); 144.2 (N02C); 127.8 (N02CCH); 117.0 
(CHCOCH2); 68.6 (OCH2); 56.4, 53.3 (C(epoxide)). HRMS Calculated for C10H9N06: 
239.04299. Found: 239.04320. FTIR (KBr) 3416; 2924; 2367; 1718; 1639; 1612; 1593; 
1560; 1522 cm-1. [a]D23 +15.2 (c 13.0, THF). 
General Procedure2.4° for the Preparation of Compounds 2.30a and 2.30b 
To a stirring solution of 0.10 mmol of the epoxy alcohol (either 2.28a or 2.28b) in 
CH2Cb (0.5 ml), were added dimethylaminopyridine (12 mg, 0.10 mmol), EhN (12 mg, 
0.12 mmol), and acetylchloride (9 mg, 0.12 mmol). The resultant solution was stirred for 
2 hours, filtered through a silica plug, and the filtrate was evaporated under reduced 
pressure. 
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Preparation2.4° of (2S, 3R)-(2,3-Epoxy-5-phenyl)pentyl acetate (2.30a) 
The reaction was performed as described by the general procedure, with 18 mg 
( 0.10 mmol) of 2.28a, to give 2.30a as a colourless oil (20 mg, 91%). 
Spectral data for 2.30a: 
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1H NMR (CDCh) 3 7.25 (m, 5H, ArH); 4.15 (dd, 1H, J=4.4, 12.3 Hz, CH20); 3.97 (dd, 
1H, J=7.3, 12.2 Hz, CH20); 3.15 (m, 1H, CH(epoxide)); 3.07 (m, 1H, CH(epoxide)); 2.82 
(m, 2H, PhCH2CHz); 2.09 (s, 3H, Me); 187 (m, 2H, PhC.fu). 
Preparation2.4° of (2S,3R)-[2,3-Epoxy-4-(4-nitrophenoxy)lbutyl acetate (2.30b) 
The reaction was performed as described by the general procedure, with 23 mg 
(0.10 mmol) of2.28b, to give 2.30b as a colourless oil (22 mg, 88%). 
Spectral data for 2.30b: 
1H NMR (CDCb) 3 8.23 (d, 2H, J=9.2 Hz, ArH); 7.01 (d, 2H, J=9.3 Hz, ArH); 4.37 (m, 
2H, OC.fu); 4.18 (m, 2H, OC.fu); 3.47 (m, 1H, CH(epoxide)); 3.39 (m, lH, 
CH(epoxide)); 2.13 (s, 3H, Me). 
Shift Analysis2.4° on Compounds 2.30a and 2.30b 
To a solution of 10 mg of the acetate (either 2.30a or 2.30b) in 0.5 ml of benzene (<it;) (in 
an NMR tube) was added the shift reagent, europium (111) tris[3-
(heptafluoropropylhydroxymethylene)-d-camphorate], sequentially (10 Jll portions of a 
solution of 30 mg of shift reagent in 0.5 ml of benzene (d6)) and the acetate Me signal 
was monitored by 1 H NMR.ZAo After the addition of 250 J.Ll of shift reagent, a second 
resonance for the acetate Me was not observed for either 2.30a or 2.30b. 
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Preparation of (2R,3R, 1 'S)-N-( 1-Methoxycarbonyl-2-methylpropyl)-2,3-
epoxydodecylamide (2.31) 
Step 1 
To a stirring solution of 30 mg (0.15 mmol) 2.32 (synthesised by a literature 
procedure2'18) in benzene (1.0 ml), were added dimethylformamide (1 drop) and 
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5 equivalents of oxalyl chloride (95 mg, 0.75 mmol). The resultant solution was stirred 
for 1 hour at r.t., after which the solvent was evaporated under reduced pressure to give 
the acid chloride (2.33) as a yellow oil. 
Step 2 
To a stirring solution of0.15 mmol of the acid chloride (2.33) in CH2Clz (0.75 ml), was 
added a solution ofL-valine methyl ester hydrochloride (24 mg, 0.15 mmol) and Et3N 
(15 mg, 0.15 mmol) also in CH2Ch (0.75 ml). The resultant solution was stirred at r.t. 
overnight and the crude mixture was then washed (3x) with saturated NaHC03 followed 
by 10% hydrochloric acid (HCl), dried with MgS04, and the solvent was evaporated 
under reduced pressure. The crude product was purified by radial chromatography on 
silica (80% petroleum ether, 20% ethyl acetate) to give 2.31 as a colourless oil (7 mg, 
14%). 
Spectral data for 2.33: 
1H NMR (CDCh) 8 3.94 (d, 1H, 1=4.4 Hz, CHCO); 3.34 (m, 1H, CHCH2); 1.53 (m, 4H, 
CH(Cfu)z); 1.26 (m, 12H, (Cfu)6Me); 0.87 (t, 3H, 1=6.9 Hz, Me). FTIR (thin film) 2925; 
2855; 2360; 1805 cm-1• 
Spectral data for 2.31: 
1H NMR (CDCh) 8 6.57 (d, lH, 1=9.3 Hz, NH); 4.57 (m, IH, CHNH); 3.73 (s, 3H, 
MeO); 3.54 (d, lH, 1=4.9 Hz, NHCOCH); 3.20 (m, lH, CHCH2); 2.22 (m, lH, CH(Me)2); 
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1.61 (m, 2H, CHCHz); 1.48 (m, 2H, CHCHzCHz); 1.26 (m, 12H, (CHz)6Me); 0.92 (m, 9H, 
Me). 13C NMR (CDCh) o 171.7 (C02); 167.5 (CONH); 59.0 (CHNH); 56.4, 55.1 
(C(epoxide)); 52.1 (MeO); 31.8, 31.0, 29.5, 29.4, 29.3, 27.2, 26.1 (QH(Me)2 and 
CH(QH2) 6); 22.6 (QH2Me); 19.0, 17.5 (CH(Me)2); 14.1 (CH2Me). HRMS Calculated for 
C18H33N04 : 327.24094. Found: 327.2409 FTIR (thin film) 3424; 2925; 2854; 2348; 
1744; 1678 cm-1• [a]0 23 +1.0 (c 3.5, CHCh). 
Preparation2.41 of (2S,3R)-N-CBz-L-Valine (2,3-epoxy-5-phenylpentyl) ester (2.34a) 
To a stirring solution of 15 mg (0.08 mmol) of 2.28a in THF (1.5 ml), were added N-
CBz-L-valine (46 mg, 0.19 mmol) and triphenylphosphine (46 mg, 0.18 mmol). After 
stirring for 5 minutes, diethyl azodicarboxylate (DEAD) (31 mg, 0.18 mmol) was added 
dropwise. The resultant solution was stirred for 3 hours after which CH2Clz was added 
and the crude mixture was washed (3x) with saturated NaHC03 • The organic layer was 
dried (MgS04) and evaporated under reduced pressure. Isolation by radial 
chromatography on silica (80% petroleum ether, 20% ethyl acetate) gave 2.34a as a 
colourless oil (16 mg, 46%). 
Spectral data for 2.34a: 
1H NMR (CDCb) o 7.19-7.35 (m, lOR, ArH); 5.30 (d(br), lH, 1=8.8 Hz, NH); 5.11 (s, 
2H, COzCH2Ph); 4.36 (dd, lH, 1=4.9, 9.3 Hz, CHNH); 4.19 (dd, 1H, 1=4.4, 12.2 Hz, 
CHCH20); 4.05 (dd, 1H, J=6.8, 12.2 Hz, CHCHzO); 3.14 (m, 1H, CHCH20); 3.06 (m, 
lH, (CHz)zCH); 2.72-2.89 (m, 2H, PhCHzCH2); 2.18 (m, lH, CH(Me)z); 1.87 (m, 2H, 
CHzCHzCH); 0.94 (d, 3H, 1=6.9 Hz, Me); 0.95 (d, 3H, 1=6.9 Hz, Me). 13C NMR (CDC13) 
o 171.3 (COCH); 155.6 (NHCO); 140.1, 135.7, 128.0, 128.0, 127.9, 127.7, 127.6, 125.7 
(Ar); 66.5 (OCHzPh); 62.8 (CHCHzO); 58.5 (CHNH); 55.3 (CHzCHzCH); 53.1 
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(CHCHzCO); 32.1 (PhCHzCHz); 30.7 (CH(Me)2); 29.7 (PhCH~H2); 18.4, 16.9 (Me). 
HRMS Calculated for C24H29N05 : 411.20457. Found: 411.20493 FTIR (CHCh) 3436; 
2968; 1722; 1511 cm-1• [O:]n23 -6.1 (c 16.0, CHCh). 
General Procedure2.41 for Preparation of Compounds 2.34b and 2.35 
To a stirring solution of 10 mg (0.04 mmol) of 2.28b in THF (1.0 rnl), were added 
0.09 mmol of the amino acid and of triphenylphosphine (24 mg). After stirring for 
5 minutes, DEAD (16 mg, 0.09 mmol) was added dropwise. The resultant solution was 
stirred for 3 hours after which CH2Ch was added and the crude mixture was washed (3x) 
with saturated NaHC03. The organic layer was dried (MgS04) and evaporated under 
reduced pressure. 
Preparation2.41 of (2S,3R)-N-CBz-L-Valine [2,3-epoxy-4-( 4-nitrophenoxy)butyll 
ester (2.34b) 
The reaction was performed as described by the general procedure, with 25 mg 
(0.09 mmol) of N-CBz-L-valine. Isolation by radial chromatography on silica (30% 
petroleum ether, 70% ethyl acetate) gave 2.34b as white crystals (16 mg, 75%) m.p.57-
58 °C. 
Spectral data for 2.34b: 
1H NMR (CDCh) 8 8.21 (d, 2H, 1=9.3 Hz, N02CCH); 7.35 (s, 5H, CH2Ph); 7.00 (d, 2H, 
1=9.3 Hz, N02CCHCH); 5.26 (d(br), 1H, J=9.3 Hz, NH); 5.11 (s, 2H, CHzPh); 4.14-4.44 
(m, 5H, OCHz and CHNH); 3.45 (m, IH, CH(epoxide)); 3.36 (m, 1H, CH(epoxide)); 
2.19 (m, 1H, CH(Me)2); 0.95 (d, 3H, 1=6.8 Hz, Me); 0.96 (d, 3H, 1=6.9 Hz, Me). 
13C NMR (CDCb) 171.3 (COCH); 162.5 (COCH2); 155.6 (NHCO); 141.5 (N02C); 
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135.6, 128.0, 127.7, 127.5 (CH2Ph); 125.4 (N02CCH); 114.1 (N02CCHCH); 66.6 
(CH2Ph); 66.2 (C6~0CH2); 61.2 (CHCH20CO); 58.6 (CHNH); 53.3 (CHCH20CO); 
52.3 (C6~0CH2CH); 30.6 (CH(Me)2); 18.4, 17.0 (Me). HRMS Calculated for 
C23H26N20 8: 458.16892. Found: 458.16826. FTIR (CHCh) 3436; 2968; 1722; 
1511 cm-1• [a]0 23 +2.5 (c 8.0, CHCh). 
Preparation of (2S,3R)-N-CBz-L-Valinyl-L-valine [2,3-epoxy-4-( 4-nitrophenoxy)butyll 
ester (2.35) 
The reaction was performed as described by the general procedure, with 34 mg 
(0.09 mmol) of N-CBz-L-Valinyl-L-valine. Isolation by radial chromatography on silica 
(30% petroleum ether, 70% ethyl acetate) gave 2.35 as white crystals (11 mg, 45%) 
m.p. 92-93 °C. 
Spectral data for 2.35: 
1H NMR (CDCh) 8 8.21 (d, 2H, J=8.8 Hz, N02CCH); 7.33 (s, 5H, CH2Ph); 7.00 (d, 2H, 
1=9.3 Hz, N02CCHCH); 6.44 (m(br), 1H, NH); 5.37 (d(br), 1H, J=8.3 Hz, NH); 5.11 (s, 
2H, CfuPh); 4.55 (dd, 1H, J=4.9, 8.3 Hz, CHNH); 4.14-4.45 (m, 4H, OCI:h); 4.04 (t(br), 
1H, J=7.3 Hz, CHNH); 3.45 (m, 1H, CHCH20CO); 3.36 (m, 1H, C6~0CH2CH); 2.14 
(m, 1H, CH(Me)2); 0.94 (m, 12H, Me). 13C NMR (CDCh) 170.8 (COCH); 162.5 
(COCH2); 155.9, 150.3 (NHCO); 141.5 (N02C); 135.6, 128.0, 127.6, 127.5 (CH2Ph); 
125.4 (N02CCH); 114.1 (N02CCHCH); 66.6 (CH2Ph); 66.2 (C6~0CH2); 61.2 
(CHCH20CO); 59.9, 56.7 (CHNH); 53.3 (CHCH20CO); 52.3 (C6~0CH2CH); 31.0, 
30.3 (CH(Me)2); 18.6, 18.4, 17.3, 17.2 (Me). HRMS Calculated for C28H3sN309 (M++H): 
558.24516. Found: 558.24490. FTIR (CHCh) 3438; 2969; 1721; 1594; 1517 cm-1• 
[a]0 23 +1.0 (c 9.0, CHCh). 
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Preparation2.42 of (E,2RS,3SR)-Ethyl (2,3-epoxy-5-phenyl)-4-pentenoate (2.37) and 
(E,2RS,3SR)-Ethyl (2-bromo-3-hydroxy-5-phenyl)-4-pentenoate (2.38) 
A stirring solution of 2.7 ml (2.7 mmol) of a 1.0 M solution oflithium 
bis(trimethylsilyl)amide in THF (1.2 ml) was cooled to -78 °C under a nitrogen 
atmosphere. A solution of ethyl bromoacetate (300 mg, 1.8 mmol) in THF (0.8 ml) was 
added dropwise, the resultant solution was stirred for 10 minutes, and cinnamaldehyde 
(2.36) (211 mg, 1.6 mmol) was added. Stirring was continued for another 20 minutes, at 
-78 °C, followed by 2 hours at r.t. The reaction was poured into a mixture of iced water 
and ether. The organic layer was separated, washed (10% HCl and water), dried, and the 
solvent was evaporated under reduced pressure. Isolation by radial chromatography on 
silica (80% petroleum ether, 20% ethyl acetate) gave 2.37 (147 mg, 37%) and 2.38 
(131 mg, 24%) as colourless oils. 
Spectral data for 2.37: 
1H NMR (CDCb) 8 7.26-7.40 (m, 5H, ArH); 6.87 (d, lH, 1=16.1 Hz, PhCH); 5.88 (dd, 
lH, 1=8.3, 16.1 Hz, PhCHCH); 4.28 (dq, 2H, J=3.4, 7.4 Hz, CH2); 3.76 (m, 1H, 
CHCHC02); 3.49 (d, 1H, J=2.0 Hz, CHC02); 1.33 (t, 3H, 1=7.3 Hz, Me). 13C NMR 
(CDCh) 8 168.5 (C02); 136.4 (PhCH); 135.5, 128.7, 128.5, 126,6 (Ar); 129.9 
(PhCHCH); 61.8 (CH2); 58.3 (CHCHC02); 55.1 (CHC02); 14.1 (Me). HRMS Calculated 
for Ct3H140 3: 218.09429. Found: 218.09418. FTIR (thin film) 2984; 1747; 1678 cm-1• 
Spectral data for 2.38: 
1H NMR (CDCb) 8 7.26-7.41 (m, 5H, ArH); 6.75 (d, lH, J=l5.7 Hz, PhCH); 6,18 (dd, 
lH, 1=6.4, 16.1 Hz, PhCHCH); 4.70 (m, IH, CHOH); 4.35 (d, lH, J=5.9 Hz, CHBr); 4.25 
(dq, 2H, 1=1.5, 6.4 Hz, CH2); 1.28 (t, 3H, J=7.3 Hz, Me). 13C NMR (CDCh) 8 168.4 
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(CO); 133.9 (PhCH); 135.9, 128.6, 128.3, 126,7 (Ar); 125.8 (PhCHCH); 72.5 (CHOH); 
62.4 (CH2); 51.5 (CHBr); 13.9 (Me). HRMS Calculated for C13H1/ 9Br03 : 298.02046. 
Found: 298.02091. Calculated for C13H1l 1Br03: 300.01841. Found: 300.01837. FTIR 
(thin film) 3459(br); 2982; 2360; 1733 cm"1• 
Preparation2'45 of (E,2SR,3SR)-Ethyl (2,3-epoxy-5-phenyD-4-pentenoate (2.39) 
A stirring solution of 131 mg (0.45 mmol) of2.38 in THF (8.0 ml) was cooled to 0 °C 
under a nitrogen atmosphere and potassium tert-butoxide (55 mg, 0.45 mmol), suspended 
in THF (3.0 ml), was added dropwise while maintaining the temperature below 15 °C. 
The resultant solution was stirred for 10 minutes and the reaction was quenched by the 
addition of a 3% solution of ammonium chloride. The organic layer was separated and 
the aqueous layer was extracted with chloroform (5x). The combined organic extracts 
were dried (MgS04) and the solvent was evaporated under reduced pressure. Isolation by 
radial chromatography on silica (90% petroleum ether, 10% ethyl acetate) gave 2.39 as a 
colourless oil (102 mg, 72%). 
Spectral data for 2.39: 
1H NMR (CDCh) o 7.28-7.39 (m, 5H, ArH); 6.91 (d, 1H, 1=16.2 Hz, PhCH); 6.15 (dd, 
1H, J=8.3, 16.1 Hz, PhCHCH); 4.29 (dq, 2H, 1=3.4, 7.4 Hz, CH2); 3.78 (m, 2H, 
CH(epoxide)); 1.30 (t, 3H, 1=6.9 Hz, Me). 13C NMR (CDCh) o 167.8 (C02); 137.9 
(PhCH); 135.7, 128.7, 128.5, 126,7 (Ar); 121.5 (PhCHCH); 61.6 (CH2); 57.9, 54.6 
(C(epoxide); 14.2 (Me). HRMS Calculated for C13H140 3: 218.09429. Found: 218.09454. 
FTIR (thin film) 2930; 2860; 1732; 1580 cm·1• 
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Preparation2.43 of (2RS,3SR)-Ethyl2,3-epoxy-(5-phenyl)pentanoate (2.41) and (R,S)-Ethyl 
(2-hydroxy-5-phenyl)pentanoate (2.42) 
To a solution of 90 mg (0.42 mmol) of 2.37 in ethyl acetate (20 ml), was added 10% 
palladium on carbon (26 mg) and the resultant solution was stirred under a hydrogen 
atmosphere for 2 hours. The solution was then filtered and the solvent was evaporated 
under reduced pressure. Isolation by radial chromatography on silica (80% petroleum 
ether, 20% ethyl acetate) gave 2.41 (18 mg, 19%) and 2.42 (27 mg, 29%) as colourless 
oils. 
Spectral data for 2.41: 
1H NMR (CDCh) 3 7.18-7.33 (m, 5H, ArH); 4.22 (dq, 2H, J=2.0, 7.3 Hz, OCH2); 3.20 
(m, 2H, CH(epoxide)); 2.81 (m, 2H, PhCH2); 1.92 (m, 2H, PhCH2CH2); 1.29 (t, 3H, 
J=6.8 Hz, Me). 13C NMR (CDCb) 3 169.1 (C02); 140.5, 128.5, 128.4, 126,2 (Ar); 61.5 
(OCH2); 57.8, 53.2 (C(epoxide); 33.3 (PhC..fu); 31.9 (PhCH2CH2); 14.1 (Me). HRMS 
Calculated for C13H160 3: 220.10994. Found: 220.11040. FTIR (thin film) 3454; 3026; 
2932; 2864; 2343; 1732; 1605 cm-1• 
Spectral data for 2.42: 
1H NMR (CDCh) 3 7.17-7.31 (m, 5H, ArH); 4.23 (q, 2H, J=7.3 Hz, OCH2); 4.19 (t, 1H, 
1=4.9 Hz, CHOH); 2.90 (m(br), 1H, OH); 2.65 (m, 2H, PhCH2); 1.66-1.87 (m, 4H, 
(CH2)2CHOH); 1.28 (t, 3H, J=6.8 Hz, Me). 13C NMR (CDCb) 3175.2 (C02); 141.9, 
128.4, 128.3, 125.8 (Ar); 70.3 (QHOH); 61.6 (OCH2); 35.5 (PhCH2); 33.9, 26.5 
222.12595. FTIR (thin film) 3028; 2984; 2930; 2862; 1749; 1605 cm-1. 
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Chapter 3. Stereochemistry of the "Horner-Wadsworth-
Emmons" Reaction 
Introduction 
The controlled introduction of carbon-carbon double bonds is of considerable interest in 
organic chemistry?·1• 3·2 The development of the Wittig reaction, over 30 years ago, 
provided the first general and effective method of carbon-carbon double bond 
formation.3·2 The conventional Wittig reaction involves the reaction of a phosphorous 
ylide with an aldehyde or ketone to form an olefin and a phosphine oxide (Scheme 
3.1).3·1•3·2 This reaction and subsequent modifications rapidly became widely used, 
changing the face of olefin synthesis for all time.3·2 
Scheme 3.1 
Almost a decade after the disclosure of the Wittig reaction, a complementary reaction was 
developed by Homer et al. 3.1 and by Wadsworth and Emmons. 3.1 This reaction is 
variously called the "modified Wittig" reaction, the "Wittig-Harner" reaction, the 
"Homer-Emmons" reaction, and the "Homer-Wadsworth-Emmons" reaction. This thesis 
refers to it as the "Horner-Wadsworth-Emmons" (HWE) reaction. The HWE reaction 
employs a resonance stabilised phosphonate carbanion which undergoes reaction with an 
aldehyde or ketone, as shown in Scheme 3.2, to give an olefin and a phosphate ion.3.1 
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The HWE reaction possesses a number of advantages over the Wittig reaction.3·1 Most 
importantly, phosphonate carbanions are more nucleophillic than phosphonium ylides. 
This is attributed to a decreased stabilisation of the negative charge by valence shell 
expansion of the phosphorous atom in the phospho nate carbanion. 3'1 Therefore, 
phosphonate carbanions react with a wider variety of aldehydes and ketones and under 
milder conditions. Further, this enhanced reactivity allows for alkylation of the carbon, 
alpha to the phosphorous atom. On a practical note, phosphonates are readily prepared 
by the Arbuzov reaction3·3 and the phosphate ion by-product is water soluble, allowing 
for easy removal from the reaction mixture. 
Part 1. Mechanism of the HWE Reaction 
The widely accepted mechanism of the HWE reaction, presented in Scheme 3.3, is 
analogous to that of the conventional Wittig reaction.3·1• 3·2• 3.4, 35 The first step involves 
the base promoted formation of the phosphonate carbanion (see Scheme 3.3), stabilised 
by the electron withdrawing group (R 1) and the phosphoryl group. Step 2 is a reversible 
aldol condensation, giving two diastereoisomeric oxyanions (betaines) (see Scheme 3.3). 
The irreversible decomposition of these betaines to ole fins is thought to involve syn 
elimination via a four membered cyclic transition state which may have some double 
bond character. Thus, the erythro betaine leads, stereospecifically, to the Z olefin and the 
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threo betaine gives theE olefin (see Scheme 3.3). There is no appreciable 
interconversion of the E and Z olefins under the reaction conditions. 3.1 Kinetic studies, 
performed by Larsen and Aksnes, found the reaction was first order with respect to the 
aldehyde, the base, and the phosphonate, and third order overalL 3·2 The rate limiting step 
being the initial condensation of the aldehyde with the phosphonate. 3'2 
Scheme 3.3 
Base 
,.. 
R2 
- I 
(ROhPO-C + 
\ 
Rl 
Phosphonate Carbanion 
(R0h0~4-R Rl 
-o 
R3 
Erythro Oxyanion (betaine) 
~~ 
B.2 
= 
(RO)z"~ I R Rl 
0 
R3 
~ 
ZOlefin 
(ROh~OR. Rl 
-o 
R4 
Threo Oxyanion (betaine) 
+ k, 
B.2 
. 
(RO)z-~ I R1 
0 
R4 
~ 
E Olefin 
Although there has been no direct observation of the intermediates, the isolation of 
~-hydroxyphosphonates (protonated oxyanions) has provided strong supporting evidence 
for the intermediacy of an oxyanion.35 For example, Scheme 3.4 shows that an alkyl 
phosphonate which has a methyl group on the carbon alpha to the phosphorous (rather 
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than an electron withdrawing substituent), yields a P-hydroxyphosphonate upon treatment 
with base, followed by reaction with benzophenone and subsequent hydrolysis?·5 The 
P-hydroxyphosphonate does not undergo elimination to form an olefin even under basic 
conditions. A phosphonate with an electron withdrawing substituent on the carbon alpha 
to the phosphorous generally leads to spontaneous decomposition to olefins (see Scheme 
3.2). This suggests that the transition state for elimination has a considerable build up of 
negative charge on the carbon alpha to the phosphorous atom.3.4, 35 However, the use of a 
magnesium cation results in a more stable intermediate (since magnesium salts have more 
covalent character) and Scheme 3.5 illustrates the formation of a pair of resonance 
stabilised B-hydroxyphosphonates. 35 Thermal decomposition of these isolated 
intermediates was shown to be highly stereospecific, occurring in a syn fashion. 35 
Scheme 3.4 
Me ) 
(MeO)zOP 
Alkylphosphonate 
Scheme 3.5 
l. n-BuLi 
2.CO(Ph)z 
3.H20 )Jio 
1. iso-PrMgCI 
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3.H20 
M>-IOH 
(MeO)zOP Ph Ph 
~-Hydroxyphosphonate 
B 
(PhO)zo~· H CN 
HO 
Ph 
(PhO)zo~· 
+ p CN 
HO 
H 
A study by Seyden-Penne et al. demonstrated that the intermediate betaines (see Scheme 
3.3) are capable of both retroaldolisation and interconversion.3·6 The erythro 
B-hydroxyphosphonate, shown in Scheme 3.6, was prepared, isolated, and reacted with 
4-chlorobenzaldehyde (two equivalents) and sodium hydroxide (NaOH) in 
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tetrahydrofuran (THF) (analogous studies were performed on the equivalent threo 
~-hydroxyphosphonate).3 ·6 The product mixture contained 80% 4-chlorocinnamonitrile, 
demonstrating that the ~-hydroxyphosphonate was capable of retroaldolisation (via 
pathway 1, Scheme 3.6).3·6 Further, the 20% cinnamonitrile formed (via pathway 2, 
Scheme 3.6) had a similar stereochemical ratio as the direct reaction between the 
phosphonate carbanion and benzaldehyde. This demonstrates that the erythro 
intermediate is capable of direct epimerisation to the threo form (any phosphonate 
carbanion formed by retroaldolisation would be trapped by the more reactive 
4-chlorobenzaldehyde).3·6 Note that a hydrogen on the carbon alpha to the phosphorous 
atom is required for epimerisation.3·5• 3·6 
Scheme 3.6 
2. )=={ 
Ph CN 
NaOH 
Erytho 
P-Hydroxyphosphonate 
20% 
Part 2. Stereochemistry of the Olefin Products 
Initial studies of HWE olefm formation reported exclusively E stereochemistry. 3.1, 3.4, 3·5 
However, reports of Z olefins soon began to appear.3·1• 3.4, 3·5 For example, an early 
study3·5 showed that small, but appreciable, quantities of the Z isomer were obtained 
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when citral was reacted with a phosphonate anion, where the anion has an ethyl group on 
the carbon, alpha to the phosphorous atom (Scheme 3.7). 
Scheme 3.7 
~e Et 
I ~-
<Me)zc=cH(cH2)2 c\ (R0)
2
P/ "'-coR 
Citral ro _____ _,,...,..... 
H 
It is generally accepted that the stereochemistry of the olefin formed depends upon the 
relative rates of formation (k1, Scheme 3.3) and of decomposition (k1 'I k2, Scheme 3.3-
k 1 'I k2 is often referred to as the "reversibility factor"3·7) of both the erythro and threo 
betaines.3.4, 3·7• 3·8 It is well established that the "reversibility factor" is of prime 
importance in determining the stereochemical outcome of the reaction.3.4. 3·7• 3·8• 3 ·9 The Z 
olefin is favoured when the "reversibility factor" decreases. For example, the reaction of 
cyclic phosphonates with an aldehyde (Scheme 3.8), led to a high proportion of the Z 
olefm in every case studied.3'10 This was attributed to a decrease in the "reversibility 
factor" due to an increase in the rate of decomposition (k2), promoted by the release of 
ring strain (upon passing from a four co-ordinate to a five co-ordinate intermediate).3·10 
Conversely, theE olefin is favoured when k1' (Scheme 3.3) is large, for example in the 
case of aromatic aldehydes.3·8 It is generally accepted that the more stable E olefin forms 
as a result of thermodynamic controi.3·8 
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Scheme 3.8 
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A number of factors, including the reaction conditions and nature of the reactants, have 
been shown to affect the stereochemical outcome of the reaction. 3.1, 3·2• 3.4, 3·5• 3·7• 3·8• 3·9• 3·10 
For example, studies on the influence of the metal cation (supplied by the base) have 
shown that lithium offers the best E selectivity. 3·5• 3·7 This has been attributed to a high 
degree of association between lithium and the intermediate betaines, resulting in a 
decrease in the rate of decomposition to product (and a consequent increase in the 
"reversibility factor").3'7 Further, the reaction temperature has considerable influence on 
the stereochemical outcome of the reaction. 3'7 A decrease in temperature leads to an 
increase in the amount of Z product, attributed to a decrease in the reversibility of the 
reaction at low temperatures. 3·7 
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The effect on the HWE reaction of the nature of the aldehyde and of modifications to the 
phosphoryl reagent are the subject of this chapter. The effect of the reaction temperature 
and the solvent are also discussed briefly. 
Part 3. Applications of the HWE Reaction in Synthesis 
The HWE reaction has been employed to extend the scope of the traditional Wittig 
reaction.3.4 The stereospecifity and experimental simplicity of the HWE reaction have 
made it a method of choice for the synthesis of many alkenes.35 As discussed above, the 
phosphonate carbanion requires the presence of an electron withdrawing group at R1 (see 
Scheme 3.2). Therefore, the synthesis is generally limited to alkenes containing at least 
one activating group alpha to the double bond.3·4 Modifications to the structure of the 
phosphonate allows the preparation of a,~-unsaturated products containing a wide variety 
of functional groups. For example, an appropriate substituent at R1 of the phosphonate 
carbanion enables the synthesis of a,~-unsaturated acids, esters, amides, and nitriles in 
excellent yields (see Scheme 3.2).3.4 The superior reactivity of the HWE reaction, over 
the Wittig reaction, allows the synthesis of a,~-unsaturated ketones, although poor yields 
have been noted in some cases.3.4 
Scheme 3.2 
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Various sulfur compounds may also be prepared in high yields.3.4. 3·5 For example, 
Scheme 3.9 shows the synthesis of a vinyl sulfide from a modified phosphonate and an 
aldehyde.3·5 
Scheme 3.9 
l.NaH 
2.RCHO )=<H 
4-BrC6H4S R 
Vinyl Sulfide 
Modification of the carbonyl co-reactant widens the scope of the HWE reaction. For 
example, the synthesis of allenes from ketenes, shown in Scheme 3.10, is preferred to the 
Wittig route due to the milder reaction conditions required.3.4 Further, dienes may be 
prepared from unsaturated carbonyl compounds, as shown in Scheme 3.11.3.4 Although 
competing reactions can sometimes interfere, the yield is often better than that from the 
corresponding Wittig reaction.3.4 
Scheme 3.10 
1. Base 
Scheme 3.11 
I. Base 
2. R1 
~0 
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The HWE reaction has been used extensively in the synthesis of natural products.M 3'5 
Indeed its development has occurred largely in this area?·5 The predominantly E 
stereochemistry of the product olefin has rendered the reaction particularly attractive in 
the synthesis of isopreniods and prostaglandins.3.4. 3·5 For example, the reaction of 
2-oxoheptylphosphonate with an aldehyde, shown in Scheme 3.12, has become the 
method of choice for the introduction of the C8 side chain of prostaglandins.3.4 The HWE 
reaction has also been used extensively to prepare potential pharmacologically active 
steroid derivatives3.4, 35 and to synthesise branched chain sugars and nitrogen 
heterocycles. 3.4 
Scheme 3.12 
0 0 
Me Me 
H COC5H11 
148 
Chapter 3 
Results and Discussion 
Part 1. Effect of the Aldehyde on the HWE Reaction 
In the HWE reaction (Scheme 3.13), between a phosphonate (3.1/3.2) and an aldehyde 
(3.3) or ketone (3.4), it has been noted that the nature of the carbonyl substituent(s) 
(R3/R 4) can effect the E:Z stereochemistry of the product. 3·2• 3.4, 35• 3·7• 3·11• 3·12• 3·13 
Heathcock and Thompson,3·7 on studying the HWE reaction with various aldehydes, 
stated that, of all the reaction variables, the nature of the alkyl substituent of the aldehyde · 
had the greatest effect on the stereochemistry of the product. However, the emergence of 
clear trends has been elusive. Our investigations have sought to establish a relationship 
between the nature ofthe aldehyde (3.3, Scheme 3.13) and the stereochemical outcome of 
the reaction and to compare this with literature investigations. 
Scheme 3.13 
R2 
I c-
___ B_a_se __ ,...,... (ROhOP/ 'ce>zRl 
3.1 Unsubstituted Phosphonate ( R2=H) 
3.2 a-Substituted Phosphonate (R2=alkyl) R>=o 
R4 
3.3 Aldehyde (R4=H) 
3.4 Ketone (R4=alkyl) 
R>=<R' + (RO),PO,-
R4 C02R1 
Three classes of aldehydes (3.3) were studied, where R3 is either conjugated, unbranched 
aliphatic, or alpha-branched aliphatic (see Table 3.1 for numbering of the aldehydes 
(3.3)). Each class gave characteristic results. The aldehydes (3.3) were reacted with the 
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corresponding anions of the phosphonates (3.la, 3.1b, or 3.lc) as shown in Scheme 3.14. 
The reactions were performed as described by Heathcock and Thomspson,3·7 using n-
butyllithium (n-BuLi) as the base and tetrahydrofuran (THF) as the solvent, at either 
room temperature (r.t.) or at -78 °C. The E:Z isomer ratio of the olefin products was 
determined by 1H NMR analysis of the crude reaction mixture. 
Scheme 3.14 
(RO)zOP~C02R1 
3.1a R, R 1=Me 
3.1b R, R 1=Et 
3.1c R=Ph, R1=Me 
n-BuLi/THF/-78 °C or r.t. 
.. 
Table 3.1. Numbering ofthe Aldehydes (3.3) 
Aldehyde (R3CHO) 
3.3a 
3.3b 
3.3c 
3.3d 
3.3e 
3.3f 
3.3g 
3.3h 
3.3i 
3.3j 
2.25a 
2.25b 
Ph 
PhCH=CH 
Me 
Et 
Me(CH2)s 
Me(CH2)9 
(Me)2CH 
(Et)2CH 
cyclohexyl 
Me(CH2)8(Me )CH 
PhCH2CH2 
4-nitroC6RtOCH2 
R)={ 
H C02R
1 
3.5 R1=Me 
3.6 R1=Et 
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The effect of a conjugated aldehyde (3.3, where R3 is unsaturated or aromatic) on the 
stereochemical outcome of the HWE reaction was investigated using benzaldehyde (3.3a) 
and cinnamaldehyde (3.3b). As shown in Table 3.2, the aldehydes (3.3a and 3.3b) were 
reacted with the anion of trimethyl phosphonoacetate (3.1a), at -78 °C, in THF, using n-
BuLi to generate the anion. The results, presented in Table 3.2, demonstrated a very 
strong preference for the formation of the E olefin. 
Table 3.2. Product ratios obtained with Conjugated Aldehydes (3.3) 
1. n- BuLiffHF/-78 °C 
2. R3CHO (3.3) R3HC=CHC02Me (3.5) 
Aldehyde (3.3) E:Z ratio 
3.3a (R3=Ph) >19:1 
3.3b (R3=PhCH=CH) >19:1 
A predominance of the olefin in the HWE reaction of conjugated aldehydes has been 
noted in other systems.3.4. 3·12' 3.14 For example, Popoft et al. 3.1 4 studied the reaction of 
various aldehydes (3.3, where R3 has the ability to conjugate) with the phosphonate 
(Et0)2POCH2S02Et, as shown in Scheme 3.15. Their investigation showed that theE 
isomer predominated when R3 is conjugated.3'14 It was suggested that the E isomer was 
favoured because of the increased steric bulk of R3 when it is conjugated.3.14 However, 
our work on aliphatic aldehydes (see later) suggested that the steric effect ofR3 is not 
straightforward and that bulkier groups do not necessarily promote formation of the E 
isomer. Further, a predominance of theE isomer has also been noted3.1 2 for the reaction 
between the alpha-substituted phosphonate (3.2 R=Et, R1,R2=Me) and alpha, beta-
unsaturated aldehydes (3.3) (see Scheme 3.13 for a general scheme). 
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Scheme 3.15 
1. Base 
2. R)=o 
H 3.3 
Therefore, our findings that the conjugated aldehydes, benzaldehyde (3.3a) and 
cinnamaldehyde (3.3b ), reacted with trimethyl phosphonoacetate (3.la) to give a 
predominance of theE olefin (Table 3.2) was consistent with literature reports on similar 
systems.3.4. 3'12' 3.14 In every case presented in this chapter, reaction with benzaldehyde 
(3.3a) resulted in a larger proportion of the E product than any of the aliphatic aldehydes 
studied, under the same reaction conditions. It was not considered necessary to 
investigate this area further. 
The effect of the alkyl group of a non-conjugated aldehyde (3.3, where R3 is a straight 
chain) on the stereochemical outcome of the HWE reaction was investigated using the 
four aldehydes, acetaldehyde (3.3c), propionaldehyde (3.3d), heptaldehyde (3.3e), and 
undecanal (3.3f). As shown in Table 3.3, the aldehydes were reacted with the anion of 
trimethyl phosphonoacetate (3.la), at -78 oc and at r.t., in THF, using n-BuLi to generate 
the anion. An examination of the results presented in Table 3.3 reveals that in all cases 
the olefin predominated, but that in most cases a significant amount of the Z isomer 
was formed. The proportion of the Z isomer formed, both at r.t. and -78 °C, appeared to 
vary with the length of the carbon chain at R3. The pattern observed for the four aliphatic 
aldehydes (3.3c-3.3f, Table 3.3) investigated, indicated that the longer the carbon chain at 
R3, the greater the proportion of Z product. 
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Table 3.3. Product ratios obtained with Unbranched Aliphatic Aldehydes (3.3c-f) 
1. n- BuLi/THF/-78 °C orr.t. 
(Me0hPOCH2C02Me (3.1a) 2. R3CHO (3.3) R3HC=CHC02Me (3.5) 
Aldehyde (3.3) 
3.3c (R3=Me) 
3.3d (R3=Et) 
3.3e (R3=Me(CH2)s) 
3.3f (R3=Me(CH2)9) 
E:Z Product Ratio 
at -78 °C at r.t. 
8.0:1 11:1 
3.6:1 7.0:1 
2.0:1 5.5:1 
2.0:1 5.7:1 
To our knowledge, this is the first report of such a pattern of variance for the reaction of 
phosphonates of the type 3.1 with unbranched aliphatic aldehydes (3.3) (see Scheme 3.13 
for a general scheme). However, a literature investigation3.1 1 of the reaction between the 
alpha-substituted phosphonate (3.2 R,R1=Et, R2=Me/Et) and the aldehyde (3.3 R3=Me/Et) 
showed that the proportion of Z product was significantly enhanced when R3=Et rather 
than R3=Me-i.e. for the longer chain aldehyde (see Scheme 3.13 for a general scheme). 
This was not particularly commented upon by the authors. 
Scheme 3.13 
3.1 Unsubstituted Phosphonate ( R2=H) 
3.2 a-substituted Phosphonate (R2=alkyl) 
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The effect of the alkyl group of a non-conjugated aldehyde (3.3, where R3 is alpha-
branched) on the stereochemical outcome of the HWE reaction was investigated, using 
the four aldehydes isobutyraldehyde (3.3g), 2-ethylbutyraldehyde (3.3h), 
cyclohexanecarboaldehyde (3.3i), and 2-methylundecanal (3.3j). As shown in Table 3.4, 
the aldehydes were reacted with the anion of trimethyl phosphonoacetate (3.1a), at -78 °C 
and at r.t., in THF, using n-BuLi to generate the anion. The isomer ratios, presented in 
Table 3.4, demonstrate that the reaction with the alpha-branched aldehydes (3.3g-3.3j) 
gave a significant proportion of the Z product, both at -78 °C and at r.t. This was most 
obvious at -78 °C, since all the alpha-branched aldehydes studied (3.3g-3.3j, Table 3.4) 
gave a predominance of the Z product. Further, at r.t. a higher proportion of Z product 
was obtained with the alpha-branched aldehydes (3.3g-3.3j) than for unbranched 
aldehydes with a carbon chain of the same length. For example, the reaction of 3.1a with 
the alpha-branched aldehyde (3.3g) resulted in an E:Z product ratio of 4.5:1 (Table 3.4), 
whereas reaction with the unbranched aldehyde (3.3d) gave a E:Z product ratio of 7.0:1 
(Table 3.3). 
Table 3.4. Product ratios obtained with Alpha-Branched Aliphatic Aldehydes (3.3) 
1. n- BuLi!THF/-78 °C or r.t. 
(Me0)2POCH2C02Me (3.1a) 2. R3CHO (3.3) R3HC=CHC02Me (3.5) 
Aldehyde (3.3) 
3.3g (R3=(Me)zCH) 
3.3j (R3=Me(CHz)8(Me)CH) 
3.3i (R3=cyclohexyl) 
3.3h (R3=(Et)2CH) 
E:Z Product Ratio 
at -78 °C 
1:2.8 
1:2.8 
1:3.0 
1:5.0 
at r.t. 
4.5:1 
3.8:1 
3.4:1 
3.6:1 
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Interestingly, at -78 °C, reaction of the anion of 3.1a with isobutyraldehyde (3.3g) or with 
2-methylundecanal (3.3j), resulted in identical E:Z product ratios of 1:2.8 (see Table 3.4). 
Both 3.3g and 3.3j have a methyl group at the 2-position. Scheme 3.16 details a report3.1 3 
of another aldehyde with a methyl group at the 2-position, reported to give an almost 
identical E:Z product ratio (on reaction with 3.1a, under similar reaction conditions to the 
currentstudy). However, when 3.1a was reacted with 2-ethylbutyraldehyde (3.3h), 
which has an ethyl group at the 2-position, the E:Z isomer ratio decreased to 1 :5.0 (Table 
3.4). These observations suggest that, when the reaction is performed at -78 °C, the 
important factor in determining the isomer ratio of the product may be the group at the 2-
position of the aldehyde. 
Scheme 3.16 
Me Me 
BzlO, ~ 
~ "CHO 
tert-BuOKTHF/-18 °C 
BzlO~ 
E:Z = 1:3 C02Me 
To investigate, further, the influence of the aldehyde (3.3), the unbranched aldehydes 
(3.3d and 3.3e), and the alpha-branched aldehydes (3.3g and 3.3h), were reacted with the 
anion of triethyl phosphonoacetate (3.1b ). The reactions were performed both at -78 °C 
and at r.t., in THF, using n-BuLi to generate the anion (see Table 3.5). The data 
presented in Table 3.5 shows that both alpha-branched aldehydes (3.3g and 3.3h) reacted 
with 3.lb to produce a significant proportion of the Z product. This was also observed 
for the reaction of both 3.3g and 3.3h with the phosphonate (3.la) (Table 3.4). The 
results for the reaction of the two unbranched aldehydes (3.3d and 3.3e) with 3.lb are 
also shown in Table 3.5. The reaction appeared to be relatively insensitive to the chain 
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length of the aldehyde. This was not observed for the reactions of 3.3d and 3.3e with the 
phosphonate (3.1a) (Table 3.3). 
Table 3.5. Product ratios obtained with the Phosphonate (3.1b) 
Aldehyde (3.3) 
3.3d (R3=Et) 
3.3e (R3=Me(CH2)s) 
3.3g (R3=(Me)2CH) 
3.3h (R3=(Et)2CH) 
1. n-BuLiffHF/-78 °C or r.t. 
2. R3CHO (3.3) 
E:Z Product Ratio 
at -78 °C 
9.3:1 
9.4:1 
1.5:1 
1.5:1 
atr.t. 
19:1 
>19:1 
13:1 
12:1 
Further work in this area involved the investigation of methyl diphenylphosphonoacetate 
(3.1c). As shown in Table 3.6, the unbranched aldehydes (3.3d and 3.3e) and the alpha-
branched aldehydes (3.3g, 3.3h, and 3.3j) were reacted with the anion of 3.1c. The 
reactions were performed both at -78 °C and at r.t., in THF, using n-BuLi to generate the 
anion. The results, presented in Table 3 .6, demonstrate that for the unbranched aldehydes 
(3.3d and 3.3e), the longer chain aldehyde (3.3e) reacted with 3.1c to form a higher 
proportion of Z product. This was also observed when the aldehydes (3.3d and 3.3e) 
were each reacted with the phosphonate (3.1a) (Table 3.3) but not with the phosphonate 
(3.lb) (Table 3.5). 
The alpha-branched aldehydes (3.3g, 3.3h, and 3.3j) reacted with the phosphonate (3.1c) 
to form a higher proportion of the Z product than unbranched aldehydes of the same 
chain length (compare the results obtained with 3.3d and 3.3g, shown in Table 3.6). This 
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phenomenon was also observed for the reactions with 3.1a (Tables 3.3 and 3.4) and with 
3.1b (Table 3.5). 
As a consequence of our work on HIV protease inhibitors (Chapter 2), the aldehydes 
(2.25a and 2.25b-Table 3.6) were both reacted with the anion of the phosphonate (3.1c). 
The reactions were performed at -78 °C and at r.t., in THF, using n-BuLi to generate the 
anion. The results are displayed in Table 3.6. The stereochemical outcome of the 
reaction of 2.25a with the phosphonate (3.lc) was very similar to that obtained for 
heptaldehyde (3.3e) under the same conditions. Unexpectedly, the reaction of 3.1c with 
2.25b resulted in a considerably smaller proportion of the Z isomer than that obtained for 
2.25a. 
Table 3.6. Product ratios obtained with the Phosphonate (3.1c) 
Aldehyde (3.3) 
3.3d (R3=Et) 
3.3e (R3=Me(CH2)s) 
3.3g (R3=(Me)2CH) 
3.3h (R3=(Et)2CH) 
3.3j (R3=Me(CH2) 8(Me)CH) 
2.25a (R3=PhCHzCHz) 
2.25b (R3=4-nitroC6~0CHz) 
1. n-BuLi/fHF/-78 °C 
2. R3CHO (3.3) 
E:Z Product Ratio 
1:1.3 
1:7.0 
1:3.3 
1:3.8 
1:5.7 
1:6.4 
1:3.4 
Overall, for the three phosphonates investigated (3.1a, 3.1b, and 3.1c), a high proportion 
of the Z product was obtained on reaction with alpha-branched aldehydes such as 
isobutyraldehyde (3.3 R3=(Me)2CH). This is, to our knowledge, the first comprehensive 
study ofphosphonates of the type 3.1 (Scheme 3.13) with alpha-branched aldehydes. 
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However, several investigators3' 11' 3'12 have reported significant increases in the proportion 
of Z product when alpha-branched aldehydes were reacted with alpha-substituted 
phosphonates of the type 3.2 (Scheme 3.13). For example, Seyden-Penne et al. 3'12 
reported the reaction of alpha-branched aldehydes, such as isobutyraldehyde (3.3 
R3=(Me)2CH), with the phosphonate (3.2 R=Et, R1,R2=Me) to give stereoselectively Z 
olefins (see Scheme 3.13 for a general scheme). The reactions were performed with n-
BuLi in THF at low temperature. Further, Kinstle et al. 3·11 showed that the reaction of the 
phosphonate (3.2 R,R1=Et, R2=Me/Et) with the aldehyde (3.3 R3=Et/(Me)2CH/tert-Bu) 
gave a significant increase in the proportion of Z product when R3=Et was replaced by 
R3=(Me)2CH (see Scheme 3.13 for a general scheme). The proportion decreased again 
when R3=tert-Bu. These workers concluded that steric factors were responsible for the 
trends, the precise nature of which was not stated.3·11 
Scheme 3.13 
3.1 Unsubstituted Phosphonate ( R2=H) 
3.2 a-substituted Phosphonate (R2=alkyl) R3 
\_0 ;-
H 3.3 
R3 R2 
\-/ + (R0)2P02• 1-\ 
H C02R1 
Heathcock and Thompson3·7 studied the reaction of unbranched and alpha-branched 
aldehydes with trimethyl phosphonoacetate (3.la), under various conditions of solvent, 
temperature, and cation. These conditions included the use of n-BuLi in THF, at -78° and 
at r.t, as was the case in our investigations (Scheme 3.14). Their results focused on the 
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finding that regardless of the reaction conditions, the aldehyde (3.3 R3=tert-Bu) resulted 
in the exclusive formation of theE olefin. This was attributed to a greater propensity for 
the formation of the intermediates giving rise to the E olefin (for steric or kinetic 
reasons,
3
'
7 the precise nature of which was not stated). However, their published data 
showed that, for every set of conditions studied, isobutyraldehyde (3.3 R3=(Me)2CH) 
gave a greater proportion of the Z olefin than the unbranched aldehyde (3.3 
R3=CH2CH2C(Me)2CH2CH=C(Me)2). This trend was not commented upon by the 
authors. Similarly, in the current study, a high proportion of the Z olefin was obtained for 
reactions of alpha-branched aldehydes such as isobutyraldehyde (3.3g) with the 
phosphonate (3.la) and further with the phosphonates (3.lb and 3.1c)-see Tables 3.4, 
3.5, and 3.6. 
Scheme 3.14 
(R0)20P~C02R1 
3.1a R, R 1=Me 
3.1b R, R 1=Et 
3.1c R=Ph, R 1=Me 
n-BuLi/THF/-78 °C orr.t. 
R3 H 
>=< H C02R1 
3.5 R1=Me 
3.6 R1=Et 
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Part 2. Effect of the Phosphonate on the HWE Reaction 
During our earlier investigations on the stereochemical outcome of the HWE reaction 
(Part 1) it was noted that, under identical conditions, trimethyl phosphonoacetate (3.1a) 
always produced a greater proportion of the Z olefin than triethyl phosphonoacetate 
(3.1b) .. This observation was supported by a literature report3.15 where the phosphonates 
(3.1a and 3.1b) were each reacted with an alpha-branched aldehyde as shown in Scheme 
3.17. The reaction with 3.1a resulted in a 1: 1 ratio of isomeric ole fins whereas reaction 
with 3.1b gave an excess of theE olefin (12:1). 
Scheme 3.17 
QR 
~CHO + (R0h0P~C02R1 3.1a R, R 1=Me 
3.lb R, R 1=Et 
NaHffHF 
.. 
-60 or -78 °C 
QR 
~co2R1 
To investigate this observation, studies were carried out using the four phosphonate 
reagents, trimethyl phosphonoacetate (3.1a), triethyl phosphonoacetate (3.1b), ethyl 
dimethylphosphonoacetate (3.1d), and methyl diethylphosphonoacetate (3.1e). These 
phosphonates were chosen to investigate the influence of the substituents (R) and (R 1 ). 
The anions of these phosphonates (3.1a, 3.1b, 3.1d, and 3.1e) were each reacted with 
heptaldehyde (3.3e), isobutyraldehyde (3.3g), and benzaldehyde (3.3a), as shown in 
Table 3.7. The reactions were performed in THF, at -78 °C, using n-BuLi to generate the 
anion (conditions previously established as conducive to the formation of the Z isomer as 
this was often the minor isomer). 
(R0h0P~C02R1 
3.1 
3.1a R, R1=Me 3.1b R, R 1=Et 3.ld R=Me, R1=Et 3.1e R=Et, R1=Me 
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Table 3.7. Product Ratios obtained with the Phosphonates (3.la, 3.lb, 3.ld, & 3.1e) 
1 (RO)zPOCH2C02R (3.1) 
1. n-BuLiffHF/-78 °C 
2. R3CHO (3.3) 
Aldehyde (3.3) Phosphonate Reagent (3.1) 
R Rt 
3.3e (R3=Me(CH2)s) 3.1a Me Me 
3.1d Me Et 
3.1b Et Et 
3.1e Et Me 
3.3g (R3=(Me)zCH) 3.1a Me Me 
3.1d Me Et 
3.1b Et Et 
3.1e Et Me 
3.3a (R3=Ph) 3.1a Me Me 
3.1d Me Et 
3.1b Et Et 
3.1e Et Me 
3 1 R HC=CHC02R (3.5/3.6) 
E IZ Product Ratio 
2.0:1 
1.2:1 
9.4:1 
6.7:1 
1:2.8 
1:2.9 
1.5:1 
2.4:1 
>19:1 
>19:1 
>19:1 
>19:1 
The results presented in Table 3.7 show that for each reaction, the stereochemical 
outcome was dependent on the nature of R. For example, reactions performed on 
isobutyraldehyde (3.3g) resulted in an almost threefold excess of the Z product with both 
3.1a and 3.1d (where R is methyl), but with 3.1b and 3.1e (where R is ethyl) a significant 
excess of theE product resulted. However, the product ratio was relatively insensitive to 
whether the phosphonate had a methyl or an ethyl group at R 1• 
In summary, the results presented in Table 3.7, indicate that: 
(1) The group at R1, whether ethyl or methyl, had minimal effect on the stereochemical 
outcome of the reaction. 
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(2) The nature ofR, whether ethyl or methyl, had an important influence on the 
stereochemical outcome of the reaction. In particular, R=methyl appeared to favour the 
formation of the Z isomer. 
Literature reports3·16' 3·17 substantiate our findings that, for the phosphonate (3.1), changes 
at R1 had a minimal influence on the stereochemical outcome ofHWE reactions. For 
example, Still3.16 reported that HWE reactions are relatively insensitive to changes at R 1 
of phosphonate reactant (3.1) and that only slightly elevated E:Z ratios were obtained 
when R1 was cyclohexyl rather than methyl. Further, Wadsworth et al.3·17 attempted to 
promote the formation of the Z isomer, by combining large napthyl groups at R1 and R3 
(Scheme 3.18). This strategy was designed to promote the formation of the erythro 
betaine (which gives rise to the Z isomer) for steric reasons (Figure 3.1), but was not 
particularly successfuL 3·17 
Scheme 3.18 
R3 )=o 
H 
R 1, R3=1-naphthyl 
NaOMe~ R'r<Me 
H C02R1 
6.4% z 
66.7%E 
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Figure 3.1. The use of napthyl groups to promote the formation of the erythro betaine. 
Literature reports3'13• 3.1 8 support our finding that the R group of the phosphonate (3.1) had 
an important influence on the stereochemical outcome of the HWE reaction. Kishi et al. 
state that, in general, a phosphonate reagent with a large phosphonate ester group yields a 
predominance of the E olefin. 3'13 For example, the reaction of the phosphonate 3.1 
(R=iso-Pr, R 1=Et) with an alpha-branched aldehyde was reported to give a 120 times 
excess of theE product (Scheme 3.19).3.18 The promotion of theE product by a large 
phosphoryl ester is consistent with our findings, shown in Table 3.7. 
Scheme 3.19 
(iso-PrO)zOP~ C~Et 
3.1 
tert-BuOK 
... 
E:Z 120:1 C02Et 
To corroborate these findings, the phosphonate (3.1f) was synthesised.3·19 The anion of 
3.1fwas reacted with each heptaldehyde (3.3e), isobutyraldehyde (3.3g), and 
benzaldehyde (3.3a). The reactions were again performed in THF, at -78 °C, using n-
BuLi to generate the anion. The results, shown in Table 3.8, demonstrate that for each 
aldehyde (3.3a, 3.3e, or 3.3g), the reaction with 3.1f led to a high proportion of 
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product. In fact, Table 3.8 clearly shows that for the phosphonate (3.1), increasing the 
size ofR, from Me (as in 3.1a) to Et (as in 3.1e) and to iso-Pr (as in 3.1f), increased the 
proportion of E product. 
(ROhOP~C02R1 
3.1 
3.1f R= iso-Pr, R1=Me 
These findings imply that the influence of the phosphonate ester is entirely steric. 
Examination of the literature, 3.1 6 however, reveals that this is only part of the story. For 
example, Still developed a phosphonate reagent (3.1 R=F3CCH2), which yielded a 
dramatically higher proportion of the Z olefin (compared to the phosphonate (3.1a) under 
identical conditions) (Scheme 3.20).3'16 For example, benzaldehyde (3.3a) was converted 
almost stereoselectively to Z-cinnamate by the Still reagent (3.1 R=F3CCH2)?·16 
However with the phosphonate (3.1a R=Me), a 12 fold excess of E-cinnamate was 
produced (Scheme 3.20).3·16 Clearly, steric factors alone do not account for these results. 
Scheme 3.20 
Ph 
>::a 
H 3.3a 
+ (R0h0P~C02Me 
3.1 
Still Reagent R=C:f~CH2 
3.1aR=Me 
Ph H 
KN(TMSh/18-crown-6/THF "=J 
--------------~--~ ~---~ 
H C02Me 
Cinnamate 
Further, a recent paper3'19 reported a new phosphonate, ethyl diphenylphosphonoacetate 
(3.1 R=Ph, R1=Et) which gave Z olefins with up to 90% selectivity. We suggested that 
the phenyl group of the phosphoryl ester may be responsible for the high Z selectivity. 
To demonstrate this, methyl diphenylphosphonoacetate (3.1c. R=Ph, R1=Me) was 
3.19 
synthesised. The reaction of the anion of 3.1c with each heptaldehyde (3.3e ), 
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isobutyraldehyde (3.3g), and benzaldehyde (3.3a) was studied and the results are 
presented in Table 3.8. These reactions were again performed in THF, at -78 oc , using 
n-BuLi to generate the anion. The results were compared to those obtained with 
trimethyl phosphonoacetate(3.1a), and with triethyl phosphonoacetate (3.1b), and with 
the literature result for the reaction of ethyl diphenylphosphonoacetate (3.1 R=Ph, R1=Et) 
with 3.3a (Table 3.8).3.1 9 
(RO)zOP~C02R1 
3.1 
3.1c R=Ph, R1=Me 
Table 3.8. Product ratios obtained with the Phos12honates (3.1a, 3.1c,3.1e, & 3.1{) 
L n-BuLitrHF/-78 °C 
1 (ROhPOCH2C02R (3.1) 2. R
3CHO (3.3) R3HC=CHC02R 1 (3.5/3.6) 
Aldehyde (3.3) Phosphonate (3.1) R R' E:ZProduct Ratio 
3.3e (R3=Me(CH2)s) 3.1a Me Me 2.0:1 
3.1e Et 6.7:1 
3.1f iso-Pr >19:1 
3.1c Ph 1:7.0 
3.3g (R3=(Me)2CH) 3.1a Me Me 1:2.8 
3.1e Et 2.4:1 
3.1f iso-Pr 10:1 
3.1c Ph 1:3.3 
3.3a (R3=Ph) 3.1a Me Me >19:1 
3.1e Et >19:1 
3.1f iso-Pr >19:1 
3.1c Ph 1:2.2 
3.3a (R3=Ph) 3.1d Me Et >19:1 
3.1h Et >19:1 
3.19 
3.1 Ph 1:2.0 
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An examination of Table 3.8 shows that for phosphoryl esters, where R is aliphatic, a 
larger R group promoted the formation of the E product. However, when R was phenyl 
high Z selectivity resulted. For example, the reaction of isobutyraldehyde (3.3g) with 
3.1f (R=iso-Pr) gave a 10 fold excess of theE olefin, whereas with 3.1c (R=Ph) a three 
fold excess of the Z olefin resulted. Such results could not be explained by steric 
considerations alone. Therefore, the electronic effect of the phenyl ring was considered. 
Scheme 3.3 
R2 
- I Base ,... (RO)zPO-C + 
\ 1 
R 
Phosphonate Carbanion 
kt' 1~ k, 
R2 
(RO)z~ ki R Rl 
-o 
R3 
Erythro Oxyanion (betaine) 
~ kz 
B.2 
(RO)z-~ I R Rl 
0 
R3 
~ 
ZOlefin 
k,' 1~ kl 
B.2 
(RO),~ Rl 
-o 
R4 
Threo Oxyanion (betaine) 
+ kz 
B.2 
(RO)z-~ I R1 
0 
R4 
~ 
E Olefin 
We hypothesised that the large increase in the amount of Z olefin produced, when the R 
group of the phosphoryl ester was phenyl, was due to an increase in the electrophilicity of 
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the phosphorous atom in the betaine intermediate (see Scheme 3.3). Since the lone pairs 
on the phenoxy oxygen are conjugated to the ring, less electron density is available to the 
phosphorous atom. Increased phosphorous atom electrophilicity in tum increases the rate 
of nucleophilic attack at the phosphorous. As already discussed in the introduction to this 
chapter, an increase in the rate of decomposition (k2) of the betaines to product, results in 
a decrease in the "reversibility factor" and this leads to an increase in the proportion of 
the Z product. 
This explanation is supported by previous work by Deschamps et al. 3·9 where the 
phosphorous atom electrophilicity of various phosphonates was modified (by modifying 
the R group) resulting in changes to the E:Z product ratio. For example, the reaction of a 
number of aldehydes, such as benzaldehyde (3.3a), with the phosphonate (3.7) showed 
that when R was Me2N a greater proportion of the E olefin was produced than when R 
was OEt (Scheme 3.21).3'9 Since a dimethylamino group is a better electron donor than 
an ethoxy group, the authors suggested that the phosphorous atom would be less 
electrophilic when R=Me2N. 3·9 This would make ring closure less attractive, reducing the 
rate of decomposition (k2, Scheme 3.3) of the betaine intermediates to product.
3
'
9 
Thus, 
there would be an increase in the "reversibility factor" and subsequently in the proportion 
3.9 
of E product. 
Scheme 3.21 
Me 
(R),OPAcN 
3.7 
R=EtO!MezN 
tert-BuOK or n-BuLi R>=<
3 
Me 
------------~--~ ---THF 
H CN 
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To investigate the importance of the electrophilitcity of the phosphorous atom, two new 
phosphonates, (3.1g and 3.1h), were synthesised. It was reasoned that: 
(1) for the phosphonate (3.1g), the presence of an electron donating substituent at the 
para position of the phenyl ring would decrease delocalisation of the phenoxy oxygen 
lone pair into the ring and hence make the phosphorous less electrophillic. Thus on 
reaction with an aldehyde, such as 3.3g, an increase in proportion of the E product may 
be obtained (as compared to 3.1c, where the phenyl ring is unsubstituted). 
(2) for the phosphonate (3.1h), an electron donating substituent at the meta position of 
the phenyl ring would not effect the delocalisation of electron density from the phenoxy 
oxygen and therefore a similar result (on reaction with an aldehyde such as 3.3g) may be 
expected to that obtained for the phosphonate (3.1c). 
(RO)zOP~C02R 1 
3.1 
3.1g R=4-MeOC6H4, R 1=Me 3.1h R=3-MeOC6H4, R1=Me 
The anions of the new phosphonates (3.1g and 3.1h) were each reacted with 
heptaldehyde (3.3e), isobutyraldehyde (3.3g), and benzaldehyde (3.3a). The results are 
shown in Table 3.9. The reactions were again performed in THF, at -78 °C, using n-BuLi 
to generate the anion. The results obtained were exactly in agreement with our 
predictions. In particular, reaction with the phosphonate (3.1g), which has the electron 
donating substituent at the para position of the phenyl ring, resulted in an increase in the 
E:Z ratio (relative to 3.1c where the phenyl ring is unsubstituted) for the aldehydes (3.3a, 
3.3e, and 3.3g). For example, the reaction of 3.3e with 3.1g gave a four fold excess of the 
Z olefin, whereas with 3.lc, a seven fold excess was observed. Further, the results for the 
reaction of the phosphonate (3.1h), where the electron donating substituent is at the meta 
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position of the phenyl ring, were very similar to the those obtained for the phosphonate 
(3.lc) (with each of 3.3a, 3.3e, and 3.3g). For example, reaction of 3.3g with either 3.lh 
or 3.1c both resulted in a E:Z product ratio of 1:3.3. 
Table 3.9. Product ratios obtained with the Phosphonates (3.lc, 3.lg & 3.lh) 
1 (ROhPOCH2C02R (3.1) 
Aldehyde (3.3) 
3.3e (R3=Me(CHz)s) 
1. n-BuLi/THF/-78 °C 
2. R3CHO (3.3) 
Phosphonate Reagent (3.1, R1=Me) 
3.1g (R=4-MeOC6~) 
3.1h (R=3-MeOC6~) 
3.1c (R=Ph) 
3.1g (R=4-MeOC6~) 
3.1h (R=3-MeOC6~) 
3.1c (R=Ph) 
3.1g (R=4-MeOC6~) 
3.1h (R=3-MeOC6~) 
3.1c (R=Ph) 
E:Z Isomer Ratio 
1:4.2 
1:7.2 
1:7.0 
1:2.1 
1:3.3 
1:3.3 
1:1.3 
1:2.4 
1:2.2 
The appearance of a recent report substantiates this work.3'20 Reddy et al. on studying the 
reaction of various phosphonates (3.1) with a variety of aldehydes, including 
benzaldehyde (3.3a), have shown that phosphonates, such as 3.1i and 3.lj, which have an 
electron withdrawing group attached to the phosphorous atom, lead to Z selective 
olefination (at -78 °C).3'2° For example, reaction of the anion of either 3.1i or 3.lj with 
benzaldehyde (3.3a) resulted in an 95% excess of the Z olefin. 3·20 These reactions were 
performed in N,N-dimethylformamide or THF, at -78 °C and the anion was generated 
using either sodium hydride or potassium tertiary-butoxide . The authors' rationale for 
this observed Z selectivity is that "the equilibration of the initial adduct formed with [the] 
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carbanion and [the] aldehyde is slowed down and the subsequent step of cyclization and 
elimination is accelerated". 3·20 
(R0h0P/"-..C02R1 
3.1 
3.1i R=4-nitroC4H6, R1=Me 3.1j. R=ChCH2C, R1=Me 
Overall, we concluded that for the phosphonates (3.1c, 3.lg, and 3.lh), where R is an 
aromatic group, electronic factors were essentially responsible for the high Z selectivity 
obtained on reaction with various aldehydes such as isobutyraldehyde (3.3g). However, 
for phosphonates where R is an aliphatic group (3.la, 3.lb, 3.ld, 3.le, and 3.lf), the 
stereochemical outcome of the reaction appeared to be controlled by steric considerations, 
such that a larger R group resulted in an increase in the proportion of E product. 
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Part 3. Effect of Temperature on the HWE Reaction 
For every reaction presented here, regardless of the phosphonate (3.1) or the aldehyde 
(3.3), the proportion of Z product was greater for reactions carried out at -78 °C (rather 
than at r.t). For example, as shown in Table 3.4 (part 1), the reaction of isobutyraldehyde 
(3.3g) with the phosphonate (3.la) (in THF, with n-BuLi as the base) resulted in a three 
fold excess of the Z olefin at -78 °C. However, a four and a half fold excess of theE 
olefin was obtained when the reaction was performed at r.t. Heathcock and Thompson3·7 
report almost identical stereochemical results for these reactions. They attributed the 
increase in the Z olefin, at low temperature, to a decrease in reversibility of betaine 
formation, giving ratios which resemble the kinetic ratios rather than the thermodynamic 
ratios resembled at r.t.3·7 
Table 3.10. The E:Z product ratio verses Temperature 
1. n- BuLiffHF 
(Me0)2POCH2C02Me (3.1a) 2. (EthCHCHO (3.3h) (EthCHHC=CHC02Me (3.5) 
Temperature (°C) E:Z Product Ratio 
25 
0 
-23 
-46 
-78 
3.6:1 
2:1 
1:2.8 
1:3.0 
1:5 
Table 3.10 shows the variance in the E:Z product ratio over a range of temperatures for 
the reaction of 2-ethylbutyraldehyde (3.3h) with the phosphonate (3.la). The reactions 
were performed with n-BuLi, in THF. Overall, the proportion of Z olefin decreased when 
the reaction temperature was increased, however, a similar stereochemical result was 
obtained when the reaction was performed at either -23 °C or at -46 °C. 
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Part 4. Effect of the Solvent on the HWE Reaction 
To investigate the influence of the solvent on the stereochemical outcome of the HWE 
reaction, isobutyraldehyde (3.3g) was reacted with the anion of the phosphonates (3.1a 
and 3.lb). The reactions were performed at r.t., with n-BuLi, in either THF or benzene. 
The results, displayed in Table 3.11, demonstrate that the use of benzene (rather than 
THF) led to a significant increase in the amount of E product. For example, in the 
reaction of isobutyraldehyde (3.3g) with the phosphonate (3.1a), the E:Z isomer ratio 
increased from 4.5:1 to 10: 1 when the solvent was changed from THF to benzene. 
Heathcock and Thompson also observed a sharp increase in Z olefin formation for 
reactions in THF in comparison to reactions in 1,2-dimethoxyethane (DME), ether, or 
3.7 
benzene. 
Table 3.11. Product ratios obtained with THF and Benzene 
1. n-BuLiffHF/r.t. 
(RO:)zPOCH2C02R I 
2. (Me)lCHCHO (3.3g) 
I 1 I 3.1a ( R,R =Me) 3. b (R,R =Et) 
Phosphonate (3.1) Solvent 
3.1b (R/R1=Et) THF 
3.1b Benzene 
3.1a (RIR1=Me) THF 
3.1a Benzene 
3.1a DME 
R3HC=CHC02R 
1 
(3.5/3.6) 
E:Zratio 
13:1 
>19:1 
4.5:1 
10:1 
12:13'7 
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Part 5. Experimental Conditions and Structure Assignment 
The reaction between the phosphonate (3.1) and the aldehyde (3.3) was performed 
according to the general procedure described by Heathcock and Thompson. 3·7 In most 
examples the reaction was carried out in THF, either at r.t. or at -78 °C , using n-BuLi to 
generate the anion of the phosphonate (3.1) (Scheme 3.14). A small excess of the 
phosphonate (3.1) was used (1.2 equivalents, typically 250 mg), to ensure that all the 
aldehyde (3.3) was reacted, as it was observed that some of the aldehydes (3.3) were not 
readily separable from the reaction products (3.5 or 3.6) by chromatography. The E:Z 
isomer ratio of the olefin products (3.5 or 3.6) was determined by measurement of the 
integrals of the olefin protons in the 1H NMR spectra of the crude reaction mixtures. 
When the reaction was repeated under identical conditions the stereochemical outcome 
was found to be reproducible. 
Scheme 3.14 
(RO)zOP/"-._C02R1 
3.1 
n-BuLi!THF/-78 °C orr.t. 
.. 
R3 H >=< + (RO),P02 
H C02R
1 
3.5 R1=Me 
3.6 R1=Et 
173 
Chapter 3 
Table 3.12 Numbering of the Olefins (3.5/3.6, Scheme 3.14) 
Olefin (R3CH=CHC02R1) Rt R3 
3.5a Me Ph 
3.6a Et Ph 
3.5b Me PhCH=CH 
3.6b Et PhCH=CH 
3.5c Me Me 
3.5d Me Et 
3.6d Et Et 
3.5e Me Me(CH2)s 
3.6e Et Me(CH2)s 
3.5f Me Me(CH2)9 
3.5g Me (Me)2CH 
3.6g Et (Me)2CH 
3.5h Me (Et)2CH 
3.6h Et (Et)2CH 
3.5i Me cyclohexyl 
3.5j Me Me(CH2)s(Me )CH 
The olefin products (3.5a, 3.5b, 3.5e, 3.5f, 3.5h-i, 3.6a, 3.6b, 3.6e, and 3.6h) were 
isolated by radial chromatography in order to determine the reaction yield. In the case of 
3.5j, theE and Z olefins were obtained separately. The lower molecular weight products 
(3.5c, 3.5d, 3.5g, 3.6d, and 3.6g) proved to be volatile and the yield tended to reflect the 
amount of time spent on the rotary evaporator. Since the main purpose of the work was 
to determine the stereochemical ratio, not the yield, isolation of these volatile products 
was not generally attempted. 
The olefin products (3.5 or 3.6) were either identified by comparison of their spectra to 
published data (see Table 3.13) or where literature data was not obtainable (for 3.5e (Z), 
3.5f, 3.5h, 3.5i, 3.5j, and 3.6e (Z)), the compounds were fully characterised. 
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Table 3.13. References to published data for the olefins (3.5/3.6) 
Compound Isomer Reference 
3.5a E FTIR data3·21 
z 1H NMR data3·22 
3.6a E 1H NMR data3·23 
3.5b E,E 13C NMR data3·24 
3.5c E 1H NMR data3·25 
z 1H NMR data3'26 
3.5d 1HNMR data3'27 
z 1H NMR data3·27 
3.6d E 1H NMR data3'28 
z 1H NMR data3·28 
3.5e E 1 H NMR data3·29 
3.6e E 1H NMR data3·30 
3.5g E 1H NMR data3·31 
z 1H NMR data3·31 
3.6g E 1H NMR data3·28 
z 1H NMR data3·28 
3.6h E 1 H NMR data3·32 
z NMR data3'32 
An examination of the 1H NMR spectra of the olefms, for which published data was not 
available (3.5e (Z), 3.5f, 3.5h, 3.5i, 3.5j, and 3.6e (Z)), enabled the assignment of theE 
and Z isomers. The assignment of E and Z olefins, on the basis of the coupling constants 
of the olefin protons in 1H NMR spectra, is well documented.3·33 To illustrate this, the 
1H NMR signals of the olefin protons of 3.5 are presented in Table 3.14. All signals 
assigned to the olefin protons of theE isomer had coupling constants between 15.1 and 
17.4 Hz and all signals assigned to the olefin protons of the Z isomer had coupling 
constants between 10.2 and 11.8 Hz. These values are consistent with literature data for 
the coupling constants of E and Z olefinic protons.3·33 Further, the position of the signals 
for HA and HC was diagnostic of the stereochemistry of the olefins (3.5 or 3.6) (see 
Figure 3.2 for definition of HA, HB, and HC). To illustrate this, the chemical shifts of 
the signals for HA, HB, and HC are presented in Table 3.14. For each olefin (3.5), the 
signal for HA was shifted downfield significantly (between 0.6 and 0.9 ppm) for the 
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E isomer relative to the Z isomer. This shift was attributed to the deshielding effect of the 
carbonyl group.3.34 Further, the position of the signal for HC was shifted downfield 
significantly (between 0.3 and 1.3 ppm.) in the Z isomer relative to theE isomer, also 
attributed to deshielding by the carbonyl group.3·34 Figure 3.2 shows that HA is close to 
the carbonyl group in theE isomer and not in the Z isomer, whereas HC is close to the 
carbonyl in the Z isomer. 
Table 3.14. 1H NMR Signals (ppm) and for HA, HB, and HC (3.5) 
(Coupling Constants are in Hz) 
Compound Eisomer Zisomer 
HA HB HC HA HB HC 
3.5c 6.95 5.81 1.81 6.31 5.77 2.10 
(J=15.1) (J=15.6) (J=10.8) # 
3.5d 6.97 5.76 2.18 6.16 5.68 2.60 
(J=15.6) (J=15.6) (J=ll.7) (J=ll.2) 
3.5e 6.96 5.81 2.18 6.23 5.76 2.64 
(J=15.6) (J=15.6) *(J=ll.8) (J=ll.3) 
3.5f 6.93 5.77 2.14 6.18 5.72 2.61 
(J=15.6) (J=15.6) (J=ll.2) (J=11.8) 
3.5g 6.94 5.76 2.43 6.00 5.64 3.58 
(J=16.2) (J=16.1) (J=ll.7) (J=ll.2) 
3.5h 6.73 5.78 1.94 5.89 5.81 3.26 
(J=15.6) (J=15.6) *(J=l1.7) (J=ll.7) 
3.5i 6.92 5.76 2.10 6.03 5.66 3.29 
(J=17.3) (J=17.4) (J=10.2) (J=10.7) 
3.5j 6.86 5.77 2.27 5.97 5.70 3.45 
(J=15.2) (J=15.6) (J=ll.3) (J=10.8) 
*Coupling constant calculated after irradiation at HC 
# Coupling constant not able to be calculated due to overlap of the signal for HB (E isomer). 
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Figure 3.2. Identification ofHA, HB, and HC 
HC 
E 
HA HB 
HC 0 
z 
Allylic coupling was observed, in the signals for HB, in the 1H NMR spectra of 3.5j (E), 
3.5e (Z), and 3.5j (Z). The coupling constants were as follows: 
1.4 Hz (3.5j (E)) 
1.5 Hz (3.5e (Z)) 
0.9 Hz (3.5j (Z)) 
For each compound where literature 1H NMR data was not available (3.5e (Z), 3.5f, 3.5h, 
3.5i, 3.5j, and 3.6e (Z)-see Table 3.12 for numbering), the signals for HA, HB, and HC 
were irradiated to ensure their correct assignment. The results are summarised in Table 
3.15. For each compound, irradiation of the signal for HC collapsed the signal for HA (to 
a doublet), irradiation of the signal for HA collapsed the signal for HB and HC, and 
irradiation of the signal for HB collapsed the signal for HA. 
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Table 3.15. Decoupling experiments on HA, HB, and HC (3.5 and 3.6) 
Compound Signal Irradiated (ppm) Signal Collapsed (ppm) (J in Hz.) 
3.5e (Z) 6.23 (HA) 5.76 (HB) to d (1==1.5) and 
2.64 (HC) tot (J==7.7) 
5.76 (HB) 6.23 (HA) tot (J==7.8) 
2.64 (HC) 6.23 (HA) tod (J==11.8) 
3.5f (E) 6.93 (HA) 5.77 (HB) to sand 2.14 (HC) tom 
5.77 (HB) 6.93 (HA) to m 
2.14 (HC) 6.93 (HA) to d (J==15.6) 
3.5f (Z) 6.18 (HA) 5.72 (HB) to s and 
2.61 (HC) tot (1=7.3) 
5.72 (HB) 6.18 (HA) tom 
2.61 (HC) 6.18 (HA) to d (J=11.2) 
3.5h (E) 6.73 (HA) 5.78 (HB) to sand 1.94 (HC) tom 
5.78 (HB) 6.73 (HA) to d (1==8.8) 
1.94 (HC) 6.73 (HA) to d (1=15.6) 
3.5h (Z) 5.89 (HA) 3.26 (HC) tom 
3.26 (HC) 5.89 (HA) to d (J=ll.7) 
*Irradiation of HB not performed due to overlap of HA and HB signals 
3.5i (E) 6.92 (HA) 5.76 (HB) to sand 2.10 (HC) tom 
5.76 (HB) 6.92 (HA) to d (J=6.8) 
2.10 (HC) 6.92 (HA) to d (J=17 .3) 
3.5i (Z) 6.03 (HA) 5.66 (HB) to s and 3.29 (HC) tom 
5.66 (HB) 6.03 (HA) to d (J=9.8) 
3.29 (HC) 6.03 (HA) to d (J=l0.2) 
3.5j (E) 6.87 (HA) 5.77 (HB) to d (J=l.4) and 
2.27 (HC) to m 
5.77 (HB) 6.87 (HA) to d (J=7.8) 
2.27 (HC) 6.87 (HA) to d (J=15.2) 
3.5j (Z) 5.97 (HA) 5.70 (HB) to d (J=0.9) and 
3.45 (HC) tom 
5.70 (HB) 5 97 (HA) to d (J=10.2) 
3.45 (HC) 5 97 (HA) to d (J=11.3) 
3.6e (Z) 6.21 (HA) 5.74 (HB) to sand 
2.62 (HC) tot (J=7.8) 
5.74 (HB) 6.21 (HA) tot (J==7.8) 
2.62 (HC) 6.21 (HA) tod (J=l1.3) 
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The 13C NMR spectra were consistent with the olefins (3.5e (Z), 3.5f, 3.5h, 3.5i, 3.5j, and 
3.6e (Z)-Table 3.12) and were assigned on the basis of chemical shift. The signals for 
the olefin carbons appeared between o 156.3 and o 149.2 (COCH=CH) and between 
o 120.7 and o 117.0 (COCH). The chemical shift of the signal for the methyl ester (3.5) 
showed very little variation between the compounds: approximately 1 ppm for the CO 
carbon (o 167.5-166.1) and less than 1 ppm for the Me carbon (o 51.0-50.3.). A 
distortionless enhancement by polarisation transfer (DEPT) experiment was performed to 
distinguish the alkyl carbons of 3.5j (E). This allowed the assignment of the CHMe 
carbon to the signal at o 36.4, the CHMe carbon to the signal at o 19.4, and the CH2Me 
carbon at o 14.0 (the olefin carbons were used as the reference carbons). The eight 
signals between o 35.9 and o 22.5 were shown by the DEPT to be due to methylene 
groups and were assigned to the eight CH2 carbons of the alkyl chain. The 13C NMR 
spectrum of 3.5j (Z) was assigned by comparison to that of 3.5j (E). In the 13C NMR 
spectrum of 3.5e (Z), only three signals attributable to CH2 carbons were observed. 
However, the peak at o 28.8 ppm was disproportionately large and likely due to more 
than one CH2 group. 
High resolution mass spectra (HRMS), obtained for 3.5e, 3.5f, 3.5h, 3.5i, 3.5j, and 3.6e, 
were consistent with the calculated mass. Since theE and Z isomers of 3.5e, 3.5f, 3.5h, 
3.5i, and 3.6e were not readily separable by radial chromatography, HRMS was 
performed on isomeric mixtures. The E:Z mixtures of 3.5f, 3.5h, and 3.5i were separable 
by gas chromatography mass spectrometry (GCMS) to give low resolution MS data on 
each separate isomer (the minor isomer, separated by GCMS, was assumed to be the 
minor isomer as shown by the 1H NMR spectrum of the mixture). Interestingly, the 
fragmentation patterns of each isomer were slightly different. For example, for both 3.5h 
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(E) and 3.5i (E), the ion M+ -(MeOH) was a significant contributor to the spectrum. This 
is presumably due to the availability of a proton in theE arrangement of the double bond. 
Whereas in the MS of 3.5h (Z) and 3.5i (Z), M+ -(Me) and M+ -(MeO) were both 
significant ions. 
The phosphonate reagents were either purchased (if commercially available) or 
synthesised by the method of Ando.3.1 9 For the synthesised phosphonates (3.1c, 3.1f, 
3.lg, and 3.lh), the isolation procedure was modified slightly to emit the washing of the 
filtered reaction mixture with NaOH and brine since it was observed that some of the 
phosphonates were soluble in aqueous media. The synthesis3.1 9 of the phosphonate (3.1, 
R=tert-Bu, R1=Me) was attempted but no desired product was formed. Perhaps this 
phosphonate does not form readily, due to steric crowding around the phosphorous by the 
bulky tert-butyl group. 
(ROhOP~C02R1 
3.1 
3.1c R=Ph, R 1=Me 3.1f R=iso-Pr, R 1=Me 3.1g R=4-MeOC6~, R 1=Me 3.1h. R=3-MeOC6~, R 1=Me 
A literature search revealed that the phosphonates 3.1g and 3.1h were previously 
unknown and they were, therefore, fully characterised. In the 1H NMR spectra of 3.1g 
and 3.1h the signals for the Cfu protons appeared as doublets (J=21.5 Hz) due to 
coupling to the phosphorous atom. The 13C NMR spectra also displayed phosphorous 
coupling. For 3.lg and 3.1h, the signals due to the CH2 and CHCO carbons appeared as 
doublets (1=136.7-140.8 Hz (CH2) and 8.3 Hz (CHCO)). In fact, the CHCO carbon was 
assigned on the basis of this coupling. For 3.1h and 3.1g, the signal for the C02 carbon 
appeared as a doublet (J=6.3 Hz). 
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Experimental 
General Procedure 
Nuclear Magnetic Resonance (NMR) spectra were recorded on either a Varian CFT300 
or a XT300 spectrometer. Mass spectra (MS) were obtained on a Kratos MS80RFA 
spectrometer. Infrared (IR) spectra were recorded on a Shimadzu FTIR-8201PC 
spectrophotometer. Radial chromatography was performed on a Chromatotron (Harrison 
and Harrison) using Merck type 60 PF254 silica gel. The aldehydes (3.3a-j) and the 
phosphonates (3.la, 3.1b, 3.ld, and 3.le) were comercially available. 
General Procedure3·7 for Reactions with Trimethyl phosphonoacetate (3.1a) 
A stirring solution of250 mg (1.4 mmol) oftrimethyl phosphonoacetate (3.la) in 2.5 m1 
of dry tetrahydrofuran (THF) was cooled to 0 °C under a nitrogen atmosphere and 
0.88 m1 (1.4 mmol) of a 1.6 M solution of n-butyllithium (n-BuLi) in hexane was added 
dropwise. After 10 minutes, the reaction was brought to the desired temperature and the 
aldehyde (1.2 mmol) was added dropwise. The resultant mixture was stirred for 
1.5 hours, quenched by the addition of 3.0 m1 of water, and further diluted with 5.0 m1 of 
ether. The aqueous layer was removed and the organic layer was washed with saturated 
brine, dried with magnesium sulfate (MgS04), filtered, and the solvent was evaporated 
under reduced pressure. The crude product was analysed directly by 1 H NMR and where 
indicated, purified by radial chromatography on silica (80% petroleum ether, 20% ethyl 
acetate). 
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Preparation of Methyl cinnamate (3.5a) 
The reaction was performed as described by the general procedure, at -78 °C, with 
127 mg (1.2 mmol) of benzaldehyde (3.3a). The E:Z ratio of the crude product (3.5a) 
was found to be >19:1, by 1H NMR. Isolation by radial chromatography (80% petroleum 
ether, 20% ethyl acetate) gave 3.5a (E) as a colourless oil (quantitative recovery). The 
FTIR spectrum of 3.5a (E) was identical to published data.3·21 
Preparation ofMethyl5-phenyl-2,4-pentadienoate (3.5b) 
The reaction was performed as described by the general procedure, at -78 °C, with 
158 mg (1.2 mmol) of cinnamaldehyde (3.3b ). The E:Z ratio of the crude product (3.5b) 
was found to be >19:1, by 1H NMR. Isolation by radial chromatography (80% petroleum 
ether, 20% ethyl acetate) gave 3.5b (E,E) as a colourless oil (quantitative recovery). The 
13C NMR spectrum of 3.5b (E,E) was identical to published data.3·24 
Preparation ofMethyl2-butenoate (3.5c) 
The reaction was performed as described by the general procedure, both at -78 oc and at 
room temperature (r.t.), with 53 mg (1.2 mmol) of acetaldehyde (3.3c). Analysis, by 
1H NMR, of the reaction performed at -78 °C indicated the E:Z ratio of the crude product 
(3.Sc) to be 8.0:1. Analysis, by 1H NMR, of the reaction performed at r.t. indicated the 
E:Z ratio of the crude product (3.5c) to be 11: 1. Purification by chromatography was not 
attempted due to the volatility of the product. The 1H NMR spectrum of the product 
(3.5c) was identical to published data?·25• 326 
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Preparation of Methyl 2-pentenoate (3.5d) 
The reaction was performed as described by the general procedure, both at -78 °C and at 
r.t., with 70 mg (1.2 mmol) of propionaldehyde (3.3d). Analysis, by 1H NMR, ofthe 
reaction performed at -78 °C indicated the E:Z ratio of the crude product (3.5d) to be 
3.6:1. Analysis, by 1H NMR, of the reaction performed at r.t. indicated the E:Z ratio of 
the crude product (3.5d) to be 7.0:1. Isolation was not attempted due to the volatility of 
the product. The 1H NMR spectrum of the product (3.5d) was identical to published 
data.3'27 
Preparation of Methyl 2-nonenoate (3.5e) 
The reaction was performed as described by the general procedure, both at -78 °C and at 
r.t., with 137 mg (1.2 mmol) of heptaldehyde (3.3e). Analysis, by 1H NMR, of the 
reaction performed at -78 °C indicated the E:Z ratio of the crude product (3.5e) to be 
2.0:1. Isolation by radial chromatography (80% petroleum ether, 20% ethyl acetate) gave 
an inseparable mixture of E and Z as a colourless oil (180 mg, 81 %). Analysis, by 
1H NMR, of the reaction performed at r.t. indicated the E:Z ratio of the crude product 
(3.5e) to be 5.5:1. Isolation by radial chromatography (80% petroleum ether, 20% ethyl 
acetate) gave an inseparable mixture of E and Z as a colourless oil (164 mg, 74%). The 
1H NMR spectrum of 3.5e (E) was identical to published data.3·29 
Spectral data for 3.5e (Z) (from mixture): 
1H NMR (CDCl3) 8 6.23 (m, 1H, COCHCH); 5.76 (dd, lH, 1=1.5, 11.3 Hz, COCH); 3.70 
(s, 3H, MeO); 2.64 (m, 2H, CHCH2); 1.28-1.43 (m, 8H, Me(CH2) 4); 0.87 (t, 3H, 1=6.8 
Hz, CH2Me). 13C NMR (CDCh) 8 166.6 (C02); 150.8 (COCHCH); 119.0 (COCH); 50.7 
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(MeO); 31.5, 28.8, 22.4 (CH2); 13.8 (CH2Me). HRMS (on mixture) Calculated for 
C10H180 2: 170 13068. Found: 170.13040. FTIR (on mixture) (thin film) 2957; 2930; 
2858; 1726; 1647 cm-1• 
Preparation of Methyl 2-tridecenoate (3.5f) 
The reaction was performed as described by the general procedure, both at -78 oc and at 
r.t., with 204 mg (1.2 mmol) of undecanal (3.3f). Analysis, by 1H NMR, of the reaction 
performed at -78 °C indicated the E:Z ratio of the crude product (3.5f) to be 2.0: 1. 
Isolation by radial chromatography (80% petroleum ether, 20% ethyl acetate) gave an 
inseparable mixture of E and Z, as a colourless oil (quantitative recovery). Analysis, by 
1H NMR, of the reaction performed at r.t. indicated the E:Z ratio of the crude product 
(3.5f) to be 5.7:1. Isolation by radial chromatography (80% petroleum ether, 20% ethyl 
acetate) gave an inseparable mixture of E and Z, as a colourless oil (quantitative 
recovery). 
Spectral data: 
3.5f (E) (from mixture). 1H NMR (CDCh) () 6.93 (dt, 1H, J=7.4, 15.6 Hz, COCHCH); 
5.77 (d, lH, J=15.6 Hz, COCH); 3.67 (s, 3H, MeO); 2.14 (q, 2H, J=7.3 Hz, CHCfu); 1.39 
(s(br), 2H, CHCH2CH2); 1.21 (s(br), 14H, (CHz)7); 0.83 (t, 3H, J=6.3 Hz, CH2Me). 
13C NMR (CDCh) () 166.5 (C02); 149.2 (COCHCH); 120.2 (COCH); 50.7 (MeO); 31.6, 
31.3, 29.0, 28.9, 28.8, 28.7, 28.5, 27.4, 22.1 ((CH2) 9); 13.5 (CH2Me). GCMS (Eisomer) 
(m/z) 195 (22%, M+-OMe); 152 (23%, M+-MeC02Me); 113 (37%); 87 (100%). 
3.5f (Z) (from mixture). 1H NMR (CDC13) () 6.18 (dt, lH, J=7.8, 11.2 Hz, COCHCH); 
5.72 (d, lH, J=11.8 Hz, COCH); 3.65 (s, 3H, MeO); 2.61 (m, 2H, CHCH2); 1.39 (s(br), 
2H, CHCHzCH2); 1.21 (s(br), 14H, (CHz)?); 0.83 (t, 3H, J=6.3 Hz, CH2Me). 
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13C NMR (CDCb) o 166.1 (C02); 150.4 (COCHCH); 118.5 (COCH); 50.3 (MeO); 28.8, 
28.4, 28.4 (CH2). Other signals were obscured by theE isomer. GCMS (Z isomer) (rnlz) 
226 (7%, M+); 195 (10%, M+-OMe); 183 (3%, M+-COMe); 113 (100%). 
HRMS (on mixture) Calculated for C14H260 2: 226.19328. Found: 226.19333. FTIR (on 
mixture) (thin film) 2926; 2855; 1728; 1647 cm-1• 
Preparation of Methyl4-methyl-2-pentenoate (3.5g) 
The reaction was performed as described by the general procedure, both at -78 °C and at 
r.t., with 87 mg (1.2 mmol) of isobutyraldehyde (3.3g). Analysis, by 1H NMR, of the 
reaction performed at -78 °C indicated the E:Z ratio of the crude product (3.5g) to be 
1 :2.8. Analysis, by 1H NMR, of the reaction performed at r.t. indicated the E:Z ratio of 
the crude product (3.5g) to be 4.5:1. Purification by chromatography was not attempted 
due to the volatility of the product. 
The reaction was also performed as described by the general procedure, using benzene in 
place of THF as the solvent. This reaction was performed at r.t., with 87 mg (1.2 mmol) 
of isobutyraldehyde (3.3g). The E:Z ratio of the crude product (3.5g) was found to be 
10:1, by 1H NMR. Purification by chromatography was not attempted due to the 
volatility of the product. 
The 1H NMR spectrum of 3.5g was identical to published data.3·31 
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Preparation of Methyl4-ethyl-2-hexenoate (3.5h) 
The reaction was performed as described by the general procedure, both at -78 oc and at 
r.t., with 120 mg (1.2 mmol) of 2-ethylbutyraldehyde (3.3h). Analysis, by 1H NMR, of 
the reaction performed at -78 °C indicated the E:Z ratio of the crude product (3.5h) to be 
1:5. Isolation by radial chromatography (80% petroleum ether, 20% ethyl acetate) gave 
an inseparable mixture of E and Z, as a colourless oil (128 mg, 68%). Analysis, by 
1 H NMR, of the reaction performed at r. t. indicated the E:Z ratio of the crude product 
(3.5h) to be 3.6:1. Isolation by radial chromatography (80% petroleum ether, 20% ethyl 
acetate) gave an inseparable mixture of E and Z, as a colourless oil ( 149 mg, 80%). 
Spectral data: 
3.5h (E) (from mixture). 1H NMR (CDCb) () 6.73 (dd, 1H, J=8.8, 15.6 Hz, COCHCH); 
5.78 (d, 1H, J=15.6 Hz, COCH); 3.72 (s, 3H, MeO); 1.94 (m, 1H, CHCH2); 1.32-1.48 (m, 
4H, CHCHz); 0.83 (t, 6H, CH2Me). Be NMR (CDCb) () 167.5 (C02); 153.2 (COCHCH); 
120.7 (COCH); 51.0 (MeO); 45.8 (CHzCH); 26.6 (CH2); 11.3 (CH2Me). GCMS (E 
isomer) (m/z) 156 (13%, M+); 141 (18%, M+-Me); 124 (44%, M+-MeOH). 
3.5h (Z) (from mixture). 1H NMR (CDCb) () 5.89 (m, 1H, COCHCH); 5.81 (d, 1H, 
J=11.7 Hz, COCH); 3.67 (s, 3H, MeO); 3.26 (m, 1H, CHCH2); 1.44-1.52 (m, 4H, CH2); 
0.84 (t, 6H, J=7.3 Hz, CH2Me). Be NMR (CDC13) () 166.0 (COz); 154.9 (COCHCH); 
119.4 (COCH); 50.5 (MeO); 40.9 ~HCHz); 27.5 (CH2); 11.3 (CH2Me). GCMS (Z 
isomer) (m/z) 156 (44%, M+); 141 (46%, M+-Me); 127 (62%, M+-Et); 124 (33%, M+-
MeOH). 
HRMS (on mixture) Calculated for C9H1602: 156.11503. Found: 156.11547. FTIR (on 
mixture) (thin film) 2964; 2934; 2876; 1728; 1657 cm-1• 
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Preparation ofMethyl3-cyclohexyl-2-propenoate (3.5i) 
The reaction was performed as described by the general procedure, both at -78 oc and at 
r.t., with 134 mg (1.2 mmol) of cyclohexanecarboaldehyde (3.3i). Analysis, by 1H NMR, 
of the reaction performed at -78 °C indicated the E:Z ratio of the crude product (3.5i) to 
be 1:3.0. Isolation by radial chromatography (80% petroleum ether, 20% ethyl acetate) 
gave an inseparable mixture of E and Z, as a colourless oil (109 mg, 54%). Analysis, by 
1H NMR, of the reaction performed at r.t. indicated the E:Z ratio of the crude product 
(3.5i) to be 3.4:1. Isolation by radial chromatography (80% petroleum ether, 20% ethyl 
acetate) gave an inseparable mixture of E and Z, as a colourless oil (163 mg, 81% ). 
Spectral data: 
3.5i (E) (from mixture). 1H NMR (CDCh) o 6.92 ( dd, 1H, J=6.8, 17.4 Hz, COCHCH); 
5.76 (d, 1H, J=17.4 Hz, COCH); 3.72. (s, 3H, MeO); 2.10 (m(br), 1H, CHCH2); 1.22-1.76 
(m(br), 10H, (CH2)s). 13C NMR (CDCh) o 167.0 (C02); 154.1 (COCHCH); 118.3 
(COCH); 51.0 (MeO); 40.2 CQHCH2); 31.5, 25.7, 25.5 (CH2). GCMS (E isomer) (rnlz) 
168 (57%, M+); 136 (36%, M+-MeOH); 107 (24%); 94 (52%); 87 (84%). 
3.5i (Z) (from mixture). 1H NMR (CDCh) o 6.03 (dd, 1H, J=9.8, 10.2 Hz, COCHCH); 
5.66 (d, 1H, J=10.7 Hz, COCH); 3.69 (s, 3H, MeO); 3.29 (m(br), 1H, CHCH2); 1.05-1.76 
(m(br), 10H, (CH2)5). 13C NMR (CDCh) o 166.5 (C02); 155.7 (COCHCH); 117.0 
(COCH); 50.7 (MeO); 37.1 CQH CH2); 32.2, 25.8, 25.3 (CH2). GCMS (Zisomer) (rn!z) 
168 (95% M+); 137 (28%, M+-MeO); 107 (32%); 94 (58%); 87 (78%). 
HRMS (on mixture) Calculated for C10H160 2: 168.11503. Found: 168.11518. FTIR (on 
mixture) (thin film) 2828; 2853; 1726; 1652 cm-1. 
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Preparation of Methyl4-methyl-2-tridecenaote (3.5j) 
The reaction was performed as described by the general procedure, both at -78 °C and at 
r.t., with 221 mg (1.2 mmol) of2-methylundecanal (3.3j). Analysis, by 1HNMR, ofthe 
reaction performed at -78 °C indicated the E:Z ratio of the crude product (3.5j) to be 
1 :2.8. Isolation by radial chromatography (80% petroleum ether, 20% ethyl acetate) gave 
3.5j (E) (60 mg, 21%) and 3.5j (Z) (179 mg, 62% ), both as colourless oils. Analysis, by 
1 H NMR, of the reaction performed at r. t. indicated the E:Z ratio of the crude product 
(3.5j) to be 3.8: 1. Isolation by radial chromatography (80% petroleum ether, 20% ethyl 
acetate) gave 3.5j (E) (214 mg, 74%) and 3.5j (Z) (56 mg, 20%) both as colourless oils. 
Spectral data: 
3.5j (E). 1H NMR (CDCh) 8 6.86 (dd, 1H, 1= 7.8, 15.2 Hz, COCHCH); 5.77 (dd, 1H, 
1=1.4, 15.6 Hz, COCH); 3.72 (s, 3H, MeO); 2.27 (m, 1H, CHMe); 1.24 (m, 16H, (CH2)s); 
1.03 (d, 3H, 1=6.3 Hz, CHMe); 0.87 (t, 3H, 1=7.3 Hz, CH2Me). 13C NMR (CDCh) 
8 167.2 (C02); 154.9 (COCHCH); 119.0 (COCH); 51.2 (MeO); 36.4 (CHMe); 35.9, 31.8, 
29.5, 29.5, 29.4, 29.2, 27.1, 22.5 ((CH2)8); 19.3 (CHMe); 14.0 (CH2Me). HRMS. 
Calculated for C15H280 2: 240.20893. Found: 240.20900. MS (m/z) 240 (46%, M+); 209 
(20%, M+-MeOH); 166 (13%); 128 (100%). FTIR (thin film) 2956; 2926; 2855; 1728; 
1657 cm-1. 
3.5j (Z). 1H NMR (CDCh) 8 5.97 (dd, 1H, 1=10.2, 11.3 Hz, COCHCH); 5.70 (dd, 1H, 
1=0.9, 10.8 Hz, COCH); 3.70 (s, 3H, MeO); 3.45 (m, 1H, CHMe); 1.24 (m, 16H, (CH2)8); 
0.99 (d, 3H, 1=6.8 Hz, CHMe); 0.87 (t, 3H, 1=7.3Hz, CH2Me). 13C NMR (CDCb) 
8 166.4 (C02); 156.3 (COCHCH); 117.6 (COCH); 50.6 (MeO); 36.9 (CHMe); 32.5, 31.8, 
29.6, 29.4, 29.4, 29.2, 27.2, 22.5 ((CH2)8); 19.3 (CHMe); 14.0 (CH2Me). HRMS. 
Calculated for C15H280 2: 240.20893. Found: 240.20868. MS (m/z) 240 (66%, M+); 212 
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(24%, M+-CO); 183 (6%, M+-CHC02); 127 (100%). FTIR (thin film) 2926; 2855; 1728; 
1647 cm-1• 
General Procedure3·7 for Reactions with Triethyl phosphonoacetate (3.1b) 
A stirring solution of 250 mg (1.1 mmol) oftriethyl phosphonoacetate (3.1b) in 2.5 ml of 
dry THF was cooled to 0 °C under a nitrogen atmosphere and 0.68 ml (1.1 mmol) of a 
1.6 M solution of n-BuLi in hexane was added dropwise. After 10 minutes, the reaction 
was brought to the desired temperature and the aldehyde (0.92 mmol) was added 
dropwise. The resultant mixture was stirred for 1.5 hours, quenched by the addition of 
3.0 ml of water, and further diluted with 5.0 ml of ether. The aqueous layer was removed 
and the organic layer was washed with saturated brine, dried with MgS04, filtered, and 
the solvent was evaporated under reduced pressure. The crude product was analysed 
directly by 1H NMR and where indicated, purified by radial chromatography on silica 
(80% petroleum ether, 20% ethyl acetate). 
Preparation of Ethyl cinnamate (3.6a) 
The reaction was performed as described by the general procedure, with 98 mg 
(0.92 mmol) of benzaldehyde (3.3a). The E:Z ratio of the crude product (3.6a) was found 
to be >19:1, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave 3.6a (E) as a colourless oil (180 mg, 85% ). The 1H NMR spectrum of 
3.6a (E) was identical to published data.3·23 
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Preparation of Ethyl 2-pentenoate (3.6d) 
The reaction was performed as described by the general procedure, both at -78 °C and at 
r.t., with 53 mg (0.92 mmol) ofpropionaldehyde (3.3d). Analysis, by 1H NMR, of the 
reaction performed at -78 °C indicated the E:Z ratio of the crude product (3.6d) to be 
9.3: 1. Analysis, by 1H NMR, of the reaction performed at r.t. indicated the E:Z ratio of 
the crude product (3.6d) to be 19:1. Purification by chromatography was not attempted 
due to the volatility of the product. The 1H NMR spectrum of the product (3.6d) was 
identical to published data. 3·28 
Preparation ofEthyl2-nonenoate (3.6e) 
The reaction was performed as described by the general procedure, both at -78 °C and at 
r.t., with 126 mg (0.92 mmol) ofheptaldehyde (3.3e). Analysis, by 1H NMR, of the 
reaction performed at -78 °C indicated the E:Z ratio of the crude product (3.6e) to be 
9.4:1. Isolation by radial chromatography (80% petroleum ether, 20% ethyl acetate) gave 
an inseparable mixture of E and Z as a colourless oil (112 mg, 55%). Analysis, by 
1H NMR, of the reaction performed at r.t indicated the E:Z ratio of the crude product 
(3.6e) to be >19:1. Isolation by radial chromatography (80% petroleum ether, 20% ethyl 
acetate) gave 3.6e (E) as a colourless oil (132 mg, 65% ). The 1H NMR spectrum of 3.6e 
(E) was identical to published data.330 
Spectral data for 3.6e (Z) (from mixture): 
1H NMR (CDCh) 8 6.21 (dt, 1H, J=7.8, 11.3 Hz, COCHCH); 5.74 (d, 1H, J=11.3 Hz, 
COCH); 2.62 (m, 2H, CHC.fu); 0.95 (t, 3H, J=7.3 Hz, MeCH2CO). Other signals were 
obscured by theE isomer. 13C NMR (CDCb) 8165.8 (C02); 149.9 (COCHCH); 119.3 
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(COCH); 59.1 (CH20). Other signals were obscured by theE isomer. HRMS (on 
mixture) Calculated for C11H200 2: 184.14633. Found: 184.14646. FTIR (on mixture) 
(thin film) A 2929; 2858; 2256; 1705; 1652 cm-1. 
Preparation ofEthyl4-methyl-2-pentenoate (3.6g) 
The reaction was performed as described by the general procedure, both at -78 °C and at 
r.t., with 66 mg (0.92 mmol) of isobutyraldehyde (3.3g). Analysis, by 1H NMR, of the 
reaction performed at -78 °C indicated the E:Z ratio of the crude product (3.6g) to be 
1.5: 1. Analysis, by 1H NMR, of the reaction performed at r.t. indicated the E:Z ratio of 
the crude product (3.6g) to be 13:1. Purification by chromatography was not attempted 
due to the volatility of the product. 
The reaction was also performed as described by the general procedure, using benzene in 
place of THF as the solvent. This reaction was performed at r.t. with 66 mg (0.92 mmol) 
of isobutyraldehyde (3.3g), and the E:Z ratio of the crude product (3.6g) was found to be 
>19:1, by 1H NMR. Purification by chromatography was not attempted due to the 
volatility of the product. 
The 1H NMR spectrum of the product (3.6g) was identical to published data.3·28 
Preparation of Ethyl4-ethyl-2-hexenoate (3.6h) 
The reaction was performed as described by the general procedure, both at -78 °C and at 
r.t., with 92 mg (0.92 mmol) of 2-ethylbutyraldehyde (3.3h). Analysis, by 1H NMR, of 
the reaction performed at -78 °C indicated the E:Z ratio of the crude product (3.6h) to be 
1.5:1. Isolation by radial chromatography (80% petroleum ether, 20% ethyl acetate) gave 
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an inseparable mixture of E and Z, as a colourless oil (123 mg, 78%). Analysis, by 
1H NMR, of the reaction performed at r.t. indicated the E:Z ratio of the crude product 
(3.6h) to be 12:1. Isolation by radial chromatography (80% petroleum ether, 20% ethyl 
acetate) gave an inseparable mixture of E and Z, as a colourless oil (144 mg, 92%). The 
1H NMR spectrum of the product (3.6h) was identical to published data.3'32 
General Procedure3·7 for Reactions with Methyl diphenylphosphonoacetate (3.lc) 
A stirring solution of 250 mg (0.82 mmol) of methyl diphenylphosphonoactetate (3.1c) in 
2.5 m1 of dry THF was cooled to 0 °C under a nitrogen atmosphere and 0.51 m1 
(0.82 mmol) of a 1.6 M solution of n-BuLi in hexane was added dropwise. After 
10 minutes, the reaction was cooled to -78 °C and the aldehyde (0.68 mmol) was added 
dropwise. The resultant mixture was stirred for 1.5 hours, quenched by the addition of 
3.0 m1 of water, and further diluted with 5.0 m1 of ether. The aqueous layer was removed 
and the organic layer was washed with saturated brine, dried with MgS04, filtered, and 
the solvent was evaporated under reduced pressure. The crude product was analysed 
directly by 1H NMR and where indicated, purified by radial chromatography on silica 
(80% petroleum ether, 20% ethyl acetate). 
Preparation of Methyl cinnamate (3.5a) 
The reaction was performed as described by the general procedure, with 72 mg 
(0.68 mmol) of benzaldehyde (3.3a). The E:Z ratio of the crude product (3.5a) was found 
to be 1 :2.2, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
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ethyl acetate) gave an inseparable mixture of E and Z as a colourless oil (69 mg, 63%). 
Spectral data for 3.5a was identical to published data.3·21• 3·22 
Preparation of Methyl2-pentenoate (3.5d) 
The reaction was performed as described by the general procedure, with 53 mg 
(0.68 mmol) of propionaldehyde (3.3d). The E:Z ratio of the crude product (3.5d) was 
found to be 1:13, by 1H NMR. Purification by chromatography was not attempted due to 
the volatility of the product. The 1H NMR spectrum of the product (3.5d) was identical 
to published data.3·27 
Preparation of Methyl 2-nonenoate (3.5e) 
The reaction was performed as described by the general procedure, with 78 mg 
(0.68 mmol) of heptaldehyde (3.3e). The E:Z ratio of the crude product (3.5e) was found 
to be 1:7 .0, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave an inseparable mixture of E and Z as a colourless oil (67 mg, 58%). 
The 1H NMR spectrum of 3.5e (E) was identical to published data.3·29 See section 
"Reactions with Trimethyl phosphonoacetate" for spectral data on 3.5e (Z). 
Preparation of Methyl4-methyl-2-pentenoate (3.5g) 
The reaction was performed as described by the general procedure, with 49 mg 
(0.68 mmol) of isobutyraldehyde (3.3g). The E:Z ratio of the crude product (3.5g) was 
found to be 1:3.3, by 1H NMR. Purification by chromatography was not attempted due to 
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the volatility of the product. The 1H NMR spectrum of 3.5g was identical to published 
data.331 
Preparation ofMethyl4-ethyl-2-hexenoate (3.5h) 
The reaction was performed as described by the general procedure, with 34 mg 
(0.68 mmol) of 2-ethylbutyraldehyde (3.3h). The E:Z ratio of the crude product (3.5h) 
was found to be 1:3.8, by 1H NMR. Isolation by radial chromatography (80% petroleum 
ether, 20% ethyl acetate) gave an inseparable mixture of E and Z, as a colourless oil 
(42 mg, 72%). See section "Reactions with Trimethyl phosphonoacetate" for spectral 
data. 
Preparation of Methyl4-methyl-2-tridecenaote (3.5j) 
The reaction was performed as described by the general procedure, with 63 mg 
(0.68 mmol) of 2-methylundecanal (3.3j). The E:Z ratio of the crude product (3.5j) was 
found to be 1:5.7, by 1H NMR. Isolation by radial chromatography (80% petroleum 
ether, 20% ethyl acetate) gave 3.5j (E) (9 mg, 11%) and 3.5j (Z) (52 mg, 60% ), both as 
colourless oils. See section "Reactions with Trimethyl phosphonoacetate" for spectral 
data. 
General Procedure3·7 for Reactions with Ethyl dimethylphosphonoacetate (3.ld) 
A stirring solution of 250 mg (1.3 mmol) of ethyl dimethylphosphonoactetate (3.1d) in 
2.5 ml of dry THF was cooled to 0 °C under a nitrogen atmosphere and 0.81 ml 
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(1.3 mmol) of a 1.6 M solution of n-BuLi in hexane was added dropwise. After 
10 minutes, the reaction was cooled to -78 °C and the aldehyde (1.1 mmol) was added 
dropwise. The resultant mixture was stirred for 1.5 hours, quenched by the addition of 
3.0 ml of water, and further diluted with 5.0 ml of ether. The aqueous layer was removed 
and the organic layer was washed with saturated brine, dried with MgS04, filtered, and 
the solvent was evaporated under reduced pressure. The crude product was analysed 
directly by 1H NMR and where indicated, purified by radial chromatography on silica 
(80% petroleum ether, 20% ethyl acetate). 
Preparation of Ethyl cinnamate (3.6a) 
The reaction was performed as described by the general procedure, with 117 mg 
(1.1 mmol) of benzaldehyde (3.3a). The E:Z ratio of the crude product (3.6a) was found 
to be >19:1, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave 3.6a (E) as a colourless oil (quantitative recovery). The 1H NMR 
spectrum of 3.6a (E) was identical to published data. 3·23 
Preparation ofEthyl2-nonenoate (3.6e) 
The reaction was performed as described by the general procedure, with 126 mg 
(1.1 mmol) ofheptaldehyde (3.3e). The E:Z ratio ofthe crude product (3.6e) was found to 
be 1.2:1, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave an inseparable mixture of E and Z as a colourless oil (quantitative 
recovery). The 1H NMR spectrum 3.6e (E) was identical to published data?·30 See 
section "Reactions with Triethyl phosphonoacetate" for spectral data on 3.6e (Z). 
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Preparation ofEthyl4-methyl-2-pentenoate (3.6g) 
The reaction was performed as described by the general procedure, with 79 mg 
(1.1 mmol) of isobutyraldehyde (3.3g). The E:Z ratio of the crude product (3.6g) was 
found to be 1:2.9, by 1H NMR. Purification by chromatography was not attempted due to 
the volatility of the product. The 1H NMR spectrum of the product (3.6g) was identical to 
published data.3·28 
General Procedure3·7 for Reactions with Methyl diethylphosphonoacetate (3.1e) 
A stirring solution of 250 mg (1.2 mmol) of methyl diethylphosphonoactetate (3.1e) in 
2.5 ml of dry THF was cooled to 0 oc under a nitrogen atmosphere and 0.75 ml 
(1.2 mmol) of a 1.6 M solution of n-BuLi in hexane was added dropwise. After 
10 minutes, the reaction was cooled to -78 °C and the aldehyde (1.0 mmol) was added 
dropwise. The resultant mixture was stirred for 1.5 hours, quenched by the addition of 
3.0 ml of water, and further diluted with 5.0 ml of ether. The aqueous layer was removed 
and the organic layer was washed with saturated brine, dried with MgS04, filtered, and 
the solvent was evaporated under reduced pressure. The crude product was analysed 
directly by 1 H NMR and where indicated, purified by radial chromatography on silica 
(80% petroleum ether, 20% ethyl acetate). 
Preparation of Methyl cinnamate (3.5a) 
The reaction was performed as described by the general procedure, with 106 mg 
(1.0 mmol) of benzaldehyde (3.3a). The E:Z ratio of the crude product (3.5a) was found 
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to be >19:1, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave 3.5a (E) as a colourless oil (104 mg, 64%). The FTIR spectrum of 
3.5a (E) was identical to published data.3·21 
Preparation of Methyl 2-nonenoate (3.5e) 
The reaction was performed as described by the general proceedure, with 114 mg 
(1.0 mmol) of heptaldehyde (3.3e). The E:Z ratio of the crude product (3.5e) was found to 
be 6. 7:1, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave an inseparable mixture of E and Z as a colourless oil (115 mg, 68%). 
The 1H NMR spectrum of 3.5e (E) was identical to published data.3'29 See section 
"Reactions with Trimethyl phosphonoacetate" for spectral data on 3.5e (Z). 
Preparation of Methyl4-methyl-2-pentenoate (3.5g) 
The reaction was performed as described by the general procedure, with 86 mg 
(1.0 mmol) of isobutyraldehyde (3.3g). The E:Z ratio of the crude product (3.5g) was 
found to be 2.4:1, by 1H NMR. Purification by chromatography was not attempted due to 
the volatility of the product. The 1 H NMR spectrum of 3.5g was identical to published 
data.331 
General Procedure3·7 for Reactions with Methyl diisopropylphosphonoacetate (3.1f) 
A stirring solution of 33 mg (0.14 mmol) of methyl diisopropylphosphonoactetate (3.lf) 
in 0.5 m1 of dry THF was cooled to 0 °C under a nitrogen atmosphere and 0.09 m1 
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(0.14 mmol) of a 1.6 M solution of n-BuLi in hexane was added dropwise. After 
10 minutes, the reaction was cooled to -78 °C and the aldehyde (0.12 mmol) was added 
dropwise. The resultant mixture was stirred for 1.5 hours, quenched by the addition of 
0.5 ml of water, and further diluted with 1.0 ml of ether. The aqueous layer was removed 
and the organic layer was washed with saturated brine, dried with MgS04, filtered, and 
the solvent was evaporated under reduced pressure. The crude product was analysed 
directly by 1H NMR and where indicated, purified by radial chromatography on silica 
(80% petroleum ether, 20% ethyl acetate). 
Preparation of Methyl cinnamate (3.5a) 
The reaction was performed as described by the general procedure, with 12 mg 
(0.12 mmol) of benzaldehyde (3.3a). The E:Z ratio of the crude product (3.5a) was found 
to be> 19:1, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave 3.5a (E) as a colourless oil (5 mg, 26% ). The FTIR spectrum of 3.5a 
(E) was identical to published data.3·21 
Preparation ofMethyl2-nonenoate (3.5e) 
The reaction was performed as described by the general procedure, with 13 mg 
(0.12 mmol) of heptaldehyde (3.3e). The E:Z ratio of the crude product (3.5e) was found 
to be > 19: 1, by 1 H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave 3.5e (E) as a colourless oil (7 mg, 35%). The 1H NMR spectrum of 
3.5e (E) was identical to published data.3·29 
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Preparation of Methyl4-methyl-2-pentenoate (3.5g) 
The reaction was performed as described by the general procedure, with 8 mg 
(0.12 mmol) of isobutyraldehyde (3.3g). The E:Z ratio of the crude product (3.5g) was 
found to be 10:1, by 1H NMR. Purification by chromatography was not attempted due to 
the volatility of the product. The 1H NMR spectrum of 3.5g was identical to published 
data. 331 
General Procedure3·7 for Reactions with Methyl di-(4-methoxyphenyl)-
phosphonoacetate (3.1g) 
A stirring solution of 250 mg (0.65 mmol) of methyl di-(4-methoxyphenyl)-
phosphonoacetate (3.lg) in 2.5 m1 of dry THF was cooled to 0 °C under a nitrogen 
atmosphere and 0.41 m1 (0.65 mmol) of a 1.6 M solution of n-BuLi in hexane was added 
dropwise. After 10 minutes, the reaction was cooled to -78 °C and the aldehyde 
(0.54 mmol) was added dropwise. The resultant mixture was stirred for 1.5 hours, 
quenched by the addition of 3.0 m1 of water, and further diluted with 5.0 m1 of ether. The 
aqueous layer was removed and the organic layer was washed with saturated brine, dried 
with MgS04, filtered, and the solvent was evaporated under reduced pressure. The crude 
product was analysed directly by 1H NMR and where indicated, purified by radial 
chromatography on silica (80% petroleum ether, 20% ethyl acetate). 
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Preparation of Methyl cinnamate (3.5a) 
The reaction was performed as described by the general procedure, with 57 mg 
(0.54 mmol) of benzaldehyde (3.3a). The E:Z ratio of the crude product (3.5a) was found 
to be 1: 1.3, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave an inseparable mixture of E and Z, as a colourless oil (7 4 mg, 85%). 
Spectral data for 3.5a was identical to published data.3·21• 3·22 
Preparation ofMethyl2-nonenoate (3.5e) 
The reaction was performed as described by the general procedure, with 62 mg 
(0.54 mmol) of heptaldehyde (3.3e). The E:Z ratio of the crude product (3.5e) was found 
to be 1 :4.2, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave an inseparable mixture of E and Z as a colourless oil (68 mg, 75%). 
The 1H NMR spectrum of 3.5e (E) was identical to published data.3·29 See section 
"Reactions with Trimethyl phosphonoacetate" for spectral data on 3.5e (Z). 
Preparation ofMethyl4-methyl-2-pentenoate (3.5g) 
The reaction was performed as described by the general procedure, with 39 mg 
(0.54 mmol) of isobutyraldehyde (3.3g). The E:Z ratio of the crude product (3.5g) was 
found to be 1:2.1, by 1H NMR. Purification by chromatography was not attempted due to 
the volatility of the product. The 1H NMR spectrum of 3.5g was identical to published 
data.3'31 
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A stirring solution of 125 mg (0.34 mmol) of methyl di-(3-methoxyphenyl)-
phosphonoacetate (3.lh) in 1.3 ml of dry THF was cooled to 0 °C under a nitrogen 
atmosphere and 0.21 ml (0.34 mmol) of a 1.6 M solution of n-BuLi in hexane was added 
dropwise. After 10 minutes, the reaction was cooled to -78 °C and the aldehyde 
(0.28 mmol) was added dropwise. The resultant mixture was stirred for 1.5 hours, 
quenched by the addition of 1.5 ml of water, and further diluted with 2.5 ml of ether. The 
aqueous layer was removed and the organic layer was washed with saturated brine, dried 
with MgS04, filtered, and the solvent was evaporated under reduced pressure. The crude 
product was analysed directly by 1H NMR and where indicated, purified by radial 
chromatography on silica (80% petroleum ether, 20% ethyl acetate). 
Preparation of Methyl cinnamate (3.5a) 
The reaction was performed as described by the general procedure, with 30 mg 
(0.28 mmol) of benzaldehyde (3.3a). The E:Z ratio of the crude product (3.5a) was found 
to be 1:2.4, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave an inseparable mixture of E and Z, as a colourless oil (quantitative 
recovery). Spectral data for 3.5a was identical to published data.3·21 • 3·22 
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Preparation of Methyl 2-nonenoate (3.5e) 
The reaction was performed as described by the general procedure, with 32 mg 
(0.28 mmol) of heptaldehyde (3.3e). The E:Z ratio of the crude product (3.5e) was found 
to be 1:7 .2, by 1H NMR. Isolation by radial chromatography (80% petroleum ether, 20% 
ethyl acetate) gave an inseparable mixture of E and Z as a colourless oil (28 mg, 58%). 
The 1H NMR spectrum of 3.5e (E) was identical to published data.3·29 See section 
"Reactions with Trimethyl phosphonoacetate" for spectral data on 3.5e (Z). 
Preparation ofMethyl4-methyl-2-pentenoate (3.5g) 
The reaction was performed as described by the general procedure, with 20 mg 
(0.28 mmol) of isobutyraldehyde (3.3g). The E:Z ratio of the crude product (3.5g) was 
found to be 1 :3.3, by 1H NMR. Purification by chromatography was not attempted due to 
the volatility of the product. The 1H NMR spectrum of 3.5g was identical to published 
data.3'31 
General Procedure3·19 for the Preparation of the Phosphonates (3.lc, 3.1f, 3.lg, and 3.lh) 
Step 1 
Trimethyl phosphonoacetate (3.1a) (5.000 g, 27 mmol) was cooled to 0 oc and 
phosphorous pentachloride (14.000 g, 54 mmol) was added. The resultant mixture was 
heated to 7 5 °C for 10 hours and then distilled at 105-110 oc (2mm Hg) to yield the 
intermediate (CbPOCH2C02Me) (5.100 g, 98%). 
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Step 2 
To the intermediate (CbPOCH2C02Me) (1.000 g, 5.2 mmol) in 5.0 ml of benzene, at 
0 °C, was added a solution of the alcohol (10.4 mmol) and Et3N (126 mg, 12.5 mmol), 
also in benzene (2.0 ml). After stirring at r.t., the mixture was diluted with ethyl acetate, 
filtered, and the solvent was evaporated from the filtrate under reduced pressure. 
Preparation of Methyl diphenylphosphonoacetate (3.1c) 
The preparation was performed as described by the general procedure, with 979 mg 
(10.4 mmol) of phenol. The reaction mixture was stirred for 1 hour. The product (3.lc) 
was purified by radial chromatography (50% petroleum ether, 50% ethyl acetate) to give 
a colourless oil (1.15g, 72%). 
Spectral data for 3.1c: 
1H NMR (CDCh) 8 7.19-7.36 (m, lOR, ArH); 3.76 (s, 3H, Me); 3.28 (d, 2H, 1=22.0 Hz, 
CH2). 13C NMR (CDC13) 164.9 (d, 1=6.1 Hz, C02); 149.7 (d, 1=9.1 Hz), 129.6, 125.3, 
120.4, (Ar); 52.5 (OMe); 33.5 (d, 1=138.0 Hz, CH2). HRMS. Calculated for C1sH1sOsP: 
306.06571. Found: 306.06562. FTIR (thin film) 2945; 1744; 1591 cm-1. 
Preparation of Methyl diisopropylphosphonoacetate (3.10 
The preparation was performed as described by the general procedure, with 625 mg 
(10.4 mmol) of 2-propanol. The reaction mixture was stirred for 24 hours. The product 
(3.lf) was purified by radial chromatography (50% petroleum ether, 50% ethyl acetate) to 
give a colourless oil (114 mg, 9%). 
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Spectral data for 3.1f: 
1H NMR (CDCb) o 4.75 (m, 2H, CH); 3.72 (s, 3H, OMe); 2.93 (d, 2H, 1=21.5 Hz, CH2); 
1.33 (d, 12H, 1=5.9 Hz, (Me2CH). 13C NMR (CDCb) 162.3 (C02); 71.6 (d, 1=7.3 Hz, 
CH); 52.4 (OMe); 35.3 (d, 1=135.6 Hz, CH2); 24.0, 23.8, 23.7, 21.7 (Me2CH). HRMS. 
Calculated for C8H160 5P (M+-Me): 223.07354. Found: 223.07317. FTIR (thin ftlm) 
2981; 1726; 1574 cm-1• 
Preparation of Methyl di -( 4-methoxyphenyl)phosphonoacetate (3.1g) 
The preparation was performed as described by the general procedure, with 1.290 g 
(10.4 mmol) of 4-methoxyphenol. The reaction mixture was stirred for 1 hour. The 
product (3.1g) was purified by radial chromatography (50% petroleum ether, 50% ethyl 
acetate) to give a colourless oil (1.240 g, 75%). 
Spectral data for 3.1g: 
1H NMR (CDCb) o 7.14 (d, 4H, 1=9.3 Hz, ArH); 6.84 (d, 4H, 1=9.3 Hz, ArH); 3.77 (s, 
9H, Me); 3.23 (d, 2H, 1=21.5 Hz, CH2). 13C NMR (CDC13) o 165 2 (d, 1=6.2 Hz, C02); 
156.9, 143.3 (d, 1=8.3 Hz), 121.3, 114.5 (Ar); 55.2 (MeOC4H6); 52.5 (C02Me); 33.2 (d, 
1=136.7 Hz, CH2). HRMS. Calculated for C17H190 7P: 366 08684. Found: 366.08602. 
FTIR (thin film) 3479; 3003; 2955; 2012; 2839; 1744; 1595 cm-1• 
Preparation of Methyl di -(3-methoxyphenyl)phosphonoacetate (3.1h) 
The preparation was performed as described by the general procedure, with 1.290 g 
(10.4 mmol) of 3-methoxyphenol. The reaction mixture was stirred for 1 hour. The 
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product (3.1h) was purified by radial chromatography (50% petroleum ether, 50% ethyl 
acetate) to give a colourless oil (983 mg, 52%). 
Spectral data for 3.1h: 
1H NMR (CDCb) o 7.22 (m, 2H, ArH); 6.77 (m, 6H, ArH); 3.76 (s, 9H, Me); 3.27 (d, 2H, 
1=21.5 Hz, CH2). 13C NMR (CDCb) o 165 2 (d, J=6.3 Hz, C02); 160.7, 150.8 (d, J=8.3 
Hz), 130.1, 112.6, 111.5, 106.6 (Ar); 55.4 (MeOC4H6); 52.8 (C02Me); 33.7 (d, J=140.8 
Hz, CH2). HRMS. Calculated for C11H190 7P: 366 08684. Found: 366.08710. FTIR 
(thin film) 3477; 3078; 3005; 2954; 2837; 2247; 1744; 1609; 1589 cm-1. 
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Conclusion 
The work presented in this thesis has described the development of conformationally 
restricted and epoxide-based peptidomimetics. 
A dipeptide surrogate, which contains a 1,2-pyrrole moiety, has been developed as a 
conformationally restricted cis peptide bond mimic. The amino terminus of the mimic 
was protected with Boc, and chain extension, by coupling of an amino acid residue at the 
carboxyl terminus, was achieved. Future research in this area could involve the 
incorporation of the cis peptide bond mimic into a biologically active peptide. 
A series of epoxide-based peptidomimetics, designed as inhibitors of the HIV PR, have 
been developed. A series of pseudosymmetrical epoxides were designed to capitalise on 
the unique symmetry of the HIV PR. Unfortunately, these compounds were found to be 
inactive. However, a further series of epoxide-based compounds, inspired by the known 
inhibitor of the HIV PR, 1,2-epoxy-3-(p-nitrophenoxy)propane, displayed good 
inhibitory activity. 
Towards the synthesis of the epoxide-based peptidomimetics, an investigation of the 
"Homer-Wadsworth-Emmons" (HWE) reaction was undertaken. The goal being to 
establish the conditions conducive to the formation of the Z olefin. It was found that to 
maximise the proportion of Z olefin a reaction should be performed at -78 °C, in THF, 
with methyl diphenylphosphonoacetate. Future research in this area could involve an 
investigation into the affect of the cation employed in the reaction. 
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Glossary of Abbreviations 
Acetyl chloride 
Acquired Immune Deficiency Syndrome 
Alanine 
Arginine 
Asparagine 
Aspartic acid 
Benzotriazolyloxy-tris-( dimethylamino )phosphonium 
hexafluorophosphate 
Benzyl 
2-(te rt-B utoxycarbonyloxyimino )-2-pheny !acetonitrile 
tertiary-Butyl 
tertiary-Butyl hydroperoxide 
n-Butyllithium 
Carbobenzyloxy 
Correlation spectroscopy 
Cystine 
Dicyclohexylcarbodiimide 
Dicyclohexylurea 
Diethylazodicarboxylate 
Distortionless enhancement by polarisation transfer 
Diisobutylaluniniumhydride 
L-( + )-Diisopropyl tartrate 
1 ,2-Dimethoxyethane 
4-Dimethylaminopyridine 
1 ,2-Epoxy-3-(p-nitrophenoxy )propane 
Gas chromatography mass spectrometry 
Glutamic acid 
Glycine 
Heteronuclear correlation 
Heteronuclear multiple quadrapole correlation 
1,4,7,10,13,16-Hexaoxacyclooctadecane 
Histidine 
Glossary of Abbreviations 
AcCl 
AIDS 
Ala 
Arg 
Asn 
Asp 
BOP 
Bzl 
"Boc-on" 
tert-Bu 
TBHP 
n-BuLi 
Cbz 
COSY 
Cys 
DCC 
DCU 
DEAD 
DEPT 
DIBAL 
DIPT 
DME 
DMAP 
ENP 
GCMS 
Glu 
Gly 
HETCOR 
HMQC 
18-crown-6 
His 
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"Horner-Wads worth-Emmons" 
Human Immunodeficiency Virus 
Human Immunodeficiency Virus Protease 
1-Hydroxybenzotriazole 
Isoleucine 
Leucine 
Lysine 
Methionine 
Norleucine 
Nuclear Overhauser enhancement 
Optical rotation 
Oxalyl chloride 
Phenylalanine 
Potassium bis(trimethylsilyl)amide 
Potassium tertiary-butoxide 
Proline 
iso-Propyl 
Room temperature 
Ruthenium trichloride hydrate 
Serine 
Simian Immunodeficiency Virus 
Statine 
Tetrazole ring 
Threonine 
Tryptophan 
Tyrosine 
Valine 
Glossary of Abbreviations 
HWE 
HIV 
HIVPR 
HOBT 
Ile 
Leu 
Lys 
Met 
Nle 
nOe 
[a]n 
Oxalyl Cl 
Phe 
KN(TMS)2 
tert-BuOK 
Pro 
iso-Pr 
r.t. 
RuCh 
Ser 
SIV 
Sta 
'lf[CN4] 
Thr 
Trp 
Tyrr 
Val 
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